




**EASL**

Vienna, Austria  
21–24 June

CONGRESS

2023



# LIST OF ACCEPTED ABSTRACTS

[easlcongress.eu](http://easlcongress.eu)  
#EASLCongress

## Contents

|  |     |
|--|-----|
| Acute liver failure and drug induced liver injury.....   | 2   |
| Alcohol-related liver disease .....  | 7   |
| Cirrhosis and its complications: ACLF and Critical illness.....                                      | 15  |
| Cirrhosis and its complications: Experimental and pathophysiology.....                               | 20  |
| Cirrhosis and its complications: Other clinical complications except ACLF and critical illness ..... | 26  |
| Cirrhosis and its complications: Portal Hypertension .....   | 37  |
| Fibrosis / Stellate cell biology.....  | 48  |
| Gut microbiota and liver disease / Liver-organ crosstalk.....  | 54  |
| Hepatocyte biology .....   | 58  |
| Immune-mediated and cholestatic disease: Clinical aspects.....                                       | 60  |
| Immune-mediated and cholestatic: Experimental and pathophysiology .....                              | 71  |
| Liver development and regeneration.....  | 76  |
| Liver immunology.....  | 79  |
| Liver transplantation and hepatobiliary surgery.....   | 82  |
| Liver tumours: Clinical aspects except therapy.....  | 92  |
| Liver tumours: Experimental and pathophysiology .....  | 101 |
| Liver tumours: Therapy .....   | 113 |
| NAFLD: Clinical aspects except therapy .....   | 121 |
| NAFLD: Diagnostics and non-invasive assessment.....  | 132 |
| NAFLD: Experimental and pathophysiology.....   | 151 |
| NAFLD: Therapy.....  | 170 |
| Non-invasive assessment of liver disease except NAFLD.....   | 176 |
| Nurses and Allied Health Professionals.....  | 180 |
| Public Health: Except viral hepatitis.....   | 183 |
| Public Health: Viral hepatitis.....  | 187 |
| Rare liver diseases (including paediatric and genetic) .....   | 202 |
| Viral Hepatitis: Experimental and pathophysiology .....  | 216 |
| Viral hepatitis B and D: Clinical aspects .....  | 226 |
| Viral Hepatitis B and D: Current therapies .....   | 240 |
| Viral Hepatitis B and D: New therapies, unapproved therapies or strategies.....                      | 244 |
| Viral Hepatitis C: Clinical aspects including follow up after SVR .....                              | 250 |
| Viral hepatitis C: Therapy and resistance .....  | 257 |
| Late breaker .....   | 259 |

## Acute liver failure and drug induced liver injury

110

Neddylation inhibition recovers drug-induced liver injury through the stabilization of Tamm41

Poster Presentation

Presenter: Claudia Gil-Pitarch

204

Distinctive cytokine profiles in checkpoint inhibitor-induced liver injury, idiosyncratic drug-induced liver injury and autoimmune hepatitis: a potential mechanistic biomarker panel

Poster Presentation

Presenter: Edmond Atallah

356

E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects

Poster Presentation

Presenter: Xabier Buque

476

Acute liver failure, does race affect hospital outcomes?

Poster Presentation

Presenter: Raissa Nana Sede Mbakop

746

Outbreak of unexplained acute hepatitis in children: the role of viral infections

Poster Presentation

Presenter: Yael Gozlan

879

Kelch-like ECH-associated protein-1 deletion rescues cell death associated with glutathione-glutathione peroxidase 4 knockdown in hepatocytes in acute models of liver injury

Poster Presentation

Presenter: Leticia Colyn

937

Noninvasive screening for histological features of autoimmune hepatitis and prognosis of patients with antinuclear antibody-positive drug-induced liver injury

Poster Presentation

Presenter: Feiyu Zhang

1086

Prior drug allergies are associated with worse outcome in patients with idiosyncratic drug-induced liver injury: an analysis from the Spanish DILI registry

Oral Presentation  
Presenter: Raul J. Andrade

1092  
Forward programming to produce hepatocytes organoids for cell based therapy  
Poster Presentation  
Presenter: Fabian Bachinger

1240  
Clinical determinants of hospital mortality in liver failure: a comprehensive analysis of 62.717 patients  
Poster Presentation  
Presenter: Sven H Loosen

1409  
Soluble and monocyte surface CD206 is a promising indicator of sepsis in patients with acute liver failure  
Poster Presentation  
Presenter: Anna Cavazza

1442  
Impact of plasma exchange and evolution of intensive care management in patients with acute liver failure in a liver transplant center over the past decade  
Poster Presentation  
Presenter: Octavi Bassegoda

1488  
Liver transplantation in acute liver failure in Slovenia  
Poster Presentation  
Presenter: Marjana Turk Jerovšek

1558  
Clinical and histological features of drug-induced liver injury: a retrospective study in biopsy-based cohort  
Poster Presentation  
Presenter: Ting Zhang

1586  
Clinical characteristics of chronic drug-induced liver injury in mainland China: a multicenter retrospective cross-sectional study  
Poster Presentation  
Presenter: Hong Zhao

1818

Clinical and histological features of porto-sinusoidal vascular disorder in drug-induced liver injury population: a retrospective study in biopsy-based cohort

Poster Presentation

Presenter: Mengqi Li

1944

Stress-driven suppression of the hippo pathway accelerates liver injury

Poster Presentation

Presenter: Na Young Lee

1967

Bio-molecular map of albumin identifies signatures of severity and early mortality in acute liver failure

Oral Presentation

Presenter: Neha Sharma

2002

Microbiome and metabolome analysis outlines circulatory predictors of poor outcomes in ALF

Poster Presentation

Presenter: Sushmita Pandey

2122

Epigenetic modifications implicated in idiosyncratic drug-induced liver injury

Poster Presentation

Presenter: Raul J. Andrade

2323

Mesenchymal stem cell-derived small extracellular vesicles ameliorate liver injury via attenuating macrophage extracellular traps

Poster Presentation

Presenter: Zhihui Li

2402

Dysregulated lipolysis increases intrahepatic concentrations of non-esterified fatty acids in chemotherapy-associated steatohepatitis

Poster Presentation

Presenter: Martina Derler

2689

Exponential increase of paracetamol liver injury over the last decade in a Spanish referral center

Poster Presentation

Presenter: Anna Pocerull

2757

Efficacy of N-acetylcysteine to prevent anti-tuberculosis drug-induced liver injury: a randomized controlled trial

Oral Presentation

Presenter: Kittichai Samaithongcharoen

2806

Stanozolol-induced liver injury: a peculiar biochemical profile in a series of thirteen cases

Poster Presentation

Presenter: Vinicius Nunes

2813

Systematic review: patients with pre-existing chronic liver disease are more vulnerable to the severe sequelae of drug induced liver injury

Poster Presentation

Presenter: Georgia Zeng

2876

An in silico designed receptor antagonizing peptide targeting C-C motif chemokine receptor 8 attenuates monocyte/macrophage recruitment in vitro and in vivo

Poster Presentation

Presenter: Eline Geervliet

3052

Altered intestinal permeability in patients with drug-induced liver injury and other forms of acute liver injury: a sequential analysis of serum levels of LBP, CD14 and CD163

Poster Presentation

Presenter: Daniel E. Di Zeo-Sánchez

3078

Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis

Oral Presentation

Presenter: Mohsin Hassan

3121

A systems medicine approach for the identification of potential prognostic biomarkers in patients with acute decompensation of cirrhosis

Poster Presentation

Presenter: Estefania Huergo Iglesias

3192

Control compounds used to validate in vitro models of idiosyncratic drug-induced liver injury: a systematic review

Poster Presentation

Presenter: Raul J. Andrade

3412

Determinants of steroid responsiveness in patients with severe acute hepatitis of indeterminate, autoimmune hepatitis and drug induced aetiologies

Poster Presentation

Presenter: Mahdi Saeidinejad

3473

SRT-015, best-in-class apoptosis signal-regulating kinase 1 inhibitor, demonstrates preclinical efficacy in acute models of liver injury

Poster Presentation

Presenter: Kathleen Elias

3534

Chemotherapy-induced hepatotoxic reactions in patients with acute myeloid leukemia: the overweight and obesity role in the pathogenesis

Poster Presentation

Presenter: Igor Skrypnyk

3620

Serum proteomics in American adults with acute liver failure

Poster Presentation

Presenter: Katharina Remih

3676

Gender differences in liver transplantation (LT) for acute liver failure (ALF) in a multicentre ALF-LT Spanish cohort

Poster Presentation

Presenter: Victoria Aguilera Sancho

3700

Autoimmune hepatitis (AIH) or drug-Induced liver injury (DILI) – a diagnostic challenge

Poster Presentation

Presenter: Yaakov Maor

3775

CDK 4/6 inhibitors induced liver injury: 7 cases from REFHEPS registry

Poster Presentation

Presenter: Lucy Meunier

## Alcohol-related liver disease

293

Low sphingolipid levels indicate poor survival in patients with alcohol-related liver disease

Poster Presentation

Presenter: Thit Mynster Kronborg

521

Evaluation of histological differences between cirrhosis due to alcoholic-related liver disease and non-alcoholic steatohepatitis using automated fibrosis phenotyping of liver histology

Poster Presentation

Presenter: Masanori Fukushima

532

Potential gut microbial biomarkers for detection of sarcopenia in alcohol-related liver disease patients

Poster Presentation

Presenter: Haripriya Gupta

539

Disentangling the contributions of alcohol and alcohol-related liver disease towards dementia

Poster Presentation

Presenter: Sixian Zhao

612

The prevalence and prognostic impact of bariatric surgery in patients hospitalized with alcoholic liver disease

Poster Presentation

Presenter: Louis Onghena

656

Radiomic data can define phenotypes of acute alcoholic hepatitis

Poster Presentation

Presenter: Nawaz Safdar

702

Hemoglobin is a short-term prognostic factor in decompensated alcohol-associated cirrhosis: a multicenter prospective study

Poster Presentation

Presenter: José Ursic Bedoya



962

Strategies are needed to support people with alcohol use disorder and alcohol-related liver disease to take part in randomised clinical trials: results from the MIRAGE pilot trial of functional imagery training

Poster Presentation

Presenter: Ashwin Dhanda

993

The role of HSD17B13 and MBOAT7 during alcohol detoxification: different effects on fibrosis and inflammation

Poster Presentation

Presenter: Sebastian Mueller

1016

Epidemic within pandemic: alcohol-related hepatitis and COVID-19

Poster Presentation

Presenter: Natalie Marlowe

1075

A prospective study of hepatic fibrosis evaluation in an alcohol withdrawal unit of an university hospital center : role of FIB-4 and elastometry. Fibr'addict study

Poster Presentation

Presenter: Armand Abergel

1308

Risk of alcohol-related liver disease in offspring of individuals with alcohol-related liver disease: a nationwide cohort study in Denmark

Poster Presentation

Presenter: Gro Askgaard

1346

Pyroptotic MAITs link microbial translocation with severity of alcohol-related liver disease

Poster Presentation

Presenter: Li-Ping Zhang

1385

Cause-specific mortality in patients with alcohol-related liver disease: a nationwide Danish cohort study

Poster Presentation

Presenter: Anna Emilie Kann

1418

Alcohol use disorder among patients admitted with non-alcohol related conditions: a retrospective cohort study in secondary care

Poster Presentation  
Presenter: Mohsan Subhani

1419  
Adverse childhood experiences as a background for alcoholic liver disease – cohort analysis of risk score in ALD and non-ALD cirrhosis patients in comparison with the control group  
Poster Presentation  
Presenter: Karolina Sulejova

1483  
Costs of hospital management of acute alcoholic hepatitis  
Poster Presentation  
Presenter: Lucy Turner

1564  
Low doses of different hepatotoxins induce alcohol-related liver disease and drive hepatocellular carcinoma  
Poster Presentation  
Presenter: Brisa Rodope Alarcón-Sánchez

1661  
Nucleoredoxin-dependent functioning is dysregulated by chronic alcohol consumption and is associated with the establishment of cellular senescence in the liver of aged mice  
Poster Presentation  
Presenter: Osiris German Idelfonso García

1687  
Prognostic role of serum alpha-1 antitrypsin levels for waitlist mortality in patients with alcohol-associated liver disease  
Poster Presentation  
Presenter: Ronald Samuel

1690  
Granulocyte monocyte/macrophage apheresis for corticosteroid-nonresponsive or -intolerant severe alcohol-associated hepatitis: a nonrandomized controlled study  
Poster Presentation  
Presenter: Ryosuke Kasuga

1697  
Plasma lipidomics and meta-proteomics analysis classifies lipid species and microbial peptides associated with poor outcome in SAH patients  
Poster Presentation  
Presenter: Jaswinder Maras

1698

Diabetes increases risk of mortality in alcohol-related liver disease

Poster Presentation

Presenter: Richard Parker

1766

An increase in the number of activated regulatory T cells is associated with an improvement in liver function of patients with severe alcoholic hepatitis after steroid therapy

Poster Presentation

Presenter: Soon Kyu Lee

1831

Systemic dyslipidemia in Ldlr mice accelerates hepatic fibrosis after chronic-binge ethanol feeding

Poster Presentation

Presenter: Constanze Hoebinger

1890

Clinical course of biopsy-controlled alcohol-related liver disease

Oral Presentation

Presenter: Stine Johansen

1910

AKR1B10 as a novel molecular driver of alcohol-associated hepatitis

Poster Presentation

Presenter: Maria Hernandez-Tejero

1978

Increased concentration of 4-hydroxyphenyllactic acid in patients with alcohol-related liver disease could promote the growth of Lactobacillus spp

Poster Presentation

Presenter: Jin-Ju Jeong

2027

Risk factors for acute myocardial infarction in patients with alcohol-related liver cirrhosis - a nationwide register-based nested case-control study

Poster Presentation

Presenter: Emma Celia Herting

2073

Type VII collagen degradation biomarker (C7M): a new marker of alcohol-induced gut injury and bacterial translocation in steatotic liver disease

Poster Presentation

Presenter: Emil Deleuran Hansen

2125

Supplementation of choline attenuates the onset of alcohol-related liver disease

Poster Presentation

Presenter: Víctor Sánchez

2171

Risk of primary liver cancer in alcohol-related cirrhosis - Danish and English cohort studies

Poster Presentation

Presenter: Morten Daniel Jensen

2265

Impact of heavy alcohol consumption on mitochondrial metabolism

Poster Presentation

Presenter: Scott Minchenberg

2300

Pharmacological therapy for alcohol use disorder is effective and safe in patients with cirrhosis.

Systematic review and meta-analysis

Poster Presentation

Presenter: Jordi Gratacós-Gines

2368

Detrimental association between COVID-19 pandemic stages and alcoholic hepatitis admissions: a Canadian population-based study

Poster Presentation

Presenter: Abdel-Aziz Shaheen

2451

Opportunistic cirrhosis casefinding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high risk group

Poster Presentation

Presenter: Ann Archer

2481

A cost-comparison of the LiverPRO score with FIB-4, ELF, and FibroScan in 6,032 study participants

Poster Presentation

Presenter: Katrine Prier Lindvig

2685

Recompensation following an episode of alcohol-associated hepatitis mostly occurs in the first year of follow-up and is related to Child-Pugh score, levels of GGT and platelets, and alcohol abstinence

Poster Presentation

Presenter: Jordi Gratacós-Gines

2742

Tumor necrosis factor-inducible gene 6 protein suppresses release of cluster of differentiation 44 intracellular domain, and attenuates alcohol-induced liver damages and activation of hepatic stellate cells

Oral Presentation

Presenter: Jinsol Han

2761

US trends and contribution of metabolic syndrome in alcohol-associated liver disease from 1999-2018

Poster Presentation

Presenter: Brian Lee

2797

Early liver transplantation for acute alcoholic hepatitis In a spanish liver transplant center

Poster Presentation

Presenter: Victoria Aguilera Sancho

2817

Plasma multi-omics outlines association of urobilinogen with corticosteroid non-response, inflammation, intestinal permeability and outcome in severe alcoholic hepatitis

Oral Presentation

Presenter: Manisha Yadav

2895

Platelets proteome dynamics and its association with liver severity in severe alcoholic hepatitis

Poster Presentation

Presenter: Rupinder kaur Kalra

2896

The beneficial effects of the diet withdrawal and physical exercise on steatohepatitis of DUAL etiology

Poster Presentation

Presenter: Olga Estévez

2898

Cardiovascular events in patients with alcohol-related liver disease and the prognostic value of endotrophin assessed by PRO-C6

Poster Presentation

Presenter: Ida Ziegler Spedtsberg

2902

Bariatric surgery in alcohol dependence and alcohol-related liver disease

Poster Presentation

Presenter: Thomas Williams

2975

Naltrexone is safe and effective in achieving abstinence and reducing alcohol craving in cirrhotic patients : a double blind randomized placebo controlled trial

Oral Presentation

Presenter: Manasa Alla

2976

New patient referrals and alcohol consumption data in an Irish hepatology outpatient setting

Poster Presentation

Presenter: Aoife Moriarty

3076

Alcohol use disorder in patients undergoing bariatric surgery is associated with a worse prognosis

Poster Presentation

Presenter: Edilmar Alvarado-Tapias

3115

Dynamics of oxidized albumin and cognate metabolites are associated with severe inflammation in experimental model of alcohol related liver disease

Poster Presentation

Presenter: Babu Mathew

3125

Multi-omics analysis reveals the therapeutic effect and mechanism of the Chinese herbal JiGuCao capsule on acute alcoholic hepatitis in mice

Poster Presentation

Presenter: Yue Chen

3260

Implementation and outcomes of liver health check clinics in community alcohol services

Poster Presentation

Presenter: Michael Griffiths

3268

In-silico identification and ex-vivo validation in humans of distinct oncogenic potential of aldo-keto reductase AKR1B10 in hepatocellular carcinoma from alcohol induced liver injury

Poster Presentation

Presenter: Michael Waters

3313

Identification of risk factors for alcohol relapse in liver transplant patients with alcohol-related liver disease

Poster Presentation

Presenter: Dilara Turan

3360

Binge drinking acutely induces fatty liver with increased liver stiffness which is readily reversed

Poster Presentation

Presenter: Kristoffer Kjærgaard

3450

Patients with alcohol-related cirrhosis who recompensate on follow-up have a characteristic metabolomic profile with differential concentrations of lipid and amino-acid metabolites

Poster Presentation

Presenter: Helena Hernández-Èvole

3470

Histological inflammation in severe alcohol-related hepatitis is the main pre-treatment factor associated to glucocorticoid response

Poster Presentation

Presenter: Antonio Saviano

3487

Alcohol rehabilitation after alcoholic hepatitis is associated with reduced mortality: results of a 2012-2021 National retrospective study

Poster Presentation

Presenter: Vincent Mallet

3582

Validation of the Lille 4 score on a cohort of romanian severe alcoholic hepatitis patients

Poster Presentation

Presenter: Bumbu Andreea Livia

3605

Characterization of fibrogenesis in severe alcohol-related hepatitis using a 3D model of coculture of organoids and fibroblasts from patients

Poster Presentation

Presenter: Line Carolle Ntandja Wandji

3613

The synergistic impact of food insecurity and alcohol use on mortality in adults with significant liver fibrosis

Poster Presentation

Presenter: Ani Kardashian

3633

Baclofen is effective on abstinence and improvement of Child-Pugh score in patients with cirrhosis: results of a meta-analysis

Poster Presentation

Presenter: Gildas Fantognon

3643

Beneficial effects of a screening programme for alcohol-related liver fibrosis with transient elastography in people with alcohol use disorder promoting alcohol abstinence

Poster Presentation

Presenter: Emma Avitabile

3749

When is the optimal time to collect baseline data for calculating the Lille score in severe alcoholic hepatitis?

Poster Presentation

Presenter: Mina Ignat

3836

Carbohydrate-deficient transferrin is a suitable drinking marker for patients with metabolic dysfunction-associated fatty liver disease

Poster Presentation

Presenter: Kazuyoshi Kon

## Cirrhosis and its complications: ACLF and Critical illness

108

Lower free and total serum cortisol levels are associated with higher risk of bacterial infection and acute-on-chronic liver failure in stable outpatients with advanced chronic liver disease

Poster Presentation

Presenter: Lukas Hartl

130

Increased level of presepsin in patients with acutely decompensated cirrhosis predicts development of acute-on-chronic liver failure

Poster Presentation

Presenter: Alberto Zanetto

175

Serum Cytokine and Chemokine profiles and disease prognosis in hepatitis B virus-related acute-on-chronic liver failure

Poster Presentation



Presenter: Bingbing Zhu

638

ACLF grade is not independently associated with 1-year mortality after hospital discharge in cirrhotic patients admitted to ICUs in the Netherlands

Poster Presentation

Presenter: Jubi de Haan

678

Microbial cell-free DNA next-generation sequencing of ascites in acutely decompensated cirrhosis patients: a proof-of-concept study

Poster Presentation

Presenter: Beiling Li

799

Machine learning-based model is superior to CLIF-C ACLF score for predicting ICU mortality in critically ill patients with acute-on-chronic liver failure

Poster Presentation

Presenter: Maike Rebecca Pollmanns

831

Parvovirus B19 infection associated with adverse outcomes in decompensated cirrhosis patients

Poster Presentation

Presenter: Changze Hong

840

Predictors of clinical courses in patients with acutely decompensated cirrhosis. An external validation of the PREDICT study

Poster Presentation

Presenter: Enrico Pompili

1071

ACLF course profiles over screening period in the phase IIb DHELIVER study

Poster Presentation

Presenter: Frederik Nevens

1119

Outcomes, clinical trajectories and risk factors of acute kidney injury (AKI) in critically-ill patients with liver cirrhosis

Poster Presentation

Presenter: Martin Schulz

1316

Increased serum IL-6 and IL-8 are associated with echocardiographic signs of diastolic dysfunction in patients admitted for acutely decompensated cirrhosis

Poster Presentation

Presenter: Victor Dragan

1319

Acute on chronic liver failure is associated with prolonged clot initiation in rotational thromboelastometry as compared to acute decompensation, but clot formation time and firmness are similar

Poster Presentation

Presenter: Tian Yu Qiu

1478

Frequency of ACLF and predictors of in-hospital mortality in cirrhotic patients in a tertiary care hospital of Pakistan

Poster Presentation

Presenter: Sulhera Khan

1567

Impaired pituitary-thyroid signaling and low free triiodothyronine indicate increased risk for ACLF and mortality in cirrhosis

Poster Presentation

Presenter: Lukas Hartl

1694

VSIG4 as a biomarker for the diagnosis and prognosis of HBV-ACLF

Poster Presentation

Presenter: Jun Li

1708

Plasma thrombomodulin as a candidate biomarker for the diagnosis and prognosis of HBV-related acute-on-chronic liver failure

Poster Presentation

Presenter: Jun Li

1789

The risk factors for poor prognosis according to the clinical course after first acute decompensation in cirrhotic patients

Poster Presentation

Presenter: Sung-Eun Kim

1899

Albumin use in acute-on-chronic liver failure in a large national cohort

Poster Presentation

Presenter: Nadim Mahmud

1989

Long-term outcome following liver transplantation for patients with acute on chronic liver failure grade 3 (ACLF-3): a retrospective matched-controlled study

Oral Presentation

Presenter: Florent Artru

2261

The prognostic impact of each organ failure is different than that of acute-on-chronic liver failure according to the major clinical presentation in acutely decompensated cirrhosis

Poster Presentation

Presenter: Jung Hee Kim

2307

Even small amounts of alcohol consumption can worsen the prognosis in acutely decompensated patients with viral hepatitis

Poster Presentation

Presenter: Jung Hee Kim

2467

Spur cells in liver cirrhosis are predictive of ACLF and liver-related mortality regardless of severe anaemia

Poster Presentation

Presenter: MICHELE BEVILACQUA

2471

Performances of the CLIF-consortium acute-on-chronic liver failure (ACLF) score are gender specific

Poster Presentation

Presenter: Sophie-Caroline Sacleux

2710

Nosocomial infections in cirrhosis are unpredictable and vary based on region of the world: CLEARED study

Poster Presentation

Presenter: Jasmohan S Bajaj

2793

Metabolic biomarkers significantly enhance the prediction of HBV-related acute-on-chronic liver failure prognosis

Poster Presentation

Presenter: Yan Zhang

3139

Real-world evidence of reversibility in patients with acute-on-chronic liver failure that survive hospitalization

Poster Presentation

Presenter: Ahmed Elshabrawi

3143

Incidence, risk factors and outcomes of acute kidney disease in cirrhosis patients with sepsis-related acute kidney injury

Poster Presentation

Presenter: Rakhi Maiwall

3184

Different risk factors of clinical outcomes between variceal bleeding and non-variceal gastrointestinal bleeding in acutely decompensated cirrhosis

Poster Presentation

Presenter: Sung-Eun Kim

3266

Combination of CLIF-C ACLF and ammonia levels as a predictor of in-hospital outcomes in patients with acute-on-chronic liver failure

Poster Presentation

Presenter: gi Biswas

3291

High histamine levels associate with acute-on-chronic liver failure and liver-related death in patients with advanced chronic liver disease

Poster Presentation

Presenter: Michael Schwarz

3528

Disparities in hospital outcomes among patients with end- stage liver disease with palliative care collaboration: a nationwide cohort analysis (2016-2020)

Poster Presentation

Presenter: Sheza Malik

3532

Evaluation of albumin and midodrine versus albumin alone in the outcome of refractory ascites in patients with decompensated cirrhosis: a randomized controlled trial (NCT04816240)

Poster Presentation

Presenter: Priti Jain

3577

Soluble urokinase plasminogen activator receptor is a biomarker for outcome in decompensated liver cirrhosis and acute-on-chronic liver failure

Poster Presentation

Presenter: Sven Lamatsch

3621

Prediction of sepsis in patient of acute on chronic liver failure (ACLF) - a machine learning approach

Poster Presentation

Presenter: Ashok Choudhury

3653

Trajectory of outcome from acute-on-chronic liver failure is determined beyond 48 hours of admission to intensive care

Poster Presentation

Presenter: Thomas Dixon

3709

Detection of 1,3-beta-D-glucan increases with the severity of decompensation stages in liver cirrhosis and is associated with lower survival in patients with acute on chronic liver failure

Poster Presentation

Presenter: Adam Herber

## Cirrhosis and its complications: Experimental and pathophysiology

350

Restoration of epithelial and vascular intestinal barriers and splanchnic macrophage function mediates the halting of bacterial translocation by propranolol in cirrhotic rats with ascites

Oral Presentation

Presenter: Elisa Castillo

408

Study of epigenetic control of LSECtin in hepatic antigen presenting cells during experimental cirrhosis

Poster Presentation

Presenter: Enrique Angel

460

Glial transcriptional changes in experimental HE arise early and show similarities with established neuroinflammatory disorders

Poster Presentation

Presenter: Wouter Claeys

585

Bacterial DNA translocation-induced systemic inflammation is associated with overt hepatic encephalopathy and predicts mortality in patients with cirrhosis

Poster Presentation

Presenter: Kessarín Thanapirom

683

Dysregulation of the FXR-FGF19 pathway indicates impaired gut-liver axis signalling in patients with cirrhosis

Oral Presentation

Presenter: Benedikt Simbrunner

684

Extracellular vesicles carrying oxidation-specific epitopes as effectors in acute hepatic decompensation and acute-on-chronic liver failure – a pilot study

Poster Presentation

Presenter: Benedikt Simbrunner

731

Nitazoxanide counteracts lipopolysaccharide-induced hepatic and renal transcriptomic profile changes to improve systemic inflammation and organ damage in a disease model of acute-on-chronic liver failure

Poster Presentation

Presenter: Vanessa Legry

785

Novel insights on liver endothelial mechanobiology in cirrhosis: role of calcium integrin-binding protein 1

Oral Presentation

Presenter: Cong Wang

1046

Factor VIII synthesis by adipose tissue stromal cells contributes to coagulopathy in chronic liver disease

Poster Presentation

Presenter: Sanal MG

1054

Evaluation of the effect of glucocorticoids on cardiac chronotropic dysfunction in cirrhotic rats, do dopamine receptors also play a role?

Poster Presentation

Presenter: Qamar Niaz

1120

Role of extracellular vesicles in sarcopenia associated to chronic liver diseases

Poster Presentation  
Presenter: Simone Di Cola

1176  
Effects of  $\beta$ -adrenergic hyperstimulation, liver cirrhosis and acute-on-chronic liver failure (ACLF) on the small intestinal gut-vascular barrier (GVB)  
Poster Presentation  
Presenter: Marco Felber

1357  
Multi-omics reveals the regulation mechanism of the Chinese herbal AnLuoHuaXian formula on reversing liver cirrhosis in the rat  
Poster Presentation  
Presenter: Ruijia Liu

1525  
Platelets from patients with decompensated cirrhosis display pro-inflammatory features  
Poster Presentation  
Presenter: Simone Di Cola

1707  
ETS2 alleviates HMGB1 and LPS triggered excessive inflammation in acute-on-chronic liver failure  
Oral Presentation  
Presenter: Jun Li

1726  
Imperfect maturation in erythroid progenitors leads to severe anemia in cirrhotic patients  
Poster Presentation  
Presenter: Deepika Lal

1904  
Identification of complication- dependent gut microbial biomarkers for early detection of decompensated cirrhosis  
Poster Presentation  
Presenter: Satya Priya Sharma

2088  
Metabolic Derangements in Hematopoietic Stem and Progenitor Cells (HSPCs) underlie monocyte-macrophage dysfunction in cirrhosis  
Poster Presentation  
Presenter: Deepanshu Maheshwari

2134

Investigating the PD-1/PD-L pathway and macrophage responses in acute-on-chronic liver failure  
Oral Presentation  
Presenter: Evangelos Triantafyllou

2186  
MCC950 reduces glial cell activation and neuroinflammation in an animal model of thioacetamide-induced hepatic encephalopathy  
Poster Presentation  
Presenter: Syed Afroz Ali

2341  
Yaq-001, a non-absorbable, engineered carbon beads of controlled porosity impacts on gut dysbiosis, gut permeability, organ function and reduces mortality in rodent models of cirrhosis and ACLF  
Poster Presentation  
Presenter: Jinxia Liu

2459  
The gene expression profile of skeletal muscle in end-stage liver disease patients undergoing assessment for liver transplantation with muscle wasting  
Poster Presentation  
Presenter: Sophie Allen

2480  
Distinct changes in the inflammatory profile of patients with EASL-CLIF- versus APASL-acute-on-chronic liver failure  
Poster Presentation  
Presenter: Mona-May Langer

2575  
Ascites CD8 T cells express a tissue-resident bystander phenotype that may contribute to disease pathogenesis in patients with decompensated liver cirrhosis  
Poster Presentation  
Presenter: Christian Niehaus

2667  
Constant alcohol consumption exacerbates hepatic encephalopathy and leads to neuronal loss in rats with chronic liver disease  
Poster Presentation  
Presenter: Farzaneh Tamnanloo

2671  
Evaluation of myocardial inflammation and fibrosis in an experimental model of liver cirrhosis by quantitative cardio-hepatic MRI  
Poster Presentation



Presenter: Franziska Schneider

2675

Peripheral blood metabolite associations with cardiac diastolic dysfunction in advanced chronic liver disease

Poster Presentation

Presenter: Madeleine Gill

2694

Biological differences between clinically different muscle wasting phenotypes in patients with decompensated ESLD undergoing assessment for liver transplantation: a UK prospective cohort UK study

Poster Presentation

Presenter: Amritpal Dhaliwal

2908

Longitudinal change in the plasma metabolite indicates therapeutic plasma exchange in acute-on chronic liver failure patients should be done every 12 hours

Oral Presentation

Presenter: Gaurav Tripathi

3036

Single-cell RNA transcriptomics of peripheral blood mononuclear cells revealed altered gene expressions in monocyte and HLA variations in decompensated liver cirrhosis patients with sepsis

Poster Presentation

Presenter: Nirupma Trehanpati

3075

Pathophysiological biomarkers associated with resolution of ACLF in patients treated with the liver dialysis device, DIALIVE

Poster Presentation

Presenter: Fausto Andreola

3091

Development and characterization of novel rodent ACLF models

Poster Presentation

Presenter: Frank Erhard Uschner

3157

Exploration of mechanisms underlying the beneficial effect of long-term albumin in models of cirrhosis and ACLF

Poster Presentation

Presenter: Alexandra Phillips

3223

The pan-PPAR agonist lanifibranor decreases portal pressure in models of both hepatic and prehepatic portal hypertension

Poster Presentation

Presenter: Anneleen Heldens

3262

Placement of a trans-jugular intrahepatic portosystemic shunt (TIPS) modifies the expression of proinflammatory cytokines in circulating monocytes exposed to lipopolysaccharide

Poster Presentation

Presenter: Mirella Pastore

3285

Whole transcriptomic analysis of bone marrow indicates distinct pathways to be at play in different stages of chronic liver disease patients

Poster Presentation

Presenter: Pramod Gautam

3321

Neurological dysfunction is improved after faecal microbiota transplantation in rats with bile duct ligated-induced chronic liver disease

Poster Presentation

Presenter: Alexandre Bourgeois

3333

Targeting myeloid-derived suppressor cells in a carbon tetrachloride-induced murine model of chronic liver injury

Poster Presentation

Presenter: Emilio Flint

3556

Cirrhosis alters receptor mediated clearance of therapeutic antibodies by hepatic sinusoidal endothelial cells

Poster Presentation

Presenter: Bethany James

3592

Resection of mesenteric lymph nodes is associated with increased systemic immunosuppression in experimental cirrhosis following oral salmonella typhimurium challenge

Poster Presentation

Presenter: Pinky Juneja

3641

$\epsilon$ -Lysine-melittin reduces pathological bacterial translocation and enhances gut immunity in experimental decompensated cirrhosis

Poster Presentation

Presenter: Deepika Jakhar

3649

Combination of weekly albumin infusion, personalized nutrition and home-based exercise programme improves outcomes of patients with end stage liver disease (AI-Fit study)

Poster Presentation

Presenter: Sasanka Vangara

3713

The role of Toll-like receptor 4 in ammonia metabolism and as a therapeutic target for hyperammonemia

Poster Presentation

Presenter: Annarein Kerbert

3742

Effect of fibrinogen substitution in hypofibrinogaemic CTP class C patients on viscoelastic coagulation tests

Poster Presentation

Presenter: Moritz Tobiasch

3757

Distinct patterns of hepatic and systemic inflammation in different types/aetiologies of liver disease

Poster Presentation

Presenter: Benedikt Hofer

## Cirrhosis and its complications: Other clinical complications except ACLF and critical illness

148

A virtual reality-driving test to predict car accidents in patients with cirrhosis

Poster Presentation

Presenter: Simon Johannes Gairing

150

Prevalence of minimal hepatic encephalopathy in patients with cirrhosis: a multicenter study

Poster Presentation

Presenter: Simon Johannes Gairing

154

An overview on microbial population in liver cirrhosis : changing paradigm in the known bacteriology of spontaneous bacterial peritonitis

Poster Presentation

Presenter: Shirin Demma

172

Comparison of coagulation parameters as prognostic markers of decompensation and liver-related death in advanced chronic liver disease

Poster Presentation

Presenter: Maria Pallozzi

194

Development and external validation of a model to predict multi-drug resistant bacterial infections in patients with cirrhosis

Poster Presentation

Presenter: Sebastián Marciano

288

Whole body clearance and production of ammonia quantified by constant ammonia infusion – the effects of cirrhosis and ammonia targeting treatments

Poster Presentation

Presenter: Peter Lykke Eriksen

317

Substitution of even one non-vegetarian meal with plant-based alternatives associate with lower ammoniogenesis in patients with cirrhosis who follow a western diet: a randomized clinical trial

Oral Presentation

Presenter: Jasmohan S Bajaj

328

The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker exposure and key cirrhosis-related outcomes

Poster Presentation

Presenter: Roy Wang

418

Atorvastatin reduces inflammation markers TNF- $\alpha$ , CD62L and MMP2 in a randomised trial

Poster Presentation

Presenter: Thit Mynster Kronborg

445

Clinical effectiveness of human albumin in liver cirrhosis: a meta-analysis update

Poster Presentation

Presenter: 昱舍 刘

470

Nutritional status of patients with advanced chronic liver disease: descriptive baseline of a prospective study

Poster Presentation

Presenter: Jose Miguel Rosales Zabal

522

The impact of a massive transfusion protocol on the outcomes of patients with acute variceal bleeding: propensity score-matched analysis

Poster Presentation

Presenter: Aryoung Kim

621

Effect of kidney injury and hemodynamic effect after moderate abdominal paracentesis: a randomized control study

Poster Presentation

Presenter: Sakkarin Chirapongsathorn

649

Factors related to a shorter survival in patients with liver disease and followed by a specialized palliative care clinic

Poster Presentation

Presenter: Fernando Xavier e Silva

657

Rifaximin plus lactulose is more effective than lactulose alone for the prevention of overt hepatic encephalopathy in patients with or without diabetes

Poster Presentation

Presenter: Jasmohan S Bajaj

730

Development and validation of the AMMON-OHE model to risk stratify cirrhotic outpatients for occurrence of overt hepatic encephalopathy

Oral Presentation

Presenter: María Pilar Ballester

789

Six-fold increased rate of chronic kidney disease after acute kidney injury: a population-based cohort study of 46,946 patients with cirrhosis

Poster Presentation

Presenter: Anna Cederborg

796

Classification of bleeding risk from invasive procedures in patients with cirrhosis: an expert consensus

Poster Presentation

Presenter: Alix Riescher-Tuczkiwicz

876

Experiences from a palliative care clinic specialized in liver diseases – utilisation, clinical characteristics of patients and outcomes.

Poster Presentation

Presenter: Fernando Xavier e Silva

883

Validation of thigh ultrasound for measurement of sarcopenia and fat mass in patient with cirrhosis: correlation with body composition analysis. Higher fat mass, lower muscle mass and reduced functional muscle

Poster Presentation

Presenter: Reza Saeidi

885

Goals of care and end-of-life for patients with advanced liver disease followed by a specialized palliative care clinic

Poster Presentation

Presenter: Fernando Xavier e Silva

957

Pregnancy outcomes in women with liver cirrhosis: a prospective UK obstetric surveillance system national cohort study

Oral Presentation

Presenter: Melanie Nana

1005

Serum ammonia levels do not correlate with overt hepatic encephalopathy severity and time to resolution in hospitalized patients with cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

1084

Poorer results in the clinical frailty scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosis

Poster Presentation

Presenter: Eva Maria Schleicher

1102

Impact of intrapulmonary vascular dilatations and hepatopulmonary syndrome on the clinical course of patients after transjugular intrahepatic portosystemic shunt insertion

Poster Presentation

Presenter: Jim Benjamin Mauz

1109

Normalization of psychometric hepatic encephalopathy score and detection of minimal hepatic encephalopathy in patients with cirrhosis (CHESS-NCRCID 2106): a prospective, multicenter study

Poster Presentation

Presenter: Xiaolong Qi

1156

Surgical subtype predicts adverse outcomes and costs among nonalcoholic cirrhotic patients

Poster Presentation

Presenter: Carolyn Catalano

1234

Potentially inappropriate medicine' use and nonadherence in hepatic encephalopathy: a retrospective real-world cohort study

Poster Presentation

Presenter: Zhen Howe Hong

1249

Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis

Poster Presentation

Presenter: Pei-Chang Lee

1296

Anemia in cirrhotic patients is a risk factor for esophagogastric variceal bleeding and mortality

Poster Presentation

Presenter: Elena Santos Perez

1370

The effects of alfapump on ascites control and quality of life in patients with cirrhosis and recurrent or refractory ascites: pivotal trial results

Poster Presentation

Presenter: Florence Wong

1395

Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis

Poster Presentation

Presenter: Qian Zhu

1448

Safety and efficacy of continuous infusion terlipressin in acute kidney injury-hepatorenal syndrome: the Infuse study

Poster Presentation

Presenter: K. Rajender Reddy

1457

Prognostic significance of individual decompensating events in stable decompensated outpatients with cirrhosis using a multi-center cohort

Poster Presentation

Presenter: Jasmohan S Bajaj

1461

Real-world experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)

Poster Presentation

Presenter: Giulia Iannone

1506

The role of prolonged albumin replacement therapy in correction of its structure and functional properties and management of ascites

Poster Presentation

Presenter: Anastasia Turkina

1528

Gender differences in the patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites

Poster Presentation

Presenter: Florence Wong

1552

On-treatment factors predict recompensation in entecavir-treated hepatitis B patients with decompensated cirrhosis

Poster Presentation

Presenter: You Deng

1572

Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis

Poster Presentation

Presenter: Niv Zmora



1647

The relation of serum nesfatin-1 levels with disease severity and complications in patients with liver cirrhosis

Poster Presentation

Presenter: Hasan Eruzun

1696

Efficacy of arginine glutamate injection for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: a randomized controlled trial

Poster Presentation

Presenter: Yu Chen

1742

Progression of cirrhosis is not associated with clinically significant alterations in hemostasis assessed by thromboelastography

Poster Presentation

Presenter: Alina Buliarcă

1830

The combination of LACE index, MELD on discharge and a previous history of decompensation defines risk groups for early readmission in patients with liver cirrhosis

Poster Presentation

Presenter: Yolanda Sánchez

1834

Impact of allelic HLA divergence on the risk of bacterial infections in cirrhotic patients awaiting liver transplantation

Poster Presentation

Presenter: Clementine Roger

1888

Clostridioides difficile infection in patients with liver cirrhosis

Poster Presentation

Presenter: Olga Adriana Caliman-Sturdza

1897

Factors associated with inpatient albumin administration and center-level variation in a national cohort

Poster Presentation

Presenter: Marina Serper

1924

Normalisation of the psychometric hepatic encephalopathy score in a Nigerian population

Poster Presentation

Presenter: Mansur Mohammed

2000

Racial disparities in COVID-19 clinical outcomes among patients with cirrhosis in North America and Europe - an international registry study

Poster Presentation

Presenter: Umar Hayat

2051

Randomised controlled trial of intravenous versus oral iron in treatment of iron deficiency anaemia after variceal bleeding in patients with cirrhosis

Poster Presentation

Presenter: Tabish Mohammad

2205

Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study

Oral Presentation

Presenter: Paolo Gallo

2254

Efficacy and safety of branched-chain amino acids supplementation on muscle cramps in patients with cirrhosis: a randomized double-blinded controlled trial

Poster Presentation

Presenter: Thanapat Atthakitmongkol

2338

Nutritional therapy improves minimal hepatic encephalopathy in cirrhosis by improvement in sarcopenia, proinflammatory cytokines and myostatin: a double blind randomized controlled trial

Poster Presentation

Presenter: Sudhir Maharshi

2389

Correlation between mid-arm circumference and QRS alterations as markers of sarcopenia in patients with decompensated cirrhosis

Poster Presentation

Presenter: Letitia Toma

2488

Uromodulin serum levels are associated with poorer prognosis in patients with cirrhosis and hepatorenal syndrome

Poster Presentation

Presenter: Eva Maria Schleicher

2493

Quickstrop, an App-based strategy that takes <1 minute, predicts time to overt hepatic encephalopathy development and hospitalizations

Poster Presentation

Presenter: Jasmohan S Bajaj

2497

Effects of nutritional therapy on Sarcopenia in patient with liver cirrhosis – a randomised controlled trial

Poster Presentation

Presenter: Sudhir Maharshi

2569

The prevalence and prognostic impact of myosteatosis with and without sarcopenia and its association with age and severity of liver cirrhosis

Poster Presentation

Presenter: Alexandra Alexopoulou

2583

The role of renal impairment on rotational thromboelastometry (ROTEM) parameters in hospitalised patients with cirrhosis – a prospective cohort study

Poster Presentation

Presenter: Louis Wang

2625

Acute kidney injury related to metamizole in advanced chronic liver disease patients undergoing major orthopedic surgery

Poster Presentation

Presenter: Lidia Canillas

2645

Analysis of surgical risk in patients with advanced chronic liver disease and major orthopedic surgery from a gender perspective

Poster Presentation

Presenter: Lidia Canillas

2728

Comparison of prognostic value of sarcopenia and MELD score in assessing 28 days and 3 months mortality in patients with cirrhosis of liver

Poster Presentation

Presenter: shivam gupta

2745

Activation of the kynurenine pathway potentially underlies neurodegeneration in patients with covert hepatic encephalopathy

Poster Presentation

Presenter: Georgia Zeng

2791

24-Hour urinary creatinine excretion (UCE) a marker of muscle mass is associated with mortality in critically ill patients with cirrhosis

Poster Presentation

Presenter: Jaya Benjamin

2820

Availability and affordability of services affects outcome in hospitalized patients with cirrhosis-results from CLEARED consortium

Poster Presentation

Presenter: Ashok Choudhury

2880

Rotational Thromboelastometry (ROTEM) reduces need for pre-emptive transfusion in low-moderate risk procedure in cirrhosis: a randomized controlled trial

Poster Presentation

Presenter: Chin King Tan

2983

Real-world treatment of decompensated liver cirrhosis in Italy: a propensity score-matched analysis of long-term versus acute albumin therapy

Poster Presentation

Presenter: Wim LALEMAN

3005

Liver nutrition clinic improves nutritional outcomes in patients with advanced cirrhosis

Poster Presentation

Presenter: Barbara Leggett

3012

Patients with liver cirrhosis and TIPS are prone to in-hospital falls

Poster Presentation

Presenter: Nada Abedin

3158

Prucalopride : a novel and safe usage for reducing incidence of hepatic encephalopathy in decompensated cirrhosis

Poster Presentation

Presenter: Manasa Alla

3249

Smoking and obesity promote systemic inflammation in patients with compensated and decompensated cirrhosis

Poster Presentation

Presenter: Benedikt Hofer

3316

Long-term cellular immune response to COVID-19 vaccination in patients with chronic liver disease

Poster Presentation

Presenter: Mariana Moura Henrique

3343

Association of polymorphisms in genes of the innate immunity with transplant-free survival of patients with decompensated liver cirrhosis

Poster Presentation

Presenter: Janett Fischer

3357

Efficacy and safety of nalfurafine hydrochloride for pruritus in patients with chronic liver disease in Japan

Poster Presentation

Presenter: TADAMICHI KAWANO

3371

Applicability of EASL clinical guidelines recommendations of empiric antibiotic treatment for spontaneous bacterial infections in patients with cirrhosis in south america

Poster Presentation

Presenter: melisa dirchwolf

3397

Decreased platelet function is an independent predictor of liver-related and all-cause mortality in patients with advanced chronic liver disease

Poster Presentation

Presenter: Benedikt Hofer

3509

Thromboelastography-guided coagulopathy correction in cirrhotic patients decreases blood product transfusion: a systematic review and analysis

Poster Presentation

Presenter: Hamed Komeylian

3520

Improvement of the quality of care in patients with liver cirrhosis after a clinical intervention. Quasi-experimental study

Poster Presentation

Presenter: Alberto Amador

3583

A multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating LPCN 1148

Poster Presentation

Presenter: Benjamin Bruno

3586

Effectiveness and safety of anticoagulant treatment in patients with liver cirrhosis and non-tumoral splenic-portal thrombosis

Poster Presentation

Presenter: Nelson Daniel Salazar Parada

3631

Serum PDL1 levels are associated with increased risk of bacterial infections in non-hospitalised patients with cirrhosis

Poster Presentation

Presenter: Adria Juanola

3715

Validation of automatic cell counting based on impedanceometry and flow cytometry in ascitic fluid

Poster Presentation

Presenter: Aitor Odriozola Herrán

## Cirrhosis and its complications: Portal Hypertension

22

The effect of precipitating factors for hepatorenal syndrome on response to terlipressin treatment: a subgroup analysis of a pooled North American database

Poster Presentation

Presenter: Kevin Moore

107

Suppression of the pituitary-adrenal axis in stable outpatients with advanced chronic liver disease increases with disease severity and may be linked to systemic inflammation and bile acids

Poster Presentation

Presenter: Lukas Hartl

109

Application of updated diagnostic criteria for cirrhotic cardiomyopathy: evaluation of its clinical impact in liver transplantation candidates

Poster Presentation

Presenter: Sarah Raevens

125

Secondary prevention of variceal bleeding is often imperfect: a national, population-based cohort study of 5,018 patients

Poster Presentation

Presenter: Hannes Hagström

177

Clinical profile of porto-sinusoidal vascular disorder : experience from tertiary referral hospital in India

Poster Presentation

Presenter: Love Garg

190

Terlipressin has acute effects on systemic inflammation markers in patients with cirrhosis and ascites

Poster Presentation

Presenter: Nikolaj Torp

254

Validation of Baveno-VII criteria regarding non-invasive diagnosis of clinically significant portal hypertension

Poster Presentation

Presenter: Byeong Geun Song

333

Head-to-head comparison of the prognostic performance of the hepatic venous pressure gradient and non-invasive tests in compensated advanced chronic liver disease

Oral Presentation

Presenter: Mathias Jachs

346

Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial

Oral Presentation

Presenter: Angela Puente Sanchez

378

Indocyanine green clearance reflects various pathophysiological mechanisms and independently predicts liver-related events in ACLD

Poster Presentation

Presenter: Mathias Jachs

433

Administration of Lactulose, Rifaximin, or combination therapy for hepatic encephalopathy is associated with a reduction in gastrointestinal cancers

Poster Presentation

Presenter: Ankoor Patel

461

Efficacy of Simvastatin plus non-selective beta blocker in improving survival of cirrhotic patients with variceal bleed: a systematic review and meta analysis

Poster Presentation

Presenter: Jemimah Andrea Fajardo

465

Role of non neoplastic portal vein thrombosis in natural history of patients with cirrhosis and hepatocellular carcinoma

Poster Presentation

Presenter: Sarah Shalaby

467

Impact of rifaximin use post-discharge of an overt hepatic encephalopathy (OHE) hospitalization on the annual rates of OHE-related inpatient stays

Poster Presentation

Presenter: Brock Bumpass

498

Predictors and management of post-banding ulcer bleeding in cirrhosis: a systematic review and meta-analysis

Poster Presentation

Presenter: Maria De Brito Nunes

594

A multimodal deep learning network for non-invasive prediction of the hepatic decompensation risk in compensated cirrhotic people: a multicentre cohort study (CHESS1701)

Poster Presentation

Presenter: Qian Yu

675

Study the effect of serum YKL-40 as a risk of variceal bleeding in Egyptian cirrhotic patients

Poster Presentation

Presenter: Abdelfattah Hanno



682

Bacterial translocation has an early onset in cirrhosis and induces a selective inflammatory response

Poster Presentation

Presenter: Benedikt Simbrunner

691

Effects of renin angiotensin system inhibition on renal function and the clinical course of patients with decompensated liver cirrhosis and ascites

Poster Presentation

Presenter: Tammo Lambert Tergast

791

The new diagnostic criteria of portopulmonary hypertension identify a group of patients with cirrhosis at high risk of death

Oral Presentation

Presenter: Luis Téllez

953

Recently validated non-invasive tests for liver fibrosis assessment have great performance in identifying NASH patients at risk for decompensation

Poster Presentation

Presenter: Vlad Taru

973

Baveno VII algorithm can avoid endoscopic surveillance in patients with cirrhosis

Poster Presentation

Presenter: Haiyu Wang

1048

Efficacy of long term albumin therapy in treatment of decompensated cirrhosis

Poster Presentation

Presenter: Deepanshu Khanna

1105

Use and impact of transjugular intrahepatic portosystemic shunt: a twelve-year nationwide study in Germany

Poster Presentation

Presenter: Wenyi Gu

1111

Spontaneous portosystemic shunts (SPSS) regress after transjugular intrahepatic portosystemic shunt (TIPS) implantation

Poster Presentation

Presenter: Theresa Bucsics

1115

TIPS increases muscle mass in patients with decompensated cirrhosis

Poster Presentation

Presenter: Theresa Bucsics

1139

Earlier diagnosis of hepatorenal syndrome-acute kidney injury with updated guidelines – review of the Confirm trial

Poster Presentation

Presenter: Richard Frederick

1227

Correlation of lymphangiogenesis and inflammation in patients with ACLD

Poster Presentation

Presenter: Florian Offensperger

1238

MELD 3.0 score in prediction of varices and comparison with its previous versions in patients undergoing esophago-gastro-duodenoscopy for variceal screening or band ligation

Poster Presentation

Presenter: Faiza Sadaqat Ali

1313

Pressure response to TIPS does not depend on stent diameter

Poster Presentation

Presenter: Michael Schultheiss

1479

Symptoms from refractory ascites: contributions from both abdominal pressure and the patient

Poster Presentation

Presenter: Nikhilesh Mazumder

1516

Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with advanced chronic liver disease: an individual patient meta-analysis

Poster Presentation

Presenter: Elton Dajti

1550

Individualized portal pressure gradient threshold based on liver function categories in preventing rebleeding after TIPS

Poster Presentation

Presenter: Guangchuan Wang

1598

Audit assessing real-world incidence of adverse events and mortality rate in patients receiving Terlipressin for hepatorenal syndrome at Royal free hospital

Poster Presentation

Presenter: Naz Kanani Alviri

1729

Single-centre experience of spleen stiffness measurement across the spectrum of chronic liver disease

Poster Presentation

Presenter: Sarah Romero

1745

Comparison of bolus versus continuous infusion of terlipressin in cirrhosis patients with septic shock: a randomized controlled trial (NCT 04819568)

Poster Presentation

Presenter: Priti Jain

1777

Progression of portal hypertension in PBC: doppler ultrasound velocity as a non-invasive assessment

Poster Presentation

Presenter: Aiympkul Ashimkhanova

1809

Sequential BAVENO VI plus dedicated spleen stiffness measurement or a novel spleen-centered algorithm significantly enlarges non-invasive ruling out of high risk varices: results from an international derivation-validation cohort study

Poster Presentation

Presenter: Emma Vanderschueren

1825

TIPS under-dilation strategy with new controlled expansion endoprosthesis: a hemodynamic and imaging confirmation of its feasibility

Poster Presentation

Presenter: Dario Saltini

1826

Clinical practice results of the use of intrahepatic portosystemic shunt for the treatment of refractory hepatic hydrothorax

Poster Presentation

Presenter: Elena Tenorio González

1877

Outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis.

Oral Presentation

Presenter: Ahmed Hashim

1921

Predicting esophageal varices and varices needing treatment in patients with compensated advanced chronic liver disease using Baveno VI Criteria, CHESS-ALARM score, FIB-4 score, and recently proposed FIB-5 score

Poster Presentation

Presenter: Fares Mashal

2109

Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis

Poster Presentation

Presenter: SILVIA NARDELLI

2173

Randomised controlled trial of ceftriaxone versus no antibiotic to prevent infection in patients with Child-Pugh A cirrhosis with acute variceal bleeding

Oral Presentation

Presenter: ANANY GUPTA

2259

Novel non-invasive model of clinically significant portal hypertension guides carvedilol therapy in patients with compensated advanced chronic liver disease (CHESS2102): an international multicenter study

Poster Presentation

Presenter: Chuan Liu

2294

Spleen stiffness assessed by point shear-wave elastography predicts portal hypertension better than liver elastography

Poster Presentation

Presenter: Vaclav Smid

2364

Comparison of 1-day vs 3-days intravenous terlipressin in cirrhosis patients with acute variceal bleeding: open-label randomized control trial

Oral Presentation

Presenter: Manas Vaishnav

2393

Adverse outcomes following transjugular intrahepatic portosystemic shunt placement in relation to the underlying cause of portal hypertension

Poster Presentation

Presenter: Sarwa Darwish Murad

2463

Validation of a discrete event simulation model evaluating the cost-effectiveness of long-term albumin administration in real-world UK patients with recurrent ascites

Poster Presentation

Presenter: Kris Bennett

2477

Is elastography needed for diagnosing cACLD and stratifying CSPH risk?

Poster Presentation

Presenter: Georg Semmler

2478

Impact of new ESC/ERS diagnostic criteria for pulmonary hypertension in cirrhotic patients with portal hypertension on the frequency of portopulmonary hypertension

Poster Presentation

Presenter: Hiroki Ono

2479

Validation and refinement of the Baveno VII criteria for risk stratification in compensated advanced chronic liver disease after HCV-cure

Poster Presentation

Presenter: Georg Semmler

2484

A retrospective evaluation of the effectiveness and safety of palliative long-term abdominal drains for the management of refractory ascites in patients with end-stage liver disease, in comparison with large volume paracentesis

Poster Presentation

Presenter: Rodrigo Motta

2491

Collagen-proportionate area determined by semiautomated histomorphometry correlates with HVPG across different liver disease etiologies

Poster Presentation

Presenter: Thomas Sorz

2511

Hepatic venous pressure gradient predicts further decompensation in cirrhosis patients with acute esophageal variceal bleeding

Poster Presentation

Presenter: Manas Vaishnav

2615

Serum procalcitonin and interleukin-6 predict acute-on-chronic liver failure following transjugular intrahepatic portosystemic shunt implantation in patients with refractory ascites

Poster Presentation

Presenter: Lukas Sturm

2725

Predicting post-TIPSS mortality: external validation of the FIPS score in a Canadian cohort

Poster Presentation

Presenter: Shamir Malik

2739

Coagulation profile in adult patients with porto-sinusoidal vascular disease

Poster Presentation

Presenter: Sidharth Harindranath

2843

Clinical features and analysis of serum BMP9 levels in patients with portal pulmonary hypertension

Poster Presentation

Presenter: Xiaoyu Wen

2931

Detection of minimal hepatic encephalopathy: standardization of psychometric hepatic encephalopathy scale for Israeli population

Poster Presentation

Presenter: Helena Katchman

2934

Current prognosis of gastric variceal bleeding in France: preliminary results from a multicenter prospective cohort of 87 cirrhotic patients

Poster Presentation

Presenter: Delphine Weil-Verhoeven

3015

Continuous terlipressin infusion improves muscle function but not muscle mass in patients with cirrhosis and portal hypertension

Poster Presentation

Presenter: Ryma Terbah

3048

Robust identification of patient subgroups in acute decompensated cirrhosis

Poster Presentation

Presenter: Sara Palomino

3051

Outcome of sucralfate vs proton pump inhibitor vs sucralfate and proton pump inhibitor combination post endoscopic esophageal variceal band ligation - A randomized controlled trial

Poster Presentation

Presenter: Arun Vaidya

3096

Adoption of a clinical assessment service in hepatology

Poster Presentation

Presenter: Sarah Clark

3210

Impact of non-selective beta-blockers on first and further hepatic decompensation after transjugular intrahepatic portosystemic shunt insertion

Poster Presentation

Presenter: Anja Tiede

3280

Diabetes impairs the hemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes for hepatic decompensation

Poster Presentation

Presenter: Rafael Paternostro

3284

Real-world practice of pre-emptive tips: an Asia perspective based on Singapore nationwide variceal bleeding audit

Poster Presentation

Presenter: Yu Jun Wong

3336

Detection of candida species in hospitalized patients with decompensated liver cirrhosis and ascites indicates an unfavorable clinical course and outcome

Poster Presentation

Presenter: Marie Griemsmann

3403

Predicting the efficacy of splenic embolization on refractory ascites using a computational model of portal hypertension

Poster Presentation  
Presenter: Nikhilesh Mazumder

3416  
Natural history of patients with NAFLD-associated compensated advanced chronic liver disease stratified according to severity of portal hypertension  
Poster Presentation  
Presenter: Rafael Paternostro

3423  
Clinical utility of liver and spleen elastography in the management of patients living with liver disease  
Poster Presentation  
Presenter: Carmen Lara Romero

3679  
Hemodynamic response determines further decompensation and survival in patients with decompensated cirrhosis  
Oral Presentation  
Presenter: Claudia Pujol

3704  
Ultrasound predictors of hemodynamic TIPS dysfunction: friends or foes?  
Poster Presentation  
Presenter: Andreea Fodor

3721  
Preoperative transjugular intrahepatic portosystemic shunt and in-house mortality in patients with liver cirrhosis undergoing surgery  
Poster Presentation  
Presenter: Felix Piecha

3735  
Systemic inflammation remains a critical determinant of the dynamic component of portal hypertension in abstinent patients with alcohol-related cirrhosis  
Poster Presentation  
Presenter: Benedikt Hofer

3740  
MELD-sarcopenia and clinically significant portal hypertension as independent risk factors in the evolution of liver cirrhosis  
Poster Presentation  
Presenter: Elba Llop



3771

Refractory hepatic hydrothorax is associated with Increased mortality compared to cirrhosis and refractory ascites

Poster Presentation

Presenter: Binu John

3849

To study effect of the combination of midodrine and tolvaptan versus tovalptan alone in patients with severe hyponatremia in cirrhosis - an open label RCT (TOLMINA Trial-NCT05060523)

Poster Presentation

Presenter: srinivasa reddy golamari

## Fibrosis / Stellate cell biology

133

Amelioration of CCl<sub>4</sub> induced hepatic fibrosis in-vitro and in-vivo by bone marrow derived mesenchymal stromal cells lysate loaded nanostructured lipid carriers

Poster Presentation

Presenter: Sabeen Malik

167

Novel insights on the contribution of collagen degradative macrophages to liver fibrosis resolution

Oral Presentation

Presenter: Maria Fernandez-Fernandez

255

Atypical Chemokine receptors regulate the induction of 'disease-associated' LSEC by modulating Endothelial-to-Mesenchymal transition (EndMT) during liver fibrosis

Oral Presentation

Presenter: Neil Dufton

304

Novel Pathways implicated in the seladelpar-mediated reductions of established liver fibrosis are identified from RNA-SEQ data using plex search and two independent mouse pharmacology datasets

Poster Presentation

Presenter: Edward Cable

316

Analysis of alpha adrenoblocker as antifibrotic and hepatoprotective agent in a Wistar rat model of cirrhosis

Poster Presentation

Presenter: Mariana Yazmin Medina Pizaño

639

Bulk and single cell RNA sequencing profiling of human hepatic stellate cells and the potential biomarkers for liver cirrhosis

Poster Presentation

Presenter: Xu Liu

726

Spatial lipidomics reveal dysregulated sphingolipid metabolism in liver fibrosis

Poster Presentation

Presenter: Aleksandra Gruevska

819

Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancer

Poster Presentation

Presenter: Qi Ruan

847

The proto-oncogene Bmi1 is a novel regulator of the activated hepatic stellate phenotype

Poster Presentation

Presenter: Kim Su

874

Hepatic stellate cells from zone 1 do not transform into myofibroblasts but engage in capillarization in preclinical models of liver fibrosis

Poster Presentation

Presenter: Andreas Friebe

952

Identification of pseudo-immune tolerance for chronic hepatitis B patients : development and validation of a non-invasive prediction model

Poster Presentation

Presenter: Shuo Li

1002

Novel natural killer cell immunotherapy through synthesized Neuroligin-4 peptides improved liver fibrosis

Poster Presentation

Presenter: Johnny Amer

1198

Cathepsin D expressed in hepatocytes does not participate in the development of liver fibrosis after chronic CCl4 administration

Poster Presentation

Presenter: Paloma Ruiz-Blazquez

1338

Advancement of artificial intelligence in digital pathology: from exploratory endpoint to primary endpoint in non-alcoholic steatohepatitis clinical trials

Poster Presentation

Presenter: Dean Tai

1384

Hepatic CD40-mediated natural killer T cell apoptosis stimulates liver fibrosis

Oral Presentation

Presenter: Kyurae Kim

1399

3D engineered perihepatic endothelial cell implants reduce fibrosis and inflammation, boosting liver regeneration in fibrotic hepatectomized mice

Poster Presentation

Presenter: Mireia Medrano-Bosch

1403

Selective RNF41 restoration in hepatic macrophages from thioacetamide-induced fibrotic mice reduces liver fibrosis and inflammation

Poster Presentation

Presenter: Alazne Moreno-Lanceta

1410

Hepatic stellate cell-derived extracellular matrix to model aetiology-and patient-specific matrix remodelling and fibrosis progression

Poster Presentation

Presenter: Sara Campinoti

1414

Role of the hepatocyte Epidermal Growth Factor Receptor (EGFR) pathway on the cellular interactome within the liver fibrotic niche

Poster Presentation

Presenter: Isabel Fabregat

1443

Multimodal decoding of the mesenchymal landscape of human biliary fibrosis

Poster Presentation

Presenter: David Wilson

1486

CLOCK $\Delta$ 19 circadian disruption primes myofibroblasts for accelerated activation and fibrotic progression

Oral Presentation  
Presenter: Elliot Jokl

1599  
Gender differences in repair mechanisms of chronic cholangiopathies with progressive fibrosis  
Oral Presentation  
Presenter: Luca Fabris

1718  
Therapeutic effect of recombinant human Cytoglobin against mouse liver fibrosis and stellate cell activation via ROS scavenger function and activation of JAK-STAT1 pathway  
Poster Presentation  
Presenter: Norifumi Kawada

1947  
Repeatability and reproducibility assessment and its acceptable standard error of means for qFibrosis system in multi-site NASH clinical trials  
Poster Presentation  
Presenter: Pik Eu Jason Chang

2055  
Hepatic proteomic analysis identifies proteins linked to hepatic sympathetic neuronal degeneration and disorganization which promotes liver fibrosis in bile duct ligation murine model  
Poster Presentation  
Presenter: Sadam H Bhat

2086  
Liver cell-type specific molecular signatures marking transition from advanced fibrosis to cirrhosis in human non-alcoholic steatohepatitis  
Poster Presentation  
Presenter: Martin Rønn Madsen

2150  
The anti-HIV drug Rilpivirine downregulates migration and proliferation of activated hepatic stellate cells: relevance for the purpose of drug repurposing in liver fibrosis  
Poster Presentation  
Presenter: Ana Benedicto

2200  
MicroRNA-29b involves in the progression of NAFLD to liver fibrosis  
Poster Presentation  
Presenter: qihua duan

2241

Characterizing the long-term stability of human pluripotent stem cell-derived non-parenchymal liver cells

Poster Presentation

Presenter: Ingrid Wilhelmsen

2249

Is the fibrosis phenotype in pre- and post-menopausal F2/F3 women the same?

Poster Presentation

Presenter: Isabel Fernández-Lizaranzu

2262

MCPIP1 inhibits hepatic stellate cell activation in autocrine and paracrine manner

Poster Presentation

Presenter: Jerzy Kotlinowski

2395

The anti-fibrotic efficacy of Adelmidroi depends in the level of hepatic ppar gama

Poster Presentation

Presenter: Huanyu Xiang

2449

X-box binding protein 1(XBP1) in hepatic stellate cells (HSC) mitigates liver fibrosis

Oral Presentation

Presenter: Hanghang Wu

2457

Myeloperoxidase from neutrophile granulocytes accomplish destruction of Schistosoma mansoni eggs

Poster Presentation

Presenter: Ricarda Sölter

2564

Does sex influence the development of sarcopenia in liver fibrosis?

Poster Presentation

Presenter: Katia Sayaf

2578

TLC-3595, a selective acetyl-CoA carboxylase 2 (ACC2) inhibitor, improves steatosis and fibrosis in murine models of NASH via pleiotropic mechanisms

Poster Presentation

Presenter: Archana Vijayakumar

2596

Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast attenuates profibrogenic gene expression of myofibroblasts in human liver explant tissue with biliary fibrosis

Poster Presentation

Presenter: Johanna Schaub

2722

Artificial Intelligence analysis of liver biopsies in pre-cirrhotic NASH: qFibrosis explained

Poster Presentation

Presenter: Pol Boudes

2933

Functional and mechanistic role of lncRNA-C1 in cholestatic liver diseases

Poster Presentation

Presenter: Joan Blázquez Vicens

3001

Cyclophilin inhibition exhibits preventive and curative antifibrotic effects via extracellular matrix remodelling

Poster Presentation

Presenter: Una Rastovic

3085

An integrative multi-omic approach defines therapeutic pathways associated with altered cell state and chromatin organisation in human liver fibrosis

Oral Presentation

Presenter: Karen Piper Hanley

3198

Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis

Oral Presentation

Presenter: Atish Mukherji

3431

3D Extracellular matrix human liver hydrogels for the investigation of genetic variants in hepatic stellate cells

Poster Presentation

Presenter: Elisabetta Caon

3444

Composition of the bile salt pool critically modulates liver fibrosis – towards humanization of murine models of liver disease

Poster Presentation

Presenter: Jingguo Li

3513

Evaluation of anti-fibrotic compounds effect in 3D human NASH model using quantitative digital pathology

Poster Presentation

Presenter: Radina Kostadinova

3752

Single-cell multiomics defines candidate transcription factors regulating pathogenic macrophage differentiation in murine liver fibrosis

Oral Presentation

Presenter: ELENI PAPACHRISTOFOROU

3778

Discovery of novel small molecule inhibitors of HDAC6 that suppress liver fibrosis

Poster Presentation

Presenter: Derek Mann

## Gut microbiota and liver disease / Liver-organ crosstalk

174

Prebiotic activity of lactulose optimizes gut metabolites and prevents systemic infection in liver disease patients

Poster Presentation

Presenter: Matthew Odenwald

559

The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency

Poster Presentation

Presenter: Francesco Annunziata

921

Lactobacillus protects against leaky gut, future decompensation, and hepatic encephalopathy in patients with cirrhosis

Oral Presentation

Presenter: Patricia Bloom

980

Tissue resident NK NTCP- transplanted to immunosuppressed mice exhibiting liver fibrosis and fed with high fat diet (HFD) alleviate intestinal fibrosis

Poster Presentation

Presenter: Johnny Amer

1138

Faecal microbiota transplant restores gut barrier function and augments ammonia metabolism in patients with advanced cirrhosis: a randomised single-blind placebo-controlled trial

Oral Presentation

Presenter: Lindsey A Edwards

1303

Offspring of obese mothers have a higher risk for hepatocellular carcinoma through the transmission of an altered gut microbiome

Oral Presentation

Presenter: Beat Moeckli

1423

Microbiota-targeted interventions in the gut-liver axis for chronic liver disease of DUAL etiology

Poster Presentation

Presenter: Raquel Benedé

1588

Altered gut microbiome and stool bile acids in sarcopenia in cirrhosis

Poster Presentation

Presenter: Benard Aliwa

1863

Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

1957

Association of gut microbiome with prospective risk of hepatocellular carcinoma in chronic hepatitis B patients: a prospective nested case-control study

Oral Presentation

Presenter: Zhixian Lan

1983

Pasteurized Akkermansia muciniphila inhibits fibrosis progression in mouse cirrhosis model and induces changes in the gut microbiome

Poster Presentation

Presenter: Sung-Min Won

2068

The novel class of microbially conjugated bile salts activate the main host bile salt receptors FXR and TGR5



Poster Presentation  
Presenter: Ümran Ay

2070

Unexpected function of the cell cycle kinase Cyclin E/CDK2 for control of intestinal barrier: implications for gut-liver communication, liver fibrosis and liver cancer

Oral Presentation

Presenter: Anna Verwaayen

2379

Culturomics study of gut microbiota in NASH patients and healthy controls

Poster Presentation

Presenter: Babacar Mbaye

2401

Impact of human gut microbiota from PSC patients on a mouse model of biliary disease

Poster Presentation

Presenter: Petra Hradicka

2468

Characterization of pattern recognition receptor expression for regulating myeloid cell responses in the gut-liver axis in non alcoholic fatty liver disease and cholangiopathies

Poster Presentation

Presenter: Alix Bruneau

2695

Investigating the correlation of a poly-metabolic risk score to clinical features in non-alcoholic fatty liver disease patients throughout a faecal microbiota transplant clinical trial

Poster Presentation

Presenter: Nadeen Habboub

2723

Gut microbial proteomic changes from commensal bacteria are associated with development of first decompensation in cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

2763

The bile acid chenodeoxycholic acid increases muscle insulin sensitization via FOXO1

Poster Presentation

Presenter: Roshni Rebecca Singaraja

2773

Identification of gut microbiota signature for differentiating between viral- and non-viral related hepatocellular carcinoma

Poster Presentation

Presenter: Pisit Tangkijvanich

2782

Long-term benefit of direct-acting antivirals on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection

Poster Presentation

Presenter: Natthaya Chuaypen

2874

Edible exosomes oral administration restores gut homeostasis and reduces systemic ammonia level in rodent model

Poster Presentation

Presenter: P. Debishree Subudhi

2897

The intestinal immune barrier is associated with bile acid pool modifications in mice suffering from non-alcoholic steatohepatitis

Poster Presentation

Presenter: Simon Peschard

2915

Serum villin-1 level – a tell-tale sign of gut barrier failure in patients with cirrhosis and acute decompensation

Oral Presentation

Presenter: David Tornai

3250

Oral microbiome signature associated with liver graft dysfunction

Poster Presentation

Presenter: Shruti Sureshan

3273

Phascolarctobacterium as a predictor for survival in cirrhotic patients

Poster Presentation

Presenter: Rosa Haller

3315

Identifying the role of gut-vascular barrier associated macrophages in liver cirrhosis

Poster Presentation

Presenter: Lena Smets

3359

Pemafibrate modulates microbiota profile in a dietary model of fatty liver in rat

Poster Presentation

Presenter: Roger Bentanachs

3375

Gut viral and bacterial alterations modulate the presence and dynamics of minimal hepatic encephalopathy at baseline and longitudinally

Poster Presentation

Presenter: Jasmohan S Bajaj

3378

Altered levels of secondary bile acids in enterohepatic circulation impairs liver regeneration in a rat model of partial hepatectomy

Poster Presentation

Presenter: Impreet Kaur

3570

Intestinal dysbiosis exacerbates gut barrier dysfunction via inhibiting FXR-FGF15 in intra-abdominal sepsis

Poster Presentation

Presenter: Shuwen Qian

3843

Gut-liver crosstalk in hepatocellular carcinoma and non-selective beta-blockers: is there a link?

Poster Presentation

Presenter: Yasmeen Attia

## Hepatocyte biology

302

Magnesium content decreases and transient receptor potential melastatin-subfamily member 7 expression increases in hepatocytes as liver inflammation and cirrhosis worsen in liver transplant candidates

Poster Presentation

Presenter: Simona Parisse

392

Dickkopf-1 inhibitor enhances the anti-tumor effects of sorafenib through inhibition of PI3K/Akt/Wnt signaling in hepatocellular carcinoma

Poster Presentation

Presenter: Sang Hyun Seo

599

Liver spheroids engrafted in the anterior chamber of the eye - a novel platform to study hepatic physiology and pathology

Poster Presentation

Presenter: Francesca Lazzeri-Barcelo

663

Multiomic profiling associated with lipid remodeling in senescent primary human hepatocytes

Poster Presentation

Presenter: Sin-Tian Wang

755

Integrated metabolomic and transcriptomic analyses implicate specific metabolic pathways in crocin-induced apoptosis of HCC cells

Poster Presentation

Presenter: Amr Amin

977

With-in patient comparison of single-cell versus single-nucleus sequencing on human transjugular liver biopsies

Poster Presentation

Presenter: Lukas Van Melkebeke

1307

DNA damage induced-senescence shifts the cellular bioenergetics capacity from glycolysis to oxidative phosphorylation in mouse hepatocytes

Oral Presentation

Presenter: Pavitra Kumar

2111

Long-term effects in primary human hepatocytes (PHH) after exogenous exposure to human intestinal microbiome secretome peptides

Poster Presentation

Presenter: Natalia Sanchez-Romero

2206

Accumulation of apical bulkheads and hepatocyte rosettes as adaptive responses upon impaired bile flow in liver diseases

Poster Presentation

Presenter: Carlotta Mayer

2235

Tick-tock – Uncovering new aspects of circadian-regulated liver metabolism by kinetic modeling

Poster Presentation

Presenter: Christiane Körner

2435

3D digital histopathology: a new methodology for morphological characterization of the human liver

Poster Presentation

Presenter: Mathieu de Langlard

2568

Three-dimensional single-cell digital atlas of liver tissue architecture

Poster Presentation

Presenter: Fabián Segovia-Miranda

3241

Insulin determines TGF- $\beta$  effects on HNF4 $\alpha$  transcription in liver injury and hepatocyte epithelial-to-mesenchymal transition

Poster Presentation

Presenter: Steven Dooley

## Immune-mediated and cholestatic disease: Clinical aspects

57

Antibodies against multiple post-translationally modified proteins aid in diagnostic work-up of autoimmune hepatitis and associate with complete biochemical response to treatment

Poster Presentation

Presenter: Anna Stoelinga

332

Biliary microbial patterns in primary sclerosing cholangitis are linked to disease outcome

Poster Presentation

Presenter: Burcin Özdirik

404

INTEGRIS-PSC phase 2a study: evaluating the safety, tolerability, and pharmacokinetics of bexotegrast (PLN-74809) in participants with primary sclerosing cholangitis

Poster Presentation

Presenter: Gideon Hirschfield

419

A two-step algorithm avoids corticosteroids in two-thirds of cancer patients with severe immune-mediated hepatitis due to immune checkpoint inhibitors

Poster Presentation

Presenter: Mar Riveiro Barciela

420

Norucholic acid for the treatment of primary sclerosing cholangitis: baseline data from a phase III trial

Poster Presentation

Presenter: Michael Trauner

425

A novel web-based online nomogram to predict advanced liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome

Poster Presentation

Presenter: Zhiyi Zhang

500

Long-term prospective follow-up of a primary biliary cholangitis (PBC) multicenter cohort treated with Obeticholic Acid (OCA). Interaction effect of triple therapy with fibrates

Poster Presentation

Presenter: Conrado Fernandez-Rodriguez

506

Autoimmune hepatitis (AIH) in Greece: first results from the Hellenic autoimmune liver diseases study group of the Hellenic association for the study of the liver (HASL)

Poster Presentation

Presenter: Nikolaos Gatselis

565

Peri-procedural complications in people with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography - evaluating a high-volume programme

Poster Presentation

Presenter: Kristel Leung

583

Prognostic significance of liver stiffness progression in primary biliary cholangitis

Oral Presentation

Presenter: Christophe Corpechot

603

Risk of cancer and subsequent mortality in primary biliary cholangitis: a population-based cohort study of 3,052 patients

Oral Presentation

Presenter: Axel Wester

631

Clinical significance of F-actin IgA and gliadin IgA antibodies in primary sclerosing cholangitis

Poster Presentation

Presenter: Ewa Wunsch

858

Patient reported gaps between current practice and new practice guidelines for primary sclerosing cholangitis

Poster Presentation

Presenter: Annika Bergquist

877

The association between cholestatic biochemical markers and clinical symptoms in patients with non-end-stage primary sclerosing cholangitis

Poster Presentation

Presenter: Tim Middelburg

888

Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome

Poster Presentation

Presenter: Gideon Hirschfield

893

Results of the prospective multicentre European R-LIVER registry reveal the unmet clinical needs of autoimmune hepatitis

Oral Presentation

Presenter: Ida Schregel

898

Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Poster Presentation

Presenter: Richard J. Thompson

903

Maralixibat leads to significant reductions in bilirubin for patients with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Oral Presentation

Presenter: Lorenzo D'Antiga

907

Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Poster Presentation

Presenter: Alexander Miethke

922

Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)

Oral Presentation

Presenter: Antonio De Vincentis

931

May symptom combinations at initial diagnosis of primary biliary cholangitis implicate distinct natural history?

Poster Presentation

Presenter: Atsumasa Komori

972

Change in serum bile acids correlates with improvement in itch in patients with primary biliary cholangitis receiving linerixibat

Poster Presentation

Presenter: Brandon Swift

1004

Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting

Poster Presentation

Presenter: Christophe Corpechot

1041

Increased risk of osteoporotic fracture in patients with autoimmune hepatitis

Poster Presentation

Presenter: Jihye Lim

1142

Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD)

Poster Presentation

Presenter: Richard Dean

1143

The changing clinical phenotype of autoimmune hepatitis across the millennium. A 40 year cohort study in Bologna, Italy

Poster Presentation

Presenter: Marco Ferronato

1189

Spleen stiffness measurement predicts decompensation risk in primary biliary cholangitis

Poster Presentation

Presenter: Giulia Francesca Manfredi



1210

Rechallenge with anti-PD1 monotherapy after checkpoint inhibitor hepatitis is associated with low rates of recurrence: a single centre study

Poster Presentation

Presenter: Lucy Walker

1284

The devastating impact of severe pruritus in primary biliary cholangitis

Poster Presentation

Presenter: Helen Smith

1344

Prognostic value of serum ALP levels during additional treatment in Japanese patients with primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate

Poster Presentation

Presenter: Akihito Takeuchi

1420

Transient elastography measurements of spleen stiffness are associated with treatment response to ursodeoxycholic acid in primary biliary cholangitis

Poster Presentation

Presenter: Ilkay Ergenc

1440

Associations between patient-reported outcomes, liver inflammation and fibrosis in patients with primary sclerosing cholangitis

Poster Presentation

Presenter: Emilie Eifer Møller

1484

Variation in maintenance therapy practices in a large U.S. cohort of patients with autoimmune hepatitis

Poster Presentation

Presenter: Therese Bittermann

1496

Non-adherence to standard pharmacotherapy in autoimmune hepatitis is associated with over-the-counter medication and steroid treatment. Results from the ERN online survey

Poster Presentation

Presenter: Ewa Wunsch

1505

Modulation of alkaline phosphatase levels by obeticholic acid in clinical trials and cultured human hepatocytes

Poster Presentation

Presenter: Kris Kowdley

1522

Risk of death, liver transplant or hepatic decompensation in primary biliary cholangitis increases with increased duration and degree beyond established clinical thresholds for hepatic biomarkers and fibrosis scores

Poster Presentation

Presenter: Kris Kowdley

1573

Accuracy of controlled attenuation parameter (CAP) measurement for the detection of steatosis in autoimmune liver diseases

Poster Presentation

Presenter: Silja Steinmann

1763

Clinicopathological features and prognosis of early primary biliary cholangitis with clinically significant portal hypertension

Poster Presentation

Presenter: Qi Zheng

1770

Non-invasive evaluation of progression to primary biliary cholangitis in patients with positive antimitochondrial antibodies

Poster Presentation

Presenter: ALVARO DIAZ GONZALEZ

1835

Predicting the current and future prevalence of primary sclerosing cholangitis with inflammatory bowel disease (PSC-IBD): a nationwide population-based study

Poster Presentation

Presenter: Palak Trivedi

1844

Risk of decompensated cirrhosis in patients with primary biliary cholangitis under first, second and third-line therapies

Poster Presentation

Presenter: Ana Lucena

1878

Clinical characteristics, hospitalization, and mortality outcomes of Coronavirus Disease 2019 in primary sclerosing cholangitis liver transplant patients

Poster Presentation

Presenter: Stela Celaj

1942

Impact of the metabolic profile on the response to ursodeoxycholic acid in patients with primary biliary cholangitis: results of the ColHai registry

Poster Presentation

Presenter: Andrea González Pascual

1946

Improved survival with regular surveillance imaging in patients with primary sclerosing cholangitis

Poster Presentation

Presenter: Natassia Tan

2003

Clinical, demographic, laboratory characteristics and disease progression of autoimmune hepatitis patients, asymptomatic at diagnosis, in a tertiary medical center in Israel

Poster Presentation

Presenter: Ehud Zigmond

2082

Dominant strictures in patients with primary sclerosing cholangitis: comparison between old and new definition

Poster Presentation

Presenter: Andrea Tenca

2136

Outcome and prognostic factors of primary biliary cholangitis in South Korea

Poster Presentation

Presenter: Kyung-ah kim

2158

Lack of biochemical response after diagnosis is associated with cirrhosis development during follow-up in autoimmune hepatitis

Oral Presentation

Presenter: Charlotte Slooter

2161

Mitochondrial dysfunction and lipid alterations in primary sclerosing cholangitis

Poster Presentation

Presenter: Mette Vesterhus

2190

Hepatic steatosis in patients with autoimmune hepatitis: relationship with corticosteroid treatment and long-term outcome

Poster Presentation

Presenter: Sarah Flatley

2237

Improving the diagnosis of primary biliary cholangitis through immunology protocols

Poster Presentation

Presenter: Mario de Bonis Encinosa

2256

Does fibrosis regression in autoimmune hepatitis require histological as well as biochemical remission?

Poster Presentation

Presenter: Sarah Flatley

2487

Prevalence and risk factors of osteoporosis in patients with primary biliary cholangitis in chinese population

Poster Presentation

Presenter: Jialiang Chen

2495

Results from a planned interim analysis of a randomized, double-blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis

Oral Presentation

Presenter: Frederik Nevens

2513

Chronic pruritus is associated with altered nerve fiber function and anatomy in patients with cholestatic hepatobiliary diseases

Poster Presentation

Presenter: Miriam Düll

2565

Seladelpar treatment resulted in correlated decreases in serum IL-31 and pruritus in patients with primary biliary cholangitis (PBC): post-hoc results from the phase 3 randomized, placebo-controlled ENHANCE study

Poster Presentation

Presenter: Andreas E Kremer

2577

Vitamin D associates with clinical outcomes in patients with primary sclerosing cholangitis

Poster Presentation

Presenter: Aldo J Montano-Loza

2611

The socioeconomic status, epidemiology, and outcomes of people living with primary sclerosing cholangitis - inflammatory bowel disease in Ontario, Canada: a two-decade analysis

Poster Presentation

Presenter: Kristel Leung

2636

Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study

Oral Presentation

Presenter: Francesca Terracciani

2653

Vibration-controlled transient elastography predicts clinical outcomes in patients with autoimmune hepatitis

Poster Presentation

Presenter: Aldo J Montano-Loza

2655

Symptom burden in people living with primary biliary cholangitis does not associate with transient elastography measures

Poster Presentation

Presenter: Inbal Hourii

2682

Burden, impact and variability of pruritus in primary sclerosing cholangitis (PSC) over time: a prospective observational study

Poster Presentation

Presenter: Nasir Hussain

3008

Relative enhancement and spleen volume predict clinical outcomes in primary sclerosing cholangitis

Poster Presentation

Presenter: Laura Cristoferi

3101

Collagen proportionate area is associated with adverse clinical outcomes and allows risk stratification of patients with autoimmune hepatitis

Poster Presentation

Presenter: Neil Halliday

3147

Prevalence of celiac disease in adult patients with cryptogenic liver disease

Poster Presentation

Presenter: Aditya Vikram Pachisia

3264

Drug-induced autoimmune hepatitis or drug-induced liver injury with autoimmune features: two faces of the same coin?

Poster Presentation

Presenter: Pinelopi Arvaniti

3317

To assess response to steroids and validate SURFASA score in Indian autoimmune hepatitis patients

Poster Presentation

Presenter: Harsh Gandhi

3320

The natural history and prognosis of primary sclerosing cholangitis: a multi-center, retrospective cohort study in China

Poster Presentation

Presenter: Xiong Ma

3327

Predictive models of treatment benefit in patients with autoimmune hepatitis and decompensated cirrhosis at diagnosis

Poster Presentation

Presenter: Pinelopi Arvaniti

3388

Elevated GGT levels as predictor of non-response to ursodeoxycholic acid in patients with primary biliary cholangitis

Poster Presentation

Presenter: Flor M Fernandez-Gordón Sánchez

3436

RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

Poster Presentation

Presenter: Ciro Celsa

3442

Variation in the presentation pattern of primary biliary cholangitis (PBC) in Spain according to the diagnostic period: data from the Spanish registry of cholestatic and autoimmune liver diseases (COLHAI)

Poster Presentation

Presenter: Sergio Rodriguez-Tajes

3489

Baseline characteristics and risk profiles of 1111 patients with primary biliary cholangitis (PBC) in need of second-line therapy

Poster Presentation

Presenter: Gideon Hirschfield

3510

Celiac disease in patients with autoimmune hepatitis is associated with a milder liver disease course and a better chance of immunosuppressive treatment withdrawal

Poster Presentation

Presenter: Francesco Pezzato

3589

Anti-Saccharomyces cerevisiae antibodies predict severe liver disease and advanced fibrosis in patients with primary sclerosing cholangitis and inflammatory bowel disease

Poster Presentation

Presenter: Lian Bannon

3656

Budesonide is associated with less weight gain than Prednisolone amongst patients with autoimmune hepatitis: results from long term follow-up in routine clinical care

Poster Presentation

Presenter: Josh Orpen-Palmer

3669

Unexpected high incidence of AMA positive primary biliary cholangitis in a northern Italian region

Poster Presentation

Presenter: Davide Bitetto

3795

Presence of metabolic associated liver disease in autoimmune hepatitis is associated with advanced liver fibrosis

Poster Presentation

Presenter: Alvaro Urzúa

3814

Health-related quality of life and medication adherence in adult patients after liver transplantation due to autoimmune hepatitis: a pilot, single centre study

Poster Presentation  
Presenter: Maciej K. Janik

## Immune-mediated and cholestatic: Experimental and pathophysiology

165  
Associations of fecal bile acids, diet, and intestinal microbes with markers of disease progression in primary sclerosing cholangitis disease  
Poster Presentation  
Presenter: Connie Chan

224  
Golexanolone, a GABA receptor-modulating steroid antagonist, improves peripheral inflammation, fatigue, locomotor gait, motor incoordination and short-term memory in rats with cholestasis and hepatic encephalopathy due to bile duct ligation  
Poster Presentation  
Presenter: Vicente Felipo

541  
Results of pharmacological treatment of Mcp1 knock-out mice which develop symptoms of primary biliary cholangitis  
Poster Presentation  
Presenter: Katarzyna Trzos

623  
Blockade of IL-18 via long-acting IL-18 binding protein attenuates experimental diet-induced cholestatic disease  
Poster Presentation  
Presenter: Dong-Hyun Kim

778  
The significance of patatin-like phospholipase domain-containing protein-3 I148M genetic variant in autoimmune hepatitis  
Poster Presentation  
Presenter: Nikolaos Gatselis

810  
HSD17B13 inhibitors are hepatoprotective and anti-inflammatory in a mouse model of autoimmune hepatitis  
Poster Presentation  
Presenter: Manuel Roqueta-Rivera

1080



A3907, a systemic ASBT inhibitor, improves cholestasis in mice by inhibiting multi-organ bile acid transport and shows translational relevance to human

Oral Presentation

Presenter: Francisco J. Caballero

1085

The cell cycle protein Cyclin E1 mediates pro-inflammatory signals in a mouse model of acute hepatitis and in primary macrophages

Poster Presentation

Presenter: Christian Penners

1112

Anti-nucleosome antibodies as an important marker to distinguish between autoimmune hepatitis and drug-induced liver injury

Poster Presentation

Presenter: Nasser Semmo

1151

Differential activation of regulatory CD4+ T cells via the JAK-STAT-pathway in Primary sclerosing cholangitis

Poster Presentation

Presenter: Leona Dold

1171

Non-invasive imaging method demonstrates anti-fibrotic efficacy of a dual integrin alpha-v/beta-6 and alpha-v/beta-1 inhibitor in a rat model of biliary fibrosis

Poster Presentation

Presenter: Johanna Schaub

1179

Bacteriophage therapy against pathological *Klebsiella pneumoniae* that determine the clinical course of primary sclerosing cholangitis

Poster Presentation

Presenter: Masataka Ichikawa

1267

The role of Type II and III Interferons in primary biliary cholangitis

Poster Presentation

Presenter: Yooyun Chung

1668

Cytotoxic activity of peripheral NK cells is decreased in primary sclerosing cholangitis

Poster Presentation

Presenter: Leona Dold

1879

Elevated JAG1-NOTCH Signaling is Associated with Fibrosis Stages in Patients with PSC

Poster Presentation

Presenter: Michael Trauner

1927

Pyroptosis plays a key role in primary biliary cholangitis of humans and mice

Poster Presentation

Presenter: Linxiang Huang

2001

Molecular signatures of treatment response in autoimmune hepatitis

Poster Presentation

Presenter: Bastian Engel

2044

Depletion of excess liver copper ameliorates liver damage in a mouse model of chronic cholestatic liver disease

Poster Presentation

Presenter: Dennis Koob

2048

Proteomics and metabolomics of bile reveal molecular insights and classify signatures predictive of carcinoma of gallbladder

Poster Presentation

Presenter: Nupur Sharma

2080

Loss of innate and adaptive effector lymphocytes is associated with diminished globe score prognosis in patients with primary biliary cholangitis

Poster Presentation

Presenter: Hussain Syed

2174

Cholestatic liver disease is alleviated by colitis-induced inhibition of bile acid synthesis

Poster Presentation

Presenter: Wenfang Gui

2178

Serum proteomics reveals association of CCL24 with key aspects of primary sclerosing cholangitis

Poster Presentation

Presenter: Raanan Greenman

2230

CD44 reduces fibrosis development in chronic cholestatic liver injury in Mdr2 knock-out mice

Poster Presentation

Presenter: Franziska Ihli

2419

Combination of intestinal bile salt uptake inhibition with pharmacological repression of bile salt synthesis improves liver health in cholestatic mice

Poster Presentation

Presenter: Stan van de Graaf

2504

The role of bile salts in cholestasis associated pruritus

Poster Presentation

Presenter: Frank Wolters

2579

scRNA transcriptomics reveal the role of cholangiocytes and neutrophils cross talk in PKHD1-KO mice

Poster Presentation

Presenter: Mario Strazzabosco

2590

Combination of Ileal bile acid transporter inhibitor and a non-steroidal Farnesoid X receptor agonist for reversal of cholestatic liver injury in Cyp2c70 KO mice with a humanized bile acid composition

Poster Presentation

Presenter: Caroline Klindt-Morgan

2697

Genetic predisposition for liver inflammation and response to anti-cholestatic therapy in experimental sclerosing cholangitis

Poster Presentation

Presenter: Alexander Miethke

2909

In vitro modulation of fibrogenesis and inflammation in patient-derived cholangiocyte organoids

Poster Presentation

Presenter: Anna Katharina Frank

2910

Spatial transcriptomics reveals shared gene and cellular composition in recurrent and primary sclerosing cholangitis

Poster Presentation

Presenter: Mikal Jacob Hole

2946

Temporal characteristics of cell compartments in immune-mediated cholestatic disease

Poster Presentation

Presenter: Markus Jördens

2995

Oxazolone-mediated bile duct inflammation reveals specific natural killer T cell-dependent inflammatory pathways

Poster Presentation

Presenter: Markus Jördens

2998

Development of an in vitro bile-duct-on-a-chip-platform using patient-derived cholangiocytes

Poster Presentation

Presenter: Anna Katharina Frank

3086

Production of reactive oxidant species and fatty acid uptake is increased in regulatory T-cells in autoimmune hepatitis, and associated with down-regulation of markers linked to suppressor function

Poster Presentation

Presenter: Scott Davies

3098

Phenotypic diversity and regeneration in a model of Alagille syndrome recapitulate patient heterogeneity

Poster Presentation

Presenter: Linde Sevenants

3154

The effect of the combination of metformin with propionic acid on the indicators of oxidative stress in liver tissue of rats with type 2 diabetes mellitus

Poster Presentation

Presenter: Olena Khokhliuk

3242

Laminin 511-E8 is an autoantigen in IgG4-related cholangitis patients that protects cholangiocytes against T lymphocyte-induced epithelial barrier dysfunction

Oral Presentation

Presenter: David Trampert

3318

Identification of potential targets amenable to novel therapeutics to treat symptoms in primary biliary cholangitis

Poster Presentation

Presenter: Aaron Wetten

3493

Cholestatic liver disease enhances sociability and leads to significant adaptative changes in amygdala neural circuits regulating social behavior in mice

Poster Presentation

Presenter: Wagdi Almishri

## Liver development and regeneration

367

Autologous skeletal myoblast cell-sheet transplantation for liver regeneration

Poster Presentation

Presenter: Keisuke Toya

463

Excessive proliferation after extended hepatectomy compromises liver function in mice

Poster Presentation

Presenter: Maxime De Rudder

629

Insights into DNA damage in regenerating young and aged mice livers

Poster Presentation

Presenter: Ainhoa Asensio Aldave

666

Autophagy regulates the generation and differentiation of chemically derived hepatic progenitors (CdHs)

Poster Presentation

Presenter: Hayoon Kim

862

IGF1 specifically rescues peripheral intrahepatic biliary organoids from a mouse model of Alagille syndrome

Poster Presentation

Presenter: Afshan Iqbal

987

Conditioned medium from human allogeneic liver-derived progenitor cells protects against LPS-induced endothelial hyperpermeability via shingosine-1 phosphate

Poster Presentation  
Presenter: Mustapha Najimi

1114  
Liver innervation is dysregulated in a mouse model of Alagille syndrome  
Poster Presentation  
Presenter: Elisabeth Verboven

1220  
Endothelial autophagy is not required for liver regeneration after partial hepatectomy in mice with fatty liver  
Poster Presentation  
Presenter: Adel HAMMOUTENE

1298  
Liver regeneration is regulated by intestinal sirtuin-1  
Poster Presentation  
Presenter: Sian Seaman

1304  
The silencing of Sox9 impairs ductular reaction expansion while enhancing the differentiation of DR cells into hepatocytes  
Oral Presentation  
Presenter: Arthur de Schaetzen

1354  
Hepatic progenitor cell activation through the interaction of mesenchymal stem cells and liver sinusoidal endothelial cells  
Poster Presentation  
Presenter: Su jung Park

1375  
Development of intrahepatic bile ducts during liver progenitor cell-driven liver regeneration is associated with epithelial cell adhesion molecule function  
Poster Presentation  
Presenter: Eun Young Cho

1711  
Transcriptomics confirm the establishment of a liver-immune dual-humanized mouse model after transplantation of a single type of human bone marrow mesenchymal stem cell  
Poster Presentation  
Presenter: Jun Li

1873

Neutrophils promote chronic liver injury resolution

Oral Presentation

Presenter: Silvia Ariño

2090

Lineage tracing of hepatic stellate cells with ultrasound-guided in utero nano-injection

Poster Presentation

Presenter: Jingyan He

2116

Role of GATA4 in the modulation of hepatic progenitor cell fate

Poster Presentation

Presenter: Laura Villamayor

2392

Tunable host senescence determines the success of hepatocyte transplantation in a mouse model of liver injury

Poster Presentation

Presenter: Victoria Gadd

2951

Hepatic nerve endings are rewired by cholestatic injury to connect inflamed lymphatics to sites of ductular remodelling

Oral Presentation

Presenter: Luke Noon

3228

Skin-decellularized matrix-derived microgels accelerate 3D cultures of functional primary hepatocyte spheroids in vitro

Poster Presentation

Presenter: Ashwini Vasudevan

3496

A novel organoid model of human liver bud development

Poster Presentation

Presenter: Charlotte Grey-Wilson

3760

Rescue mechanism of hHIL-6 after partial hepatectomy

Poster Presentation

Presenter: Julia Ettich

## Liver immunology

93

RIPK3-mediated XBP1-Foxo1 axis controls NOD1 function and Calcineurin/TRPM7-induced cell death in liver inflammatory injury

Poster Presentation

Presenter: Bibo Ke

537

Intermediate monocytes and associated chemokines allow differentiation of idiosyncratic drug-induced liver injury (DILI) and autoimmune hepatitis (AIH)

Poster Presentation

Presenter: Stuart Astbury

625

Immune characterization of the melanocortin-4-receptor mouse model for non-alcoholic steatohepatitis using mass cytometry and imaging mass cytometry

Poster Presentation

Presenter: Fabienne Birrer

964

Kupffer cell activation enhances systemic anti-bacterial immunity

Poster Presentation

Presenter: Christian Zwicker

1035

Comprehensive phenotypical and molecular characterization of B lymphocytes in patients affected by intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Giulia Milardi

1135

Interplay between hepatitis B virus replication and intrahepatic expression of VISTA and TIM-3 immune checkpoint markers in chronic hepatitis B patients

Oral Presentation

Presenter: Marianne Tuefferd

1362

Characterisation of invariant natural killer T cells in human hepatic biopsies

Poster Presentation

Presenter: Elena Jiménez-Martí

1391

Mast cell activation index as a novel prognostic marker in a pan-analysis of gastrointestinal cancers



Poster Presentation

Presenter: Nataliya Rohr-Udilova

1476

The ascitic environment in cirrhosis upregulates the expression of the immune checkpoint CD155 on peritoneal macrophages

Poster Presentation

Presenter: Joseph Delo

1959

The Nij1/Dusp1 axis contributes to liver ischemia reperfusion injury by regulating macrophage activation and neutrophil infiltration

Poster Presentation

Presenter: Yuanchang Hu

2062

The effect of testosterone on human T cells in health and autoimmune liver disease

Poster Presentation

Presenter: Lara Henze

2085

TIGIT inhibits the cytotoxic effects of NK cells towards biliary epithelial cells in autoimmune hepatitis

Poster Presentation

Presenter: Amber Bozward

2105

ILT2 as a biomarker of impaired natural killer cells expressing excess lipid peroxidation in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Toshihiro Sakata

2112

Developing highly pure, functional GMP grade Treg for the treatment of autoimmune liver disease

Poster Presentation

Presenter: Naomi Richardson

2159

Osteopontin serves as a potential regulator of T cell immunity in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Tengfei Si

2280

Selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity to Hepatitis B Virus (HBV)

Oral Presentation

Presenter: Matteo Iannacone

2335

Liver immunity index: circulating HBV-specific CXCR6+ CD8 T cells mirror intrahepatic anti-viral T cell immunity and predict immune control in models of chronic hepatitis B

Oral Presentation

Presenter: Hannah Wintersteller

2423

Distinct immunometabolic signatures in circulating immune cells define disease outcomes in acute-on-chronic liver failure

Poster Presentation

Presenter: Rita Furtado Feio de Azevedo

2425

Phenotypical and functional sub-classification of Kupffer cells and liver monocyte-derived macrophages in mice

Poster Presentation

Presenter: Hiroyuki Nakashima

2529

CXCL9 does not ameliorate murine macrophage activation syndrome hepatitis

Poster Presentation

Presenter: Tamir Diamond

2717

Single-cell atlas of liver myeloid cells with cure of chronic viral hepatitis

Oral Presentation

Presenter: Ang Cui

2755

2D-interactome of the tumor immune-microenvironment reveals immunosuppressive T cells in primary sclerosing cholangitis-associated cholangiocarcinoma

Oral Presentation

Presenter: Jenny Krause

2827

AAV-HBV mouse model replicates immune exhaustion patterns of chronic HBV patients at single-cell level

Poster Presentation

Presenter: Ren Zhu

3104

Liver-on-chip platform for studying recruitment and differentiation of circulating monocytes

Oral Presentation

Presenter: Aleksandra Aizenshtadt

3127

The decrease of HCV-specific neutralizing antibody responses after DAA therapy is associated with weak envelope-specific CD4 T cell immunity

Poster Presentation

Presenter: Jill Werner

3199

“Swarm hunting” of virus-specific CD8 T cells together with auto-aggressive CD8 T cells to achieve efficient killing of virus-infected hepatocytes

Poster Presentation

Presenter: Ariane Eceiza Tenreiro

3212

Rheostat function of liver sinusoidal endothelial cells and macrophages limiting antiviral CD8 T cell immunity in the liver

Poster Presentation

Presenter: Anna Fürst

3312

Liver sinusoidal scavenger cells eliminate betaherpesvirus from the blood stream

Poster Presentation

Presenter: Anett Kristin Larsen

3667

Metabolic landscape of intrahepatic regulatory T cells in health and disease

Poster Presentation

Presenter: Elena Perpnan

3781

Epigenetic conversion of CD4+ T cells to stable and functioning induced regulatory T cells via cyclin-dependent kinase inhibition and CD28 signal deprivation in patients with primary biliary cholangitis

Poster Presentation

Presenter: Vincenzo Ronca

[Liver transplantation and hepatobiliary surgery](#)

139

Access to liver transplant for women in Spain: a national registry analysis

Poster Presentation

Presenter: Marta Tejedor Bravo

140

Validation of MELD3.0 in two centres from different continents

Poster Presentation

Presenter: Marta Tejedor Bravo

161

Primary sclerosing cholangitis as an indication for liver transplantation. Results and conditioning factors: relationship with associated intestinal pathology"

Poster Presentation

Presenter: Ainhoa Fernandez

208

Defective efferocytosis by aged macrophages promotes STING signaling mediated inflammatory liver injury

Poster Presentation

Presenter: Haoran Hu

209

Risk factors associated with surgical morbidities of laparoscopic living liver donors

Poster Presentation

Presenter: Jinsoo Rhu

210

Pre-transplant mycophenolate mofetil may be associated with reduced intrahepatic cholangiopathy in ABO-incompatible liver transplantation

Poster Presentation

Presenter: Jinsoo Rhu

343

A multi-center, stratification-randomized, double-blind, placebo-controlled, phase III clinical trial of topical recombinant human thrombin for intraoperative hemostasis

Oral Presentation

Presenter: Jun Yu

352

Liver transplant recipients with autoimmune hepatitis in the Swiss transplant cohort study have a higher risk of graft loss and vascular complications

Poster Presentation

Presenter: Aurélie Rosat

374

In vitro model of liver ischemia/reperfusion injury identifies iRhom2 as new target of disease

Poster Presentation

Presenter: Giovanni Zito

377

Use and outcomes of hepatitis B virus positive grafts for renal or heart transplantation in the US (1999-2021)

Poster Presentation

Presenter: Ashwani Singal

481

Increased left ventricular dimensions are the new risk factor for acute kidney injury after living donor liver transplantation (cardio-renal interaction)

Poster Presentation

Presenter: Dheepak V

694

Outcomes in patients with new-onset atrial fibrillation after liver transplantation using the national readmission database

Poster Presentation

Presenter: Induja Nimma

732

Long-term survival after liver transplantation in patients with common variable immunodeficiency

Poster Presentation

Presenter: Ina Andersen

750

The growing prevalence and impact of type 2 diabetes among liver transplant candidates in the United States

Poster Presentation

Presenter: Zobair Younossi

906

The influence of immunosuppression and recipient geography on non-melanoma skin cancer risk after liver transplantation

Poster Presentation

Presenter: Therese Bittermann

911

Incidence and risk factors for de-novo NAFLD after liver transplantation: real-world data

Poster Presentation

Presenter: Katharina Luise Hupa-Breier

989

Clinical impact and treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after liver transplant (LT): the role of transjugular intrahepatic porto-systemic shunt (TIPS)

Poster Presentation

Presenter: Michela Triolo

999

Comorbidities and complications of patients hospitalized for liver transplantation evaluation, transplant and post-LT: a fourteen-year nationwide study in Germany

Poster Presentation

Presenter: Wenyi Gu

1019

The impact of statin utilization on mortality in liver transplant recipients independent of underlying cardiovascular risk

Poster Presentation

Presenter: Megan Ghai

1129

Donor outcomes incidence after living-donor liver transplantation: meta-analysis and systematic review

Poster Presentation

Presenter: Mark Muthiah

1147

Deep learning prediction modeling of major adverse cardiovascular events following liver transplantation

Poster Presentation

Presenter: Cui Tao

1207

Liver transplantation as treatment option for cholangiocellular carcinoma

Poster Presentation

Presenter: Gabriela Berlakovich

1259

C105SR, a novel non-peptidic small-molecule cyclophilin inhibitor with potent mitoprotective and hepatoprotective properties in the context of hepatic ischemia/reperfusion injury

Poster Presentation

Presenter: Fatima TEIXEIRA-CLERC

1360

The evolution of the muscle compartment from the listing to six-month post-transplantation: a longitudinal monocentric study

Poster Presentation

Presenter: Delorme Alicia

1365

Neoadjuvant PD-1 blockade with Pembrolizumab combined with Lenvatinib therapy in patients with hepatocellular carcinoma beyond Milan criteria before liver transplantation (PLENTY): a single-site pilot randomized controlled trial

Poster Presentation

Presenter: Hao Feng

1455

Polycystic disease: a cumbersome benign indication for transplantation

Poster Presentation

Presenter: Alberto Calleri

1464

Type of calcineurin inhibitor versus long-term outcome following liver transplantation for primary biliary cholangitis – an ELTR study

Oral Presentation

Presenter: Maria van Hooff

1480

Two-year follow-up of liver grafts from COVID-19 donors

Poster Presentation

Presenter: Margherita Saracco

1631

Body composition and MAFLD are associated with prognosis after resection of intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Isabella Lurje

1634

Prevalence of renal dysfunction is higher in patients that receive a liver transplant for non-alcoholic steatohepatitis

Poster Presentation

Presenter: Rubén Sánchez-Aldehuelo

1642

Assessment of silent coronary artery disease with functional and anatomic tests in liver transplantation: analysis of the diagnostic and prognostic capacity of a risk-adapted protocol  
Poster Presentation  
Presenter: Giulia Pagano

1778

Perfusate composition of transplanted and not transplanted livers during normothermic machine perfusion  
Poster Presentation  
Presenter: Jule Dingfelder

1805

Sex-based differences and comparative predictive value of MELD 3.0 in simultaneous liver-kidney transplantation waitlist outcomes after standardization of listing criteria in the United States  
Poster Presentation  
Presenter: Emily Leven

1813

Safety of coronary angiography with consecutive dual antiplatelet therapy in patients with liver cirrhosis and esophageal varices as part of an evaluation for liver transplantation  
Poster Presentation  
Presenter: Moritz Passenberg

1900

Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on post-liver transplant mortality and major adverse cardiovascular events  
Poster Presentation  
Presenter: Kelli Kosako Yost

1972

Application of human chemically-derived hepatic progenitors organoids (hCdHO) in regenerative medicine, hepatotoxic and disease modeling  
Poster Presentation  
Presenter: Elsy Soraya Salas Silva

1977

Liver transplantation in patients with cystic fibrosis: 30 years of experience in Australia and New Zealand  
Poster Presentation  
Presenter: Thomas Wilson

2045

Evaluation of a delayed liver transplant strategy for patients listed for hepatocellular carcinoma treated with resection or thermo-ablation as a bridge to liver transplantation; the DELTAS-HCC study



Poster Presentation  
Presenter: Catherine Lamarque

2197  
Quantification of remnant liver ischaemia after hepatectomy for hepatocellular carcinoma (HCC) using advanced 3D software analysis and its impact on disease recurrence  
Poster Presentation  
Presenter: ACIDI Belkacem

2238  
Long-term outcome following liver transplantation for chronic liver disease in intensive care unit: the French nationwide experience  
Poster Presentation  
Presenter: Magdalena Meszaros

2251  
Graft steatosis and donor diabetes mellitus additively increase the risk of retransplantation and death in adult liver transplantation - data from the Eurotransplant registry  
Poster Presentation  
Presenter: Milan Sonneveld

2367  
Primary sclerosing cholangitis recurrence after liver transplantation: a nationwide survey in Italy  
Poster Presentation  
Presenter: Maria Cristina Morelli

2506  
Coronary computed tomography angiography in pre-liver transplant cardiac work-up  
Poster Presentation  
Presenter: Chiara Manuli

2691  
Safety and efficacy of glucagon-like peptide-1 receptor agonists and sodium- glucose co-transporter-2 inhibitors compared with the standard of care in a cohort of liver transplanted patients: a retrospective study  
Poster Presentation  
Presenter: Aida Rebiha

2849  
Long-term outcomes following donation after cardiac death (DCD) liver transplantation in primary sclerosing cholangitis (PSC)  
Poster Presentation  
Presenter: Arul Suthanathan

2854

De novo cancers after liver transplantation: a French nationwide cohort

Poster Presentation

Presenter: Ilias Kounis

2855

Cytomegalovirus reactivation is associated with lower hepatocellular carcinoma recurrence rates after liver transplantation

Poster Presentation

Presenter: Victoria Aguilera Sancho

3102

Long-term benefit of mTOR inhibitors for dropping calcineurin inhibitors in liver transplant recipients

Poster Presentation

Presenter: Yael Milgrom

3162

Development of metabolic disorders in transplant recipients

Poster Presentation

Presenter: GİZEM ERDEMİR

3190

CMV reactivation after liver transplantation (LT) in HIV infected is similar to non-HIV patients: a single center comparative study

Poster Presentation

Presenter: Sonia García-García

3200

Statins and metformin after liver transplantation: a nationwide cohort

Poster Presentation

Presenter: Cyrille Feray

3209

Incidence of de novo tumors after liver transplantation (LT) in HIV infected is similar to non-HIV patients: a single center comparative study

Poster Presentation

Presenter: Isabel Terol Cháfer

3237

Sarcopenia at listing for liver transplantation is a negative predictor for post-transplant survival, but not for graft survival

Poster Presentation

Presenter: Guido Stirnimann

3277

Influence of marginal organs on the drug metabolism in liver transplantation

Poster Presentation

Presenter: Laura Bütow

3301

Liver Transplantation outcomes in patients following COVID-19 infection

Poster Presentation

Presenter: Dinesh Jothimani

3319

Prehabilitation intervention to maximize early recovery (PRIMER) in liver transplantation: a randomized, controlled trial

Oral Presentation

Presenter: Marina Serper

3410

Comparing clinical outcomes of robot-assisted versus open hepatectomy for liver cancer: a systematic review and meta-analysis

Poster Presentation

Presenter: Muhammed Elfaituri

3447

APRI+ALBI score is superior to Indocyanine Green (ICG) clearance and LiMAx test in the prediction of posthepatectomy liver failure – an international multicenter study of 14581 patients

Oral Presentation

Presenter: Jonas Santol

3449

Endothelial glycocalyx damage marker Syndecan-1 measured during hypothermic oxygenated machine perfusion can predict early allograft dysfunction after liver transplantation

Poster Presentation

Presenter: Laurin Rauter

3530

Liver transplantation in patients with schistosomiasis in a reference hospital in Sao Paulo, Brazil

Poster Presentation

Presenter: Martina Zannini

3557

Liver transplantation for alcohol-related-liver disease in the era of acute on chronic liver failure-single center experience

Poster Presentation

Presenter: Dinesh Jothimani

3606

Porto-pulmonary hypertension in patients considered for liver transplantation: a cohort study

Poster Presentation

Presenter: Declan Lewis

3632

The GALAD score allows early detection of recurrent hepatocellular carcinoma after orthotopic liver transplantation

Poster Presentation

Presenter: Magdalena Hahn

3685

Biliary strictures in liver transplant recipients: novel strategies for identifying therapeutic targets of biliary fibrosis

Poster Presentation

Presenter: Alex Bofill

3691

Tailored immunosuppression with LCPT extended release Tacrolimus based on NFAT-regulated gene expression

Poster Presentation

Presenter: Judith Kahn

3708

Inequity in access to liver transplantation for critically ill patients with cirrhosis across U.S. transplant centers

Poster Presentation

Presenter: Thierry Artzner

3732

HBV re-infection or de-novo infection in the course of liver transplantation in patients chronically infected with HBV, HBV/HDV, or HCV

Poster Presentation

Presenter: Daniele Lombardo

3751

Use of von Willebrand factor antigen for surgical decision making in patients with hepatocellular carcinoma

Poster Presentation

Presenter: David Pereyra

3758

MicroRNA based prediction of posthepatectomy liver failure and mortality outperforms established markers of preoperative risk assessment

Oral Presentation

Presenter: Anna Kern

3762

Which is the best therapy for not transplantable patients with multinodular early HCC?

Poster Presentation

Presenter: Alessandro Vitale

3789

Management in hepatology: cost analysis of two opposite options for pretransplantation evaluation

Poster Presentation

Presenter: Gloria Sánchez Antolín

3794

Association between waiting time and post-transplant survival in recipients with hepatocellular carcinoma outside Milan criteria after downstaging with locoregional therapy

Poster Presentation

Presenter: Zoljargal Lkhagvajav

3821

Reassessing BCLC stage at transplant to predict risk of mortality and HCC recurrence in HCC liver transplant recipients

Poster Presentation

Presenter: George Cholankeril

3823

Post reperfusion syndrome in liver transplant after normothermic perfusion: experience of a reference center

Poster Presentation

Presenter: Luciano Beltrão Pereira

## Liver tumours: Clinical aspects except therapy

35

Targeted surveillance for hepatocellular carcinoma is cost effective in Australia: evidence from a microsimulation study

Poster Presentation

Presenter: Barbara de Graaff

102

Association of physical activity with risk of hepatocellular carcinoma among patients with diabetes: a nationwide cohort study

Oral Presentation

Presenter: Mi Na Kim

126

Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and MR imaging

Poster Presentation

Presenter: Dong Ho Lee

181

A radiogenomics study for hepatocellular carcinoma: distinct transcriptome patterns underlying different radiomics phenotypes in early recurrence

Poster Presentation

Presenter: Weijia Liao

280

Gadoxetic acid-enhanced MRI-based risk scoring system development and validation for the recurrence-free survival of a single hepatocellular carcinoma after curative surgery

Poster Presentation

Presenter: Bohyun Kim

417

Exploration of the lack of systematic surveillance for hepatocellular carcinoma for patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Theresa Hydes

571

Exploration of a holistic management procedure for liver cancer surveillance to improve the early diagnosis of liver cancer in Chinese population

Poster Presentation

Presenter: Yong Li

619

Trajectories of body composition in hepatocellular carcinoma treated with immunotherapy (chance 2215): a longitudinal, multicenter, cohort study

Poster Presentation

Presenter: Zhi-Cheng Jin

697

Multi-omic large scale risk prediction for hepatocellular carcinoma

Poster Presentation  
Presenter: Jan Clusmann

827  
Survival outcomes of patients with non-alcoholic fatty liver disease-related HCC: a retrospective cohort study  
Poster Presentation  
Presenter: Anders Mellekjær

844  
Transversal psoas muscle thickness measurement is associated with response and survival in patients with hepatocellular carcinoma undergoing immunotherapy  
Poster Presentation  
Presenter: Bernhard Scheiner

1011  
Predictors of extrahepatic recurrence after transarterial chemoembolization as first-line therapy for hepatocellular carcinoma  
Poster Presentation  
Presenter: Elisa Pinto

1025  
A machine learning enabled score based on large varices predicts 5- and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with compensated advanced chronic liver disease  
Poster Presentation  
Presenter: Sara Ascari

1056  
It takes a team for HCC: improvement of outcome with the multidisciplinary ambulatory for systemic therapy  
Poster Presentation  
Presenter: Andrea Dalbeni

1068  
Comparison of clinical manifestations and outcomes between non-viral-related and viral hepatitis-related hepatocellular carcinoma  
Poster Presentation  
Presenter: Sih-Han Liao

1081  
Developing an aptamer biomarker model for the diagnosis of hepatocellular carcinoma  
Poster Presentation  
Presenter: Mikkel Breinholt Kjær

1108

Validation of the CRAFTY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab

Poster Presentation

Presenter: Bernhard Scheiner

1124

Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm

Oral Presentation

Presenter: Wenyi Gu

1131

Prognostic value of simple non-invasive tests for the risk stratification of HCC development in patients with cirrhosis due to non-alcoholic fatty liver disease

Poster Presentation

Presenter: Amina Abdulle

1145

Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the french prospective chief cohort

Oral Presentation

Presenter: Eric Nguyen Khac

1148

Phenotypic characteristics of primary liver cancer in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study

Poster Presentation

Presenter: Alina Pascale

1153

Abbreviated magnetic resonance imaging for secondary surveillance of recurrent hepatocellular carcinoma after curative treatment

Poster Presentation

Presenter: Sun Kyung Jeon

1350

Glycemic control as a modifiable and independent risk factor for the development of liver, biliary tract and pancreatic cancer: a territory-wide study of 273,421 patients with diabetes mellitus

Oral Presentation

Presenter: Xianhua Mao



1441

Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: a nationwide cohort study

Poster Presentation

Presenter: Hae Lim Lee

1498

Presence of esophageal varices regardless their size is associated with overall survival in patients with advanced HCC treated with Atezolizumab/Bevacizumab

Poster Presentation

Presenter: Philippe Sultanik

1502

Multidimensional genomic analysis of cell-free DNA for early detection of hepatocellular carcinoma

Poster Presentation

Presenter: Ju Dong Yang

1557

A prospective multicenter study to examine the impact of acquired and genetic predictors on Hepatocellular carcinoma risk in patients with advanced NAFLD: first report

Poster Presentation

Presenter: Serena Pelusi

1665

The apparent diffusion coefficient values predict prognosis and Ki67 expression in intrahepatic cholangiocarcinoma on diffusion-weighted magnetic resonance imaging

Poster Presentation

Presenter: Daiki Hokkoku

1710

Alternative surveillance using CT/MR improves clinical outcomes by detecting early-stage hepatocellular carcinoma in High-risk patients with chronic hepatitis B

Poster Presentation

Presenter: Dong Ho Lee

1751

Similar recurrence after curative treatment of HBV-related HCC regardless of HBV replication activity

Poster Presentation

Presenter: Mi Na Kim

1753

Liver Frailty Index is associated with progression-free survival in patients with advanced HCC treated with Atezolizumab/Bevacizumab

Poster Presentation

Presenter: Philippe Sultanik

1779

Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a novel diagnostic biomarker for cholangiocarcinoma without underlying PSC

Poster Presentation

Presenter: Marcin Krawczyk

1793

Associations of pathologic features with integrated genomic and clinical characteristics of cholangiocarcinoma

Poster Presentation

Presenter: Keun Soo Ahn

1861

Impact of obesity on outcome of hepatocellular carcinoma in an Asian cohort: when should we consider obesity treatment?

Poster Presentation

Presenter: Wei-Lun Liou

1862

Characterization of the imaging signature of hepatocellular carcinoma with enhancement pattern mapping

Poster Presentation

Presenter: Newsha Nikzad

1871

Macrotrabecular-massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocellular carcinoma treated with liver resection

Poster Presentation

Presenter: Ezequiel Mauro

2035

Characterization and burden of non-hepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis

Oral Presentation

Presenter: Pierre Nahon

2274

Implication of patients experience in the liver cancer multidisciplinary approach

Poster Presentation

Presenter: Gemma Iserte

2303

Management of varices but not anticoagulation is associated with improved outcome in patients with hepatocellular carcinoma and macrovascular tumour invasion

Poster Presentation

Presenter: Lorenz Balcar

2331

A new biomarker panel for differential diagnosis of cholangiocarcinoma: results from an exploratory analysis

Poster Presentation

Presenter: Magdalena Swiatek-de Lange

2357

A novel AFP-M2BPGi score has better performance than CRAFTY score in predicting survival for patients with viral hepatocellular carcinoma undergoing immunotherapy

Poster Presentation

Presenter: Pei-Chang Lee

2369

Development, clinical validation and implementation of a novel algorithmic score (GAAD) for the detection of early-stage hepatocellular carcinoma

Poster Presentation

Presenter: Thomas Berg

2609

Sex disparities in presentation and outcome of hepatocellular carcinoma: results of a nationwide study in France

Poster Presentation

Presenter: Charlotte Costentin

2619

GALAD score outperforms aMAP and ALBI scores in the 5- and 10-year prediction of hepatocellular carcinoma (HCC) development in patients with compensated advanced chronic liver disease (cACLD): a 12-year prospective study

Poster Presentation

Presenter: Valentina Baldaccini

2632

CRAFTY score is associated with overall survival in patients with hepatocellular carcinoma treated with transarterial chemoembolisation

Poster Presentation

Presenter: Rhea Veelken

2656

Weakly supervised intrahepatic tumour classification from routine tumour biopsy: a proof of concept

Oral Presentation

Presenter: Beaufrère Aurélie

2661

Collagen proportionate area (CPA) measurement of liver parenchyma and hepatocellular carcinoma (HCC) can predict HCC recurrence after liver resection

Poster Presentation

Presenter: Chiara Sicuro

2730

Artificial intelligence assisted qFibrosis as a pathological “biomarker” to evaluate disease severity in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Kai-Wen Huang

2787

Deep learning-based model in pre-operative computed tomography for prediction of hepatocellular carcinoma recurrence after curative surgery

Poster Presentation

Presenter: Rex Wan-Hin Hui

2811

The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status: a nationwide population-based study

Poster Presentation

Presenter: Su Jong Yu

2848

Addition of des-gamma-carboxy prothrombin to standard of care is effective for HCC surveillance among high-risk patients

Poster Presentation

Presenter: Grishma Hirode

2918

Baveno VI and VII criteria are not suitable for screening of large size esophageal varices and clinically significant portal hypertension in patients with HCC

Poster Presentation

Presenter: Manon Allaire

3035

Cryptogenic non-cirrhotic HCC: clinical, prognostic and immunologic aspects of an emerging HCC etiology

Poster Presentation  
Presenter: Boris Beudeker

3167  
The Kupffer phase of Sonazoid-enhanced ultrasound as the major imaging feature for diagnosing hepatocellular carcinoma in at-risk individuals  
Poster Presentation  
Presenter: Hyo-Jin Kang

3186  
The efficacy of direct-acting antivirals for chronic hepatitis C in patients with the active oncological disease  
Poster Presentation  
Presenter: Jerzy Jaroszewicz

3215  
Natural history and management of recurrent hepatocellular carcinoma after liver transplantation: a multicenter nationwide study  
Oral Presentation  
Presenter: Massih Ningarhari

3246  
Validation of serum biomarker panels for early HCC detection: results from a large prospective European and Latin American multicenter study  
Poster Presentation  
Presenter: Boris Beudeker

3248  
Add-on benefits of AFP-L3, PIVKA-II and GALAD score to ultrasound plus AFP for surveillance of hepatocellular carcinoma  
Poster Presentation  
Presenter: Supot Nimanong

3265  
Chemerin protein in hepatocellular carcinomas is related to disease severity in European patients  
Poster Presentation  
Presenter: Christa Büchler

3299  
Initial treatment response and short-term mortality of spontaneous bacterial peritonitis in cirrhotic patients with hepatocellular carcinoma  
Poster Presentation  
Presenter: Chang Hun Lee

3587

Combined hepatocellular-cholangiocarcinoma : epidemiological, radiological and survival data from a retrospective single-center study

Poster Presentation

Presenter: Guillaume HENIN

3678

Effect of different radiologic modalities for surveillance of hepatocellular carcinoma on survival of high risk cirrhotic patients

Poster Presentation

Presenter: Ahmed El Sabagh

3707

Predicting cardiovascular risk in patients with HCC receiving tyrosine kinase inhibitors: comparison of two different scores

Poster Presentation

Presenter: Bernardo Stefanini

3716

Baseline cirrhosis in addition to the aMAP score, increased the risk of developing hepatocellular carcinoma in patients with hepatitis B

Poster Presentation

Presenter: Supakorn Chaiwiriawong

3785

Aetiology and outcomes of cirrhosis and hepatocellular carcinoma in Blantyre, Malawi

Poster Presentation

Presenter: Alexander Stockdale

3816

Liver function is a predictor of survival in patients with hepatocellular carcinoma in best supportive care

Poster Presentation

Presenter: Martina Rosi

## Liver tumours: Experimental and pathophysiology

90

Relevance of hypoxia-inducible factor 1 alpha in hepatocellular carcinoma: clinical and pre-clinical analysis

Poster Presentation

Presenter: Tania Payo-Serafin

91

MAP17 promotes an epithelial-mesenchymal-amoeboid transition in hepatocellular carcinoma by switching one-carbon metabolism

Poster Presentation

Presenter: Claudia Gil-Pitarch

94

Investigation of optimization model for predicting ICI treatment efficacy on contrast-enhanced CT images of hepatocellular carcinoma using AI

Poster Presentation

Presenter: yasuhiko nakao

156

Potential biomarkers predicting ferroptosis sensitivity in hepatocellular carcinoma

Poster Presentation

Presenter: Wan Seob Shim

163

Antitumoral activity of the G9a inhibitor EZM8266 in hepatocellular carcinoma: potential for combination with immune checkpoint inhibitors

Poster Presentation

Presenter: Maite G Fernandez-Barrena

243

Therapeutic targets associated with conserved subtypes of hepatocellular carcinoma

Poster Presentation

Presenter: Ju-Seog Lee

300

In vivo cancer-associated fibroblast specific gene silencing for anti-stromal therapy in primary liver cancer using novel siRNA loaded polypeptide nanoparticles

Oral Presentation

Presenter: Paul Schneider

376

Metabolic rewiring by increased mitochondrial respiration drives immunosuppression in liver cancer

Poster Presentation

Presenter: Naroa Goikoetxea

438

Ductular reaction is mediated by CD24 and regulated by miR-122

Poster Presentation

Presenter: Nofar Rosenberg

496

Sortilin-driven cancer secretome enhances self-renewal and metastasis of hepatocellular carcinoma via de novo lipogenesis

Poster Presentation

Presenter: Kwan Shuen Chan

502

RBCK1 promotes cancer stemness and sorafenib resistance by restoring Numb/Notch1 axis independently of its ubiquitin ligase activity in hepatocellular carcinoma

Poster Presentation

Presenter: Peng Chen

529

Myeloid IL-8 enrichment associates with immunotherapy resistance in advanced hepatocellular carcinoma

Oral Presentation

Presenter: Tsz Tung Kwong

646

Drug screening for hepatocellular carcinoma: automating and miniaturizing organoid assays for drug screening

Poster Presentation

Presenter: Tijmen Booi

733

Positive effects of PARP-1 inhibition in KRAS-mutated intrahepatic cholangiocarcinoma is mediated by CHK1 kinase

Poster Presentation

Presenter: Darko Castven

757

Multiplatform single cell spatial dissection of the invasive front of hepatocellular carcinoma (HCC) reveals molecular insights into tumor progression

Oral Presentation

Presenter: Josephine Zhang

820

Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma

Poster Presentation

Presenter: Paula Olaizola

832



Investigation of novel hepatoblastoma chemosensitizers based on the inhibition of ABC pumps-mediated drug efflux

Poster Presentation

Presenter: Rocio IR Macias

835

Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma

Oral Presentation

Presenter: Aloña Agirre Lizaso

941

Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

Poster Presentation

Presenter: Alex Claveria-Cabello

944

Hepatitis B surface antigen impairs endoplasmic reticulum stress-related autophagic flux via down-regulation of LAMP2, thereby participating in hepatocarcinogenesis

Poster Presentation

Presenter: Ruth Broering

946

Nuclear translocation of YAP drives BMI1-associated hepatocarcinogenesis in hepatitis B virus infection

Poster Presentation

Presenter: Ruth Broering

1007

Nonresolving inflammation in liver cancer; differential regulation of miR-122 signaling by BMP6 and TGF $\beta$

Poster Presentation

Presenter: Mirco CASTOLDI

1008

Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms

Poster Presentation

Presenter: Irene Olaizola

1050

Efficacy of HBV-TCR T cell therapy to eliminate circulating HBV-HCC cells in immunosuppressed whole blood

Poster Presentation

Presenter: Anthony Tan

1083

Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells

Poster Presentation

Presenter: Ainhoa Lapitz

1106

Poor sorafenib response in hepatocellular carcinoma patients is mediated by hypoxia-related 14-3-3 scaffolding proteins and induces a shift in tumor immune microenvironment

Poster Presentation

Presenter: Jovana Castven

1149

Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification

Poster Presentation

Presenter: Leidy Estefanía Zapata-Pavas

1181

Tumor-extrinsic Axl expression shapes an inflammatory microenvironment independent of tumor-cell promoting Axl signaling

Poster Presentation

Presenter: Kristina Breiteneker

1203

Identification of hepatocyte-restricted antigens, epitopes, and T cell receptors to treat recurrent hepatocellular carcinoma after liver transplantation

Poster Presentation

Presenter: Rakké Yannick

1206

Cytokine levels and circulating DNA profiling in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma

Poster Presentation

Presenter: Elena Vargas Accarino

1231

Association between gadoteric acid-enhanced MR imaging, organic anion transporters, and farnesoid X receptor in benign focal liver lesions

Poster Presentation

Presenter: Alicia Furumaya

1245

Intermittent fasting improves tumor-directed drug delivery by caveolar-mediated endocytosis

Poster Presentation

Presenter: Svea Becker

1349

Comprehensive analysis of single-cell and bulk RNA sequencing data identifies antioxidant-1 as a novel immune biomarker associated with immune cell infiltration in hepatocellular carcinoma metastasis

Poster Presentation

Presenter: Ruijia Liu

1463

Remodeling of myeloid cells during hepatocellular carcinoma driven by beta-catenin activation

Oral Presentation

Presenter: Camille Joubel

1477

Immunotherapy resistance in NASH-HCC is driven by the dysfunctional liver microenvironment of NASH

Poster Presentation

Presenter: Daniel Geh

1491

Neutrophil degranulation and ageing as potential therapeutic targets in hepatocellular carcinoma?

Poster Presentation

Presenter: Daniel Geh

1500

In vivo MRI characterization of pathological changes in liver microstructures

Poster Presentation

Presenter: xiaoyu jiang

1544

Clinicopathological analysis of polyploidization in human hepatocellular carcinoma and the development of an evaluation methodology

Poster Presentation

Presenter: Takanori Matsuura

1545

Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation

Poster Presentation

Presenter: HAOMING ZHOU

1561

Dual effects of brown-fat activation limit hepatocellular carcinoma (HCC) progress in steatotic liver

Poster Presentation

Presenter: Juan Gao

1610

Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma

Poster Presentation

Presenter: Luca Fabris

1746

Genetic variant in the hepatic sterol transporter is associated with increased gallstone risk in obese patients and with higher odds of developing gallbladder cancer in general

Poster Presentation

Presenter: Marcin Krawczyk

1748

RBCK1 promotes the stabilization of HBx by linear ubiquitination to drive the progression of HBV-associated hepatocellular carcinoma

Poster Presentation

Presenter: Zheyu Dong

1814

Circular RNA hsa\_circ\_0062682 promotes oncogenesis in hepatocellular carcinoma and binds to YBX1

Poster Presentation

Presenter: Tadeja Rezen

1892

TAK1 deficiency promotes liver injury and tumorigenesis via ferroptosis and macrophage cGAS-STING signaling

Poster Presentation

Presenter: HAOMING ZHOU

1966

CRISPR-engineered cholangiocarcinoma tumoroids generation from chemically-derived hepatic progenitor organoid for disease modelling

Poster Presentation

Presenter: Michael Adisasmita

2025

Deciphering the cellular and molecular determinants of immunotherapy resistance in NASH-associated hepatocellular carcinoma by single-cell analysis

Poster Presentation

Presenter: Lingyun Zhang

2043

The rs72613567: TA polymorphism in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) is associated with survival benefit after development of hepatocellular carcinoma

Poster Presentation

Presenter: Stephan Buch

2087

Development of new personalized therapies targeting VDAC1 in intrahepatic cholangiocarcinoma using patient-derived liver organoids

Poster Presentation

Presenter: Silvia De Siervi

2115

Myeloid-derived cells suppress CD8+ T cells by arginase-1 through interaction with stellate cells in the microenvironment of hepatocellular carcinoma

Oral Presentation

Presenter: Sung Eun Choi

2140

Epigenetic reprogramming synergizes with PD-1/PD-L1 inhibition for cell-targeted therapy in hepatocellular carcinoma

Poster Presentation

Presenter: Caecilia Sukowati

2201

Pegozafermin inhibits NASH-induced hepatocellular carcinoma in the STAM™ mouse model

Poster Presentation

Presenter: Maya Margalit

2211

Modelling hepatocellular carcinoma in precision-cut liver slices for therapeutic screening and as a precision medicine tool

Poster Presentation

Presenter: Amy Collins

2224

Differential hepatoprotective effects of semaglutide and lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC

Poster Presentation

Presenter: Malte H. Nielsen

2225

PD1-negative CD45RA effector-memory CD8 T-cells are essential for response to checkpoint inhibition in advanced hepatocellular carcinoma

Poster Presentation

Presenter: Sarah Cappuyns

2267

Chromosome engineering and CRISPR-Cas9 viability screening reveals increased metastatic capacity targetable by patient-specific synthetic lethality

Poster Presentation

Presenter: Stephanie Roessler

2276

NLRP3 and IL-1, but not IL-18, are drivers of hepatocellular carcinoma in two independent murine models

Poster Presentation

Presenter: Mona Peltzer

2286

Determination of human polyploid hepatocellular carcinoma by pathological image diagnosis utilizing artificial intelligence

Poster Presentation

Presenter: Tomonori Matsumoto

2411

Capillarization of tumor endothelial cells within tumor associated with T cell exclusion in an autochthonous mouse HCC model

Poster Presentation

Presenter: Pin-Hung Lin

2453

Morphological architectures of patient-derived hepatocellular carcinoma organoids with GSK3-beta expression dependent variability according to lenvatinib resistance

Poster Presentation

Presenter: Kyung Joo Cho

2608

Silencing CNNM4 in cholangiocarcinoma inhibits tumoral progression by means of non-canonical ferroptosis

Poster Presentation

Presenter: Maria Mercado-Gómez

2647

KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor

Poster Presentation

Presenter: Pedro Miguel Rodrigues

2673

Selective inhibition of human  $\beta$ -catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma

Poster Presentation

Presenter: Jin Hong

2857

CD40 expression in liver cancer cells is upregulated by CD4+T cells through IFN-gamma and ERK 1/2 pathway

Poster Presentation

Presenter: Hanh Ngo Vinh

2873

The mutated ENTPD6 as neoantigen in hepatocellular carcinoma

Poster Presentation

Presenter: Dongbo Chen

2883

PSMP inhibits HCC progression by regulating the polarization of tumor-associated macrophages via the PI3K/Akt pathway

Poster Presentation

Presenter: Shaoping She

2923

Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism

Poster Presentation

Presenter: Mikel Ruiz de Gauna

2950

Characterization of the immune tumor microenvironment in HCC

Poster Presentation

Presenter: Charlotte Hoffmann

2963

Prognostic and genomic portrait of hepatocellular carcinomas with bi-allelic inactivation of RB1 gene

Poster Presentation

Presenter: Jihyun An

2987

Infiltrating suppressive myeloid cells dominate the pediatric hepatoblastoma tumor immune microenvironment

Poster Presentation

Presenter: Yvonne Vercoulen

3024

Genetic biomarkers for sorafenib response in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Lydia Giannitrapani

3034

Molecular determinants of period-specific recurrences in patients with surgically resected hepatocellular carcinoma

Poster Presentation

Presenter: Jihyun An

3044

Bacterial exosomes cargo vaccine with EpCAM aptamers for targeting hepatocellular carcinoma

Poster Presentation

Presenter: Pushpa Yadav

3061

Exploiting RuvBL1 as a target to improve mTOR -driven hepatocarcinogenesis in mice

Poster Presentation

Presenter: Alice Guida

3080

Interleukin 10-mediated signaling dampens antitumor immunity and promotes liver metastasis

Poster Presentation

Presenter: Tao Zhang

3111

Lysosomotropic PIP5K inhibitors sensitize hepatic cancer to reactive oxygen species by inhibiting proliferative and adaptive pathway

Poster Presentation

Presenter: Shantanu P.A.

3114

RuvBL1 is required for mitochondrial integrity and supports the metabolic reprogramming of HCC cells



Poster Presentation  
Presenter: Tommaso Mello

3116  
Dynamic evolution of the serum metabolome reflects human hepatocarcinogenesis  
Poster Presentation  
Presenter: Johann von Felden

3134  
Constitutive signaling from an engineered IL-21 receptor programs long-lived effector TCR-T cells for HCC therapy  
Poster Presentation  
Presenter: Wei Zhu

3240  
Monitoring the local HCC immune landscape by fine needle aspiration  
Poster Presentation  
Presenter: Gloryanne Aidoo-Micah

3245  
A patient-derived hepatocellular carcinoma multicellular spheroid system modeling the tumor microenvironment for drug development and precision medicine  
Poster Presentation  
Presenter: Emilie Crouchet

3267  
PD-L1 small molecule inhibitors and Paclitaxel orchestrating CD8+ cell cytotoxicity via tumor-associated macrophages: a personalized HCC immunotherapeutic approach  
Poster Presentation  
Presenter: Israa Helal

3349  
Oncostatin M promotes a pro-tumorigenic inflammatory response in NASH-related HCC  
Poster Presentation  
Presenter: Beatrice Foglia

3408  
Anti-CD122 antibody restores specific CD8+ T cell response in non-alcoholic steatohepatitis and prevents hepatocellular carcinoma growth  
Poster Presentation  
Presenter: Stéphanie Lacotte

3629

Immunomagnetic enrichment of hepatocyte-specific extracellular vesicles using magnetic beads and click chemistry

Poster Presentation

Presenter: Richell Booijink

3686

Fibroblast growth factor 19 cooperates with Myc to promote liver carcinogenesis

Poster Presentation

Presenter: José Ursic Bedoya

3724

Combining non-selective beta-blockers with sorafenib in HCC: targeting the culprits of metastasis

Poster Presentation

Presenter: Tasnim Mahmoud

3766

Functional and mechanistic role of lncRNA-A1 in cholangiocarcinoma

Poster Presentation

Presenter: Alberto Tinahones

3776

Carbohydrate restriction inhibits tumor progression in a hepatocellular carcinoma mouse model

Poster Presentation

Presenter: Merve Erdem

3790

Expression and role of the metabotropic glutamate receptor type 3 in hepatocarcinoma

Poster Presentation

Presenter: Isabel Méndez

3797

Immunological impact of Axl/TGF-beta signaling in hepatocellular carcinoma

Poster Presentation

Presenter: Gregor Ortmayr

3800

Fatty Acid Synthase expression promotes the malignant features of cholangiocarcinoma cells and predicts shorter survival in patients

Poster Presentation

Presenter: Mirella Pastore

[Liver tumours: Therapy](#)

240

Salvage hepatectomy for recurrent hepatocellular carcinoma after radiofrequency ablation

Poster Presentation

Presenter: Jai Young Cho

330

Efficacy of Atezolizumab/Bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma according to the type of disease progression and liver disease severity

Poster Presentation

Presenter: SPYRIDON PANTZIOS

351

Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B

Poster Presentation

Presenter: Ji won Yang

468

Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma

Poster Presentation

Presenter: Luca Ielasi

542

Risk of bleeding and thromboembolic events with atezolizumab/bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter, retrospective study

Oral Presentation

Presenter: Florian P Reiter

556

Quality of life in patients with unresectable hepatocellular carcinoma treated with selective internal radiation therapy (SIRT) and Nivolumab: a sub-analysis of the NASIR-HCC trial

Poster Presentation

Presenter: Manuel de la Torre

637

Surgical resection of hepatocellular carcinoma has high feasibility, safety and survival in non-cirrhotic liver: a prospective Spanish multicentre study

Poster Presentation

Presenter: laura monserrat lopez torres

707

Downstaging hepatocellular carcinoma with checkpoint inhibitor therapy safely improves access to curative liver transplantation: a case series

Poster Presentation

Presenter: Margaret Liu

709

Multimodal integrative genomics and pathology analyses in neoadjuvant nivolumab treatment for borderline resectable HCC

Oral Presentation

Presenter: Irene Oi-Lin NG

724

Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib

Poster Presentation

Presenter: Eleonora Alimenti

783

Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib

Poster Presentation

Presenter: Sun Young Yim

969

Impact of baseline liver function on overall survival (OS) and safety in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS): results from the RATIONALE-301 study

Poster Presentation

Presenter: Masatoshi Kudo

1043

Dipeptidyl-peptidase 4 inhibitors improve survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy

Poster Presentation

Presenter: Dorothy Cheuk-Yan Yiu

1047

Impact of clinical evident portal hypertension on hepatocellular carcinoma with transarterial chemoembolization (chance-chess 2301): a multicenter cohort study

Poster Presentation

Presenter: Zhi-Cheng Jin

1077

Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the RATIONALE-301 study

Poster Presentation  
Presenter: Tim Meyer

1089  
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: focusing on hepatic safety and viral kinetics  
Poster Presentation  
Presenter: San-Chi Chen

1165  
Clinical outcomes of surgical resection vs yttrium 90 radioembolization (Y90) in hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI)  
Poster Presentation  
Presenter: Zhaozhen Zou

1172  
Impact of statin on the survival of patients with advanced hepatocellular carcinoma treated with sorafenib or lenvatinib  
Poster Presentation  
Presenter: Ji Eun Han

1266  
The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab  
Poster Presentation  
Presenter: Antonio D'Alessio

1336  
Incidence and risk factors of post-transarterial chemoembolization complications in patients with hepatocellular carcinoma: a single center retrospective cohort analysis in a large tertiary hospital  
Poster Presentation  
Presenter: Melissa April Pajinag

1436  
Application of deep learning auto-segmentation and unsupervised machine learning in developing a radiomic prognostic score to predict disease recurrence post radiofrequency ablation for hepatocellular carcinoma  
Poster Presentation  
Presenter: Mathew Vithayathil

1493  
Impact of radiological response and pattern of progression on overall survival in patients with hepatocellular carcinoma treated by atezolizumab-bevacizumab  
Poster Presentation

Presenter: Claudia Campani

1520

Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of Child Pugh B patients with advanced hepatocellular carcinoma

Poster Presentation

Presenter: Leonardo Stella

1720

Prediction for gastrointestinal bleeding in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Poster Presentation

Presenter: Kanghee Park

1771

Risk stratification for early recurrence after resection in patients with intermediate stage hepatocellular carcinoma

Poster Presentation

Presenter: Han Ah Lee

1786

Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study

Poster Presentation

Presenter: Elia Gigante

1804

Changing treatment landscape associated with improved survival in patients with hepatocellular carcinoma: a nationwide, population-based study

Poster Presentation

Presenter: Najib Ben Khaled

1822

Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study

Poster Presentation

Presenter: Vincent Jörg

1843

Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile

Poster Presentation

Presenter: Louisa Stern

1874

Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

Poster Presentation

Presenter: Claudia Fulgenzi

1909

Survival outcomes of hepatocellular carcinoma after yttrium-90 selective internal radiation therapy in an Asian population stratified by tumour volume and distribution

Poster Presentation

Presenter: Kaina Chen

1936

Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study

Poster Presentation

Presenter: Xingzhi Li

2023

Prognostic factors of intrahepatic cholangiocarcinoma after radical surgical resection

Poster Presentation

Presenter: Koo Jeong Kang

2026

Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance

Poster Presentation

Presenter: Marco Sanduzzi Zamparelli

2167

Comparison of clinical outcome between Nivolumab and Regorafenib as second-line systemic therapy after Sorafenib failure in patients with advanced hepatocellular carcinoma

Poster Presentation

Presenter: Jae Seung Lee

2279

Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures

Oral Presentation

Presenter: Sarah Cappuyns

2631

Portal-hypertension parameters are associated with survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy

Poster Presentation

Presenter: Heloise Giudicelli-Lett

2641

Fragility index of positive phase 2 and 3 randomized clinical trials of treatment of hepatocellular carcinoma (2002-2022)

Poster Presentation

Presenter: Sabrina SIDALI

2669

Sequential systemic treatment in patients with hepatocellular carcinoma: real-world data in the era of immune checkpoint inhibition

Poster Presentation

Presenter: Jana Pauly

2852

Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma

Poster Presentation

Presenter: Jeong Heo

2906

Efficacy and tolerability of stereotactic body radiation therapy in patients with hepatocellular carcinoma: a retrospective cohort study

Poster Presentation

Presenter: Dorothy Liu

2943

A simple characterization of dynamic changes in circulating CD8+PD1+ lymphocytes early predicts response to atezolizumab-bevacizumab in hepatocellular carcinoma

Poster Presentation

Presenter: Fabio Piscaglia

3161

Clinical impact of relative dose intensity over the first four weeks in cabozantinib therapy for unresectable hepatocellular carcinoma

Poster Presentation

Presenter: Kaoru Tsuchiya

3185

Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients



Poster Presentation

Presenter: Margherita Rimini

3297

Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis

Poster Presentation

Presenter: Ciro Celsa

3465

Clinical profile and outcomes of hepatocellular carcinoma in primary budd chiari syndrome

Poster Presentation

Presenter: Ankit Agarwal

3516

IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

Oral Presentation

Presenter: Pierce Chow

3524

Tolerability of first line systemic therapy in elderly patients with advanced hepatocellular carcinoma

Poster Presentation

Presenter: Davide Di Benedetto

3594

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Poster Presentation

Presenter: Mara Persano

3608

Add-on strategy of Regorafenib plus Nivolumab as second line approach in patients with hepatocellular carcinoma: the GOING trial

Poster Presentation

Presenter: Marco Sanduzzi Zamparelli

3703

Improved identification of good candidates for the treatment of intermediate/advanced hepatocellular carcinoma by Yttrium-90 transarterial radioembolization

Poster Presentation

Presenter: Carole Vitellius

## NAFLD: Clinical aspects except therapy

202

Systematic screening for NAFLD-related advanced fibrosis in high-risk population in diabetology using transient elastography: a prospective study

Poster Presentation

Presenter: Cyrielle Caussy

232

Metabolic dysfunction associated fatty liver disease and the risk of hepatocellular carcinoma

Poster Presentation

Presenter: Byeong Geun Song

354

GL0034 (Utregrlutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals

Poster Presentation

Presenter: Rajamannar Thennati

355

Relationship of hepcidin levels to metabolic factors, anthropometric indicators of adiposity and disease severity in NAFLD patients

Poster Presentation

Presenter: Claudia Cravo

369

Risk of bacterial infections in non-alcoholic fatty liver disease: a nationwide population-based cohort study

Poster Presentation

Presenter: Axel Wester

421

Association between consumption of ultra-processed foods and nonalcoholic fatty liver disease in the Framingham heart study

Poster Presentation

Presenter: Natalie Sun

432

The impact of Clostridium difficile on mortality and outcomes in patients with NAFLD vs. NASH

Poster Presentation

Presenter: Ankoor Patel

436

The growing global burden of non-alcoholic fatty liver disease (NAFLD) among teenagers  
Poster Presentation  
Presenter: Zobair Younossi

562  
Impairment of health-related quality of life among people with type 2 diabetes and advanced fibrosis  
Poster Presentation  
Presenter: Maurice Michel

567  
Stratification of liver fat content in nonalcoholic steatohepatitis patients with significant liver fibrosis using the MEFIB-Index and MRI-PDFF and its association with hepatocellular carcinoma, decompensation, and mortality  
Oral Presentation  
Presenter: Sung Won Lee

586  
Impact of PNPLA3 polymorphism on non-alcoholic fatty liver disease in Japan: a multicenter cohort study  
Poster Presentation  
Presenter: Yuya Seko

597  
Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease  
Poster Presentation  
Presenter: Grazia Pennisi

609  
Nutritional behavior and food pattern are sex-specific with higher salt intake and consumption of ultra-processed foods in a large cohort of NAFLD patients  
Poster Presentation  
Presenter: Monika Rau

618  
PNPLA3 GG genotype is associated with higher incidence of cirrhosis and liver-related events among patients with nonalcoholic fatty liver disease  
Poster Presentation  
Presenter: Karn Wijarnpreecha

651  
Cognitive impairment is frequent in obesity and not restricted to persons with biopsy-proven NAFLD  
Poster Presentation  
Presenter: Charlotte Wernberg

667

A social media listening study of patients' experiences toward NAFLD (LISTEN-NAFLD)

Poster Presentation

Presenter: Jeffrey Lazarus

704

Rheological properties of bile in patients with nonalcoholic steatohepatitis with and without obesity

Poster Presentation

Presenter: Olena Barabanchyk

734

Pilot results for a multidisciplinary community metabolic liver clinic

Poster Presentation

Presenter: Theresa Hydes

744

Prevalence and mortality of non-alcoholic fatty liver disease (NAFLD) in non-diabetics, pre-diabetics, and diabetics in the United States

Poster Presentation

Presenter: Zobair Younossi

809

Prevalence of extrahepatic manifestations in nonalcoholic fatty liver disease in lean individuals compared to non-lean individuals

Poster Presentation

Presenter: Majd Aboona

1110

Salivary analytical device (SAD) a good tool for monitoring the metabolic status of patients with fatty liver disease

Poster Presentation

Presenter: Gaia Sinatti

1125

Non-alcoholic fatty liver disease and the longitudinal risks of clinical outcomes: a meta-analysis

Poster Presentation

Presenter: Margaret Teng

1137

Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)

Poster Presentation

Presenter: Jörn Schattenberg

1243

Impact of PNPLA3 rs738409 single nucleotide polymorphism and carbohydrate intake for the personalized management of patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Nuria Pérez Diaz del Campo

1253

Interferon gamma-induced protein 10 levels increase across the spectrum of liver disease and are associated with insuline resistant components in subjects with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Marta Guariglia

1263

Influence of chronotype and adherence to the mediterranean diet on the risk of liver fibrosis in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Gabriele Castelnuovo

1290

Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non-alcoholic fatty liver disease patients

Poster Presentation

Presenter: Giordano Sigon

1329

Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy

Poster Presentation

Presenter: Wah Loong Chan

1361

Use of antidiabetic and lipid-lowering medications associated with lower scores of liver fibrosis biomarkers in nonalcoholic steatohepatitis (NASH) patients

Oral Presentation

Presenter: Jun Wang

1397

Patatin-like phospholipase domain-containing 3 (PNPLA3) risk allele increases rate of progression to end-stage liver disease outcomes and decreases survival rate over time irrespective of degree of fibrosis

Poster Presentation

Presenter: Javier Armisen

1435

Genetic and metabolic characteristics of lean non-alcoholic fatty liver disease in Asian

Poster Presentation

Presenter: Huiyul Park

1470

Frailty in metabolic dysfunction-associated fatty liver disease is related to the presence of diabetes and the severity of liver fibrosis

Poster Presentation

Presenter: Guillaume Henin

1501

The national audit of non-alcoholic fatty liver disease (NAFLD) identifies variations and shortfalls in delivery of care in the UK

Poster Presentation

Presenter: Wenhao Li

1521

Genetic risk factors for NAFLD and clinically significant fibrosis in persons living with HIV

Poster Presentation

Presenter: Eduardo Vilar Gomez

1533

Prevalence of dysmetabolic iron overload syndrome in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Noel Ravindranayagam

1546

Low-quality muscle mass predicts fibrosis progression in a prospective biopsy-proven nonalcoholic fatty liver disease cohort

Poster Presentation

Presenter: Sae Kyung Joo

1590

Effect of PNPLA3 (rs738409 C>G) and TM6SF2 (rs58542926 C>T) polymorphisms on the prognosis of non-alcoholic fatty liver disease (NAFLD) in patients with type-2 Diabetes Mellitus

Poster Presentation

Presenter: Cristiane Villela-Nogueira

1593

Histological and biopsychosocial predictors of quality of life in Spanish and UK cohorts of patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Jesús Funuyet-Salas

1622

Digital pathology using stain-free imaging indices allows direct prediction of all-cause mortality, hepatic decompensation and hepatocellular carcinoma development in patients with non-alcoholic fatty liver disease

Oral Presentation

Presenter: Timothy Kendall

1640

Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients

Poster Presentation

Presenter: Ying Shang

1662

The importance of regular screening for HCC in non-alcoholic steatohepatitis/ non-alcoholic fatty liver disease

Poster Presentation

Presenter: Taisei Keitoku

1689

Sarcopenia is an independent risk factor for non-alcoholic fatty liver disease regardless of fat mass in men: 1:1 propensity score matching analysis

Poster Presentation

Presenter: Jun-Hyuk Lee

1732

Diabetes mellitus (DM) is the strongest risk factor of significant inflammation or fibrosis in chronic hepatitis B (CHB) combined with nonalcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Jie Li

1737

A machine learning-based classification of adult-onset diabetes identifies patients at risk for liver-related complications

Poster Presentation

Presenter: Lukas Otero Sanchez

1836

Dietary patterns associated with metabolic associated fatty liver disease protection

Poster Presentation

Presenter: Carolin Victoria Schneider

1979

Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease

Poster Presentation

Presenter: Roberta Forlano

2042

Significant fibrosis is a risk factor for worse health perception and impaired mental health in people living with HIV

Poster Presentation

Presenter: Jesús Funuyet-Salas

2108

A risk prediction model for hepatocellular carcinoma for non-alcoholic fatty liver disease without cirrhosis

Poster Presentation

Presenter: Gi-Ae Kim

2168

Digital pathology with artificial intelligence analyses provides deeper insights into lifestyle intervention-induced fibrosis regression in NASH

Poster Presentation

Presenter: Haiyang Yuan

2184

Long-term prognosis of patients with non-alcoholic fatty liver disease: a retrospective cohort study to understand the impact of surrogate disease endpoints on long-term outcomes in South Korea

Poster Presentation

Presenter: Sungwon CHUNG

2287

Clinical features of non-obese NAFLD: analysis of health check-up cohort

Poster Presentation

Presenter: Shunsuke Sato

2299

Serum uric acid levels and prognosis of patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Yang Xinyi

2358

Risk factors for significant fibrosis in non-obese Asian patients with NAFLD

Poster Presentation



Presenter: Jae Yoon Jeong

2406

Effects of a one-month consumption of different non-alcoholic beers on metabolic and liver health in young men

Poster Presentation

Presenter: Henriette Kreimeyer

2421

PNPLA3 protein levels are increased in liver and decreased in adipose tissue from patients with obesity-associated nonalcoholic steatohepatitis

Poster Presentation

Presenter: Helena Castañé

2442

Stigma in NAFLD and NASH: a global survey of patients and providers

Poster Presentation

Presenter: Zobair Younossi

2532

The rising burden of non-alcoholic fatty liver disease (NAFLD) related HCC: is time running out to contain this silent epidemic?

Poster Presentation

Presenter: Saima Ajaz

2683

NAFLD prevalence in the elderly declines with age and is associated with increased frailty, reduced physical function and social disadvantage status: results from the ASPREE study

Poster Presentation

Presenter: Daniel Clayton-Chubb

2686

Histological classifications versus liver-related events: results from the multicentric, European, hepatic outcomes and survival fatty liver registry (HOTSURFR) study

Poster Presentation

Presenter: Vlad Ratziu

2707

Assessing treatment outcomes in an AIH/NAFLD overlap cohort

Poster Presentation

Presenter: Nancy S Reau

2828

Disparities in the in-hospital mortality among patients with non-alcoholic fatty liver disease admitted with acute myocardial infarction: a nationwide analysis

Poster Presentation

Presenter: Umar Hayat

2853

Differential risk of 23 specific incident cancers and cancer-related mortality in patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects

Poster Presentation

Presenter: Su Jong Yu

2954

Glycated hemoglobin as an independent predictor of hepatocyte ballooning in nonalcoholic steatohepatitis: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)

Poster Presentation

Presenter: Stephen Harrison

2961

The impact of glycemic control on progressive forms of nonalcoholic fatty liver disease: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)

Poster Presentation

Presenter: Mazen Nouredin

2967

Metabolic dysfunction-associated fatty liver disease is associated with increased risk of extrahepatic malignancies: a nationwide cohort study

Poster Presentation

Presenter: Min Kyung Park

2970

Comparison of nonalcoholic steatohepatitis severity between Hispanics and non-Hispanics: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)

Poster Presentation

Presenter: Sophie Jeannin Megnien

3057

Identification of a new gene signature that accurately predicts the risk of hepatic decompensation in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Maria Jimenez Ramos

3099

Natural history & long-term outcomes of the Newcastle non-alcoholic fatty liver disease cohort

Poster Presentation

Presenter: Jenny Gallacher

3112

Liver fibrosis is associated with cardiovascular disease burden amongst patients with non-alcoholic steatohepatitis: the unCoVer-NASH longitudinal cohort study

Poster Presentation

Presenter: Kathleen Corey

3129

Impact of visceral adiposity for coronary artery calcification progression in patients with metabolic dysfunction-associated fatty liver disease; multicenter cohort study

Poster Presentation

Presenter: KyeWhon Kim

3137

Societal costs and labor market affiliation of histologically confirmed non-alcoholic steatohepatitis – a Danish register-based study

Poster Presentation

Presenter: Henning Grønbaek

3163

Serum vitamin D is strongly associated with liver steatosis but not with liver and spleen stiffness assessed by transient elastography in patients at risk

Poster Presentation

Presenter: Gediz Dogay Us

3191

Evaluation of Google search trends for liver diseases in Europe

Poster Presentation

Presenter: Andreas Teufel

3205

The risk of liver-related long term outcomes is altered by dynamic changes in metabolic dysfunction-associated fatty liver disease status: a nationwide cohort study

Poster Presentation

Presenter: Min Kyung Park

3379

Non-alcoholic steatohepatitis disease progression in participants from the United States TARGET-NASH real world longitudinal observational study

Oral Presentation

Presenter: Philip N Newsome

3417

Effect of semaglutide 2.4 mg on alanine aminotransferase in adolescents with obesity: a post-hoc analysis of the STEP TEENS trial

Oral Presentation

Presenter: Mazen Nouredin

3439

Hepatic steatosis in people with HIV is associated with lower BMI and more liver fibrosis compared to metabolic dysfunction-associated fatty liver disease

Poster Presentation

Presenter: Floriana Santomenna

3505

Ascites is the most frequent decompensating event in stable and strictly compensated NAFLD with advanced fibrosis

Poster Presentation

Presenter: Zouhir Gadi

3522

Metabolic associated fatty liver disease: different impact of the three defining criteria on the hepatic and cardiovascular complications

Poster Presentation

Presenter: Jaqueline Currà

3666

Low rates of fibrosis scoring in the primary care records of 5,987 people living with type 2 diabetes

Poster Presentation

Presenter: James Hallimond Brindley

3683

PNPLA3 I148M polymorphism does not promote liver disease progression in severe alpha1-antitrypsin deficiency

Poster Presentation

Presenter: Ines Volkert

3690

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of type 2 diabetes mellitus

Poster Presentation

Presenter: Christoph Roderburg

3701

Study of an association of the serum iron markers, hepatic iron deposition and severity of nonalcoholic fatty liver disease: a single-centered prospective study

Poster Presentation

Presenter: Shubham Jain

3723

Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism

Poster Presentation

Presenter: Chiara Rosso

3744

Caloric input is inadequate in predicting the presence of liver steatosis and fibrosis in a population adhering to a screening program for metabolic syndrome

Poster Presentation

Presenter: Lucia Brodosi

3769

De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Chiara Rosso

3770

Nonalcoholic fatty liver disease mediates the effect of obesity on arterial hypertension

Poster Presentation

Presenter: Carlos Pirola

## NAFLD: Diagnostics and non-invasive assessment

113

Machine learning with routine laboratory tests and clinical features performs similar to current NAFLD clinical pathways

Poster Presentation

Presenter: Mazen Nouredin

176

Evaluation of serum biomarkers for the diagnosis of nonalcoholic fatty liver disease in the general population: a cross-sectional Spanish population-based study

Poster Presentation

Presenter: Jesús Rivera

245

The liver worsens in non-alcoholic fatty liver disease patients as diabetes mellitus worsens and lasts longer

Poster Presentation

Presenter: Zülal İstemihan

273

Serum levels of type IV collagen 7S can predict liver-related mortality and events as well as advanced fibrosis: a multi-center study

Poster Presentation

Presenter: Hiroshi Ishiba

294

The impact of projected increases in obesity prevalence on incident liver disease in the UK: insights from bayesian-network modelling

Poster Presentation

Presenter: Tom Waddell

395

A clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial

Oral Presentation

Presenter: Vincent Wai-Sun Wong

415

A descriptive analysis of transient elastography results and metabolic co-morbidities in people living with HIV mono-infection in an urban clinic in the UK

Poster Presentation

Presenter: Claire Mullender

486

Imaging and biomarker thresholds to accurately diagnose NASH cirrhosis in a 180 patient biopsy confirmed cohort

Poster Presentation

Presenter: Rohit Loomba

487

Predicting severe liver outcomes in NAFLD using repeated measurements of biomarkers---a cohort study in 1,260 patients

Poster Presentation

Presenter: Ying Shang

511

Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease  
Poster Presentation  
Presenter: Roberta Forlano

533  
Economic modelling of clinical management options of unexplained hyperferritinaemia in the adult general population: a proposed new model of care  
Poster Presentation  
Presenter: John Olynyk

573  
Early aminotransferase improvement in the phase 2b NATIVE study is predictive of response pattern of liver histology as well as hepatic and cardiometabolic health markers at the end of treatment in patients with non-cirrhotic NASH  
Poster Presentation  
Presenter: Quentin Anstee

676  
FIB-4 as a screening tool for significant liver fibrosis in a cohort of overweight subjects involved in a weight loss program conducted in a primary care setting  
Poster Presentation  
Presenter: Charlotte Costentin

696  
Liver stiffness measurements with a new point-of-care device, hepatoscope, using two-dimensional transient elastography showed both very good reproducibility and correlation to fibroscan  
Poster Presentation  
Presenter: Victor de Lédinghen

779  
AI-enabled virtual hematoxylin & eosin and Masson's trichrome staining for nonalcoholic fatty liver disease activity scoring from single unstained slide  
Poster Presentation  
Presenter: Peter Cimermancic

784  
Diagnostic performance of magnetic resonance imaging, vibration-controlled transient elastography and controlled attenuation parameter in predicting steatohepatitis in NAFLD patients  
Poster Presentation  
Presenter: Sun Young Yim

795  
Performance of non-invasive fibrosis tests for long-term liver and heart outcomes in Europeans with metabolic risk factors from the UK Biobank

Poster Presentation

Presenter: Federica Tavaglione

1003

A real world experience utilising the FAST score to identify patients with NASH fibrosis

Poster Presentation

Presenter: Gres Karim

1023

Metabolic and adipocytokine disorders as a background cause of the progression of nonalcoholic steatohepatitis in obese patients depending on comorbidity with chronic obstructive pulmonary disease

Poster Presentation

Presenter: Ivanna Rachynska

1037

The clinical significance of transient elastography and cap in the diagnosis and surveillance of non alcoholic fatty liver disease

Poster Presentation

Presenter: Despoina Vasileiou

1192

SAFE score yielded a better performance than FIB-4 and NFS in predicting significant fibrosis among Asian NAFLD patients

Poster Presentation

Presenter: Pimsiri Sripongpun

1251

MorphoQuant, the first fully-automated morphometric software for the assessment of liver biopsy, identified significant differences between non-alcoholic fatty liver disease and steatohepatitis biopsies

Poster Presentation

Presenter: Cindy Serdjebi

1276

A systematic review and meta-analysis of the prevalence and cross-sectional severity of South Asian patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Michael James

1309

Dynamic changes in liver stiffness assessed by transient elastography as a prognostic factor in NAFLD patients with prediabetes and type 2 diabetes

Poster Presentation



Presenter: Elias Maleh

1318

Diagnostic performance of fibrosis-4 index and NAFLD fibrosis score in at-risk group from low prevalence population

Poster Presentation

Presenter: Huiyul Park

1324

Sarcopenia is an independent risk factor for non-alcoholic fatty liver disease regardless of fat mass in men: 1:1 propensity score matching analysis

Poster Presentation

Presenter: Huiyul Park

1335

The use of non-invasive tests compared with histological fibrosis stage in predicting liver-related events in metabolic dysfunction-associated fatty liver disease

Poster Presentation

Presenter: Wah Loong Chan

1427

Fatty liver score: a novel fatty liver index based on magnetic resonance imaging-proton density fat fraction

Poster Presentation

Presenter: Chul-min Lee

1437

Impact of age as a confounding factor on non-invasive blood-based tests for the evaluation of non-alcoholic fatty liver disease: comparing NIS2+TM to established tests

Poster Presentation

Presenter: Quentin Anstee

1446

Cost effectiveness analysis of screening for advanced hepatic fibrosis in patients with various 'at-risk population' in guidelines

Poster Presentation

Presenter: Hye-Lin Kim

1462

The role of M2BPGi in screening for advanced hepatic fibrosis in diabetic patients

Poster Presentation

Presenter: Mimi Kim

1547

Fibrosis-4 score and liver stiffness measurement by vibration-controlled transient elastography predict risk of liver-related events in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Esteban Urias

1560

Which screening of advanced liver fibrosis in NAFLD?

Poster Presentation

Presenter: Paul Cales

1577

High performance of new multiparametric ultrasound in the non-invasive assessment of liver disease

Poster Presentation

Presenter: Gloria Ruiz-Fernandez

1607

Practical diagnosis of cirrhosis by liver specialists in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests

Poster Presentation

Presenter: Jerome Boursier

1612

Predictors of liver stiffness changes in consecutive cohorts of patients with non-alcoholic fatty liver disease and longitudinal follow up

Poster Presentation

Presenter: Mirko Zoncapè

1630

The prevalence and predictors of non-alcoholic fatty liver disease by vibration controlled transient elastography among lean adults in the United States

Poster Presentation

Presenter: Ifrah Fatima

1632

Glomerular hyperfiltration: a new marker of fibrosis severity in non-cirrhotic non-alcoholic fatty liver disease

Poster Presentation

Presenter: Marta Garbin

1635

Long-term liver-related outcomes in 1,260 patients with non-cirrhotic NAFLD

Poster Presentation

Presenter: Ying Shang

1639

NIS2+™ as a screening tool for optimizing patient selection in non-alcoholic steatohepatitis therapeutic trials

Poster Presentation

Presenter: Vlad Ratziu

1652

A sequential use of transient elastography followed by Agile 3+ score significantly improves the screening of advanced fibrosis in patients with NAFLD with or without severe obesity

Poster Presentation

Presenter: Cyrielle Caussy

1701

Association of non-high-density lipoprotein cholesterol trajectories with the development of non-alcoholic fatty liver disease

Poster Presentation

Presenter: Jun-Hyuk Lee

1704

High prevalence of compensated advanced chronic liver diseases among patients with type 2 diabetes mellitus (CDL 2301): a prospective community-based study

Poster Presentation

Presenter: Xiaolong Qi

1715

A diagnostic non-invasive model for liver advanced fibrosis and cirrhosis in chronic hepatitis B (CHB) concurrent with nonalcoholic fatty liver disease (NAFLD) based on machine learning (ML)

Poster Presentation

Presenter: Jie Li

1722

The role of M2BPGi for screening of advanced hepatic fibrosis in elderly patients

Poster Presentation

Presenter: Hoon Gil Jo

1724

Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective

Poster Presentation

Presenter: Mimi Kim

1725

Effect of diabetes mellitus and fatty liver on hepatic fibrosis

Poster Presentation

Presenter: Byung Ik Kim

1727

ABDA score: a non-invasive model to identify subjects with fibrotic non-alcoholic steatohepatitis in the community

Poster Presentation

Presenter: . Shalimar

1728

Cost-effectiveness of screening for advanced hepatic fibrosis by noninvasive test in general population

Poster Presentation

Presenter: Bo-Kyeong Kang

1758

Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years' experience in a tertiary referral center with genotyping facility

Poster Presentation

Presenter: Marcin Krawczyk

1761

Establishment and validation of a diagnostic model for liver inflammation in chronic hepatitis B (CHB) patients concurrent with nonalcoholic fatty liver disease (NAFLD) based on machine learning (ML)

Poster Presentation

Presenter: Jie Li

1839

Performance of novel collagen turnover biomarkers in relation to FIB-4 to detect advanced fibrosis in NAFLD

Poster Presentation

Presenter: Hannes Hegmar

1885

Utility of SomaSignal™ panels for drug response and monitoring disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis

Poster Presentation

Presenter: Kris Kowdley

1915

Development of ultra-sensitivity enzyme linked immunosorbent assay for hepatitis delta virus antibody detection

Poster Presentation

Presenter: Nomin Ariungerel

1916

ALT/AST ratio: the useful predictive marker for insulin resistance

Poster Presentation

Presenter: Han Seul ki

1998

Serum glycochenodeoxycholic acid-3-sulfate can discriminate non-alcoholic steatohepatitis from steatosis

Poster Presentation

Presenter: Barbora Nováková

2016

Analysis of correlation and predictive ability of oral glucose tolerance tests with insulin assays for liver stiffness measurement in non-cirrhotic overweight and obese patients

Poster Presentation

Presenter: Valentino Osti

2077

Using elevated plasma alanine transaminase to screen for non-alcoholic fatty liver disease in overweight and obese individuals from the Danish general population

Poster Presentation

Presenter: Elias Rashu

2133

Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interim analysis of an Italian prospective multicentre study

Poster Presentation

Presenter: Gian Paolo Caviglia

2149

A screening strategy of hidden compensated advanced chronic liver disease in diabetic outpatients using sequential and automatic fibrosis-4 and enhanced liver fibrosis scores

Poster Presentation

Presenter: Clara Amiama Roig

2154

The genetic background of NAFLD patients markedly affects their metabolomic and lipidomic signatures

Poster Presentation

Presenter: Lina Jegodzinski

2189

Accuracy of 100 Hz transient elastography-based spleen stiffness for the identification of advanced fibrosis in biopsy-proven non alcoholic fatty liver disease

Poster Presentation

Presenter: Angelo Armandi

2244

Performance of non-invasive markers in evaluating presence and severity of liver fibrosis in non-alcoholic fatty liver disease: results from a multi-ethnic Asian cohort of biopsy-proven non-alcoholic fatty liver disease patients

Poster Presentation

Presenter: EN YING TAN

2245

Comparison of performance of non-invasive indices in assessing degree of steatosis in non-alcoholic fatty liver disease

Poster Presentation

Presenter: EN YING TAN

2268

Evaluating the role of novel magnetic resonance imaging-based biomarkers in non-invasive assessment of hepatic fibrosis and activity in non-alcoholic fatty liver disease

Poster Presentation

Presenter: EN YING TAN

2282

Biomarkers of hepatocyte basement membrane turnover reflect disease activity in patients with early-stage non-alcoholic fatty liver disease

Poster Presentation

Presenter: Ida Lønsmann

2322

Lower ALT levels are associated with increased all-cause and cardiovascular mortality in patients with NAFLD in the United States population

Poster Presentation

Presenter: Bo Feng

2330

A biomarker of fibrosis resolution, CTX-III, increases after bariatric surgery in early NAFLD patients with histological liver improvements

Poster Presentation

Presenter: Ida Lønsmann

2336

Implementing a clinical care algorithm for screening of liver fibrosis in specialist diabetes care

Poster Presentation

Presenter: Muna Tajudin

2337

Associations of genetic risk panel with enhanced liver fibrosis scores among patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Zobair Younossi

2372

A validated tool consisting of bedside variables predicts high-risk NASH (HRN) in individuals with type 2 diabetes

Poster Presentation

Presenter: Eduardo Vilar Gomez

2390

One-step diagnosis: detection and stratification of incidental hepatic steatosis by multiparametric abdominal ultrasound

Poster Presentation

Presenter: Irene GONZALEZ DIAZ

2398

Risk-stratification of patients with non-alcoholic fatty liver disease (NAFLD) in primary care: lessons from the Calgary NAFLD pathway

Poster Presentation

Presenter: Abdel-Aziz Shaheen

2400

Wearable technology utilizing an electrical impedance tomography (EIT) system for hepatic steatosis quantification and the role in ambulatory monitoring

Poster Presentation

Presenter: Lung Yi Loey Mak

2428

Analysis of the diagnostic accuracy of the non-invasive fibrosis indices NFS, HFS, and FIB-4 in the staging of advanced fibrosis in patients with metabolic fatty liver: meta-analysis of comparative studies

Poster Presentation

Presenter: Carmen Lara Romero

2443

Significant dose-dependent reduction in liver stiffness using transient elastography in a phase 3 randomized placebo-controlled trial of obeticholic acid over 48 months in patients with pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis

Poster Presentation

Presenter: Rohit Loomba

2483

MRI-PDFF captures the whole spectrum of lipid composition beyond traditional histological evaluation of macrosteatosis

Poster Presentation

Presenter: David Marti-Aguado

2489

Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with nonalcoholic steatohepatitis and type 2 diabetes mellitus

Poster Presentation

Presenter: Stephen Harrison

2520

Abdominal adiposity and insulin resistance are the main predictors of CAP values in individuals with metabolic dysfunction: the liver-bible cohort

Poster Presentation

Presenter: Cristiana Bianco

2526

Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test

Poster Presentation

Presenter: Denis Ouzan

2533

Validation and expansion of the American gastroenterological association clinical care pathway for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes

Poster Presentation

Presenter: Veeral Ajmera

2548

LIVERFASt GP+ (GP+), a non-invasive blood testing for NAFLD staging, improves risk stratification of patients with indeterminate FIB-4 results

Poster Presentation

Presenter: Naim Alkhouri

2559



Prevalence of NAFLD and advanced fibrosis in Stockholm, Sweden

Poster Presentation

Presenter: Emilie Toresson Grip

2567

A stepwise screening approach using noninvasive tests to identify phenotypic nonalcoholic steatohepatitis (NASH) patients with fibrosis for clinical trials

Poster Presentation

Presenter: Naim Alkhouri

2587

LIVERFASt GP+, first-line screening tool in at-risk MAFLD patients outperforms the standard-of-care (SOC) FIB-4

Poster Presentation

Presenter: Mona MUNTEANU

2597

High performance of serological indexes in the non-invasive assessment of liver steatosis

Poster Presentation

Presenter: Beatriz Pillado Pérez

2600

Prevalence of diagnosed advanced liver fibrosis in high-risk population with metabolic-dysfunction associated fatty liver disease screened in diabetology using transient elastography

Poster Presentation

Presenter: Cyrielle Caussy

2602

Velacur ACE outperforms CAP for liver fat quantification using MRI PDFF as the gold standard

Poster Presentation

Presenter: Rohit Loomba

2664

Fully automated approach of machine learning combined with deep learning to forecast the coronary artery disease in patients with nonalcoholic fatty liver disease

Poster Presentation

Presenter: antonio cirella

2677

A gut-mycobiome-derived signature predicts advanced fibrosis in people with diabetes

Poster Presentation

Presenter: Rohit Loomba

2680

Thrombospondin-2 as a new biomarker for at risk NASH and advanced fibrosis in a large multicentric European cohort

Poster Presentation

Presenter: Vlad Ratziu

2706

Development of a novel non-invasive test for prediction of liver fibrosis in patients with clinically severe obesity defined by a BMI over 50 kg/m<sup>2</sup>

Poster Presentation

Presenter: Maximilian Joseph Brol

2748

Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease: multicenter cohort study

Poster Presentation

Presenter: Se Young JANG

2792

Utility of serum phosphatidylethanol in differentiating NAFLD from alcohol-associated liver disease among individuals with overweight and obesity: the San Diego liver study

Poster Presentation

Presenter: Monica Tincopa

2805

Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Guanlin Li

2888

Morphometric analysis of sonic hedgehog in non-alcoholic fatty liver steatohepatitis patients by MorphoQuant: a potential biomarker of disease severity

Poster Presentation

Presenter: Cindy Serdjebi

2892

Detecting early improvements in a NAFLD patient population during diet-induced weight loss

Poster Presentation

Presenter: Pietro Torre

2919

Serological biomarkers of extracellular matrix related disease activity are elevated in patients at risk of NASH with significant liver stiffness

Poster Presentation

Presenter: Thomas Møller

2922

A cost-effective non-invasive serum test for diagnosing NASH-cirrhosis (NC-3) in high-risk metabolic syndrome and/or type 2 diabetes patients

Poster Presentation

Presenter: Shira Shaham-Niv

2971

Standardized non-invasive screening for non-alcoholic fatty liver disease in people with type 2 diabetes identifies a substantial number of individuals with advanced liver disease

Poster Presentation

Presenter: Naomi Lange

2973

Performance of the AGA clinical care pathway in identifying patients with at-risk nonalcoholic steatohepatitis: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)

Oral Presentation

Presenter: Naim Alkhouri

2978

Performance of vibration controlled transient elastography and related scores to identify at-risk nonalcoholic steatohepatitis patients: combined data from multiple trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)

Oral Presentation

Presenter: Mazen Nouredin

2984

Performance of non-invasive tests as exclusion criteria for cirrhosis in trials targeting at-risk nonalcoholic steatohepatitis: combined data from multiple trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)

Poster Presentation

Presenter: Naim Alkhouri

3077

Development of loop-mediated isothermal amplification assay for detection of hepatitis delta virus

Poster Presentation

Presenter: Odgerel Oidovsambuu

3079

Prediction of outcomes in patients with nonalcoholic fatty liver disease by initial measurements and subsequent changes in magnetic resonance elastography

Oral Presentation

Presenter: Takashi Kobayashi

3107

Head-to-head comparison of Agile 3+, LSM-VCTE, NFS, and FIB-4 scores for detecting advanced fibrosis in patients with type 2 diabetes seen in diabetes clinic

Poster Presentation

Presenter: Laurent Castéra

3132

Low risk FIB-4 results in patients under 50 years accurately risk assessed patients for adverse liver outcomes over a follow-up of up to 35 years

Poster Presentation

Presenter: Jenny Gallacher

3142

Prognostic value of the Enhanced Liver Fibrosis (ELF) test to predict long-term outcomes in a NAFLD cohort with up to 35 years follow-up

Poster Presentation

Presenter: Jenny Gallacher

3176

Shortcomings of "FIB-4 First" strategy in screening for non alcoholic fatty liver disease (NAFLD) patients at risk for disease progression in a real life setting: will we be detracting therapeutic opportunities from patients?

Poster Presentation

Presenter: Simone Cappelli

3179

Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review

Poster Presentation

Presenter: Hamish Miller

3314

Screening for advanced fibrosis due to NAFLD in patients with type 2 diabetes in a retina scanning facility

Poster Presentation

Presenter: Andrea Lindfors

3332

FIB-4 predicts the risk of hepatocellular carcinoma in patients with type 2 diabetes: a longitudinal multicentre study

Poster Presentation

Presenter: Vincent Mallet

3356

Assessing the feasibility of AI-based Hamaguchi score estimation for NAFLD diagnosis using ultrasound images

Poster Presentation

Presenter: Alessia Visintin

3404

Diagnostic performance of non-invasive fibrosis markers in patients with immune-mediated disease and hepatic steatosis

Poster Presentation

Presenter: María Del Barrio Azaceta

3418

Evaluation of the performance of a novel single-nuclei digital pathology method for the continuous quantification of steatosis and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH

Poster Presentation

Presenter: Mathieu Petitjean

3434

Non-alcoholic fatty liver disease made easy for diabetologists: the automated fibrosis-4 index

Poster Presentation

Presenter: Mona Ismail

3476

Comparison between EASL and AGA algorithms for hepatology referral in 1572 outpatients with type 2 diabetes and suspected NAFLD seen in a diabetes clinic

Poster Presentation

Presenter: Laurent Castéra

3478

Impact of obesity on transient elastography accuracy among patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: María Del Barrio Azaceta

3481

Assessing the role of organokines as biomarkers for diagnosing non-alcohol related liver disease

Poster Presentation

Presenter: Andrea Jiménez Franco

3492

Non-Alcoholic Steatohepatitis impacts on visceral adipose tissue proteomic signature

Poster Presentation

Presenter: Cristian Martínez Navidad

3504

Are non-invasive tests of fibrosis effective in patients with metabolic associated fatty liver disease?

Comparative study between liver biopsy and non-invasive scores or fibroscan

Poster Presentation

Presenter: Annalisa Cespiati

3508

Patients with risk factors for liver diseases associated with hepatic steatosis constitute the target population for liver fibrosis assessment in primary care

Poster Presentation

Presenter: Rosario Hernández

3561

Two steps algorithm for the diagnosis of advanced liver fibrosis in general population. Real-life data

Poster Presentation

Presenter: Ana Pérez

3579

Validation of elastography criteria and cACLD risk model for diagnosis of compensated advanced chronic liver disease (cACLD) in NAFLD patients

Poster Presentation

Presenter: Antonio Liguori

3603

The sequential use of liver stiffness measurement and direct biomarkers of fibrosis is able to identify patients with severe non-alcoholic steatohepatitis

Poster Presentation

Presenter: filippo gabrielli

3615

Validation of Baveno VII criteria in NAFLD patients according to body mass index

Poster Presentation

Presenter: María Del Barrio Azaceta

3616

Evaluating the prevalence of liver fibrosis in children with non-alcoholic fatty liver disease using transient elastography, Dutch Fibrokids cohort

Poster Presentation

Presenter: Jalina Rooseboom

3636

Free light chains: novel serum biomarkers for NASH stratification, an update

Poster Presentation

Presenter: Francesca D'Ambrosio

3662

Soluble TREM2 and PRO-C3 as efficacy of intervention markers in NASH

Poster Presentation

Presenter: Charlotte Wernberg

3670

Echocardiography-based markers for subclinical cardiac dysfunction in patients with non-alcoholic fatty liver disease and significant fibrosis with preserved ejection fraction: preliminary data from a prospective monocentric Italian cohort

Poster Presentation

Presenter: Daphne D'Amato

3722

Correlation between serial Fibrosis-4 scores and liver stiffness measurements in patients with low-risk non-alcoholic fatty liver disease

Poster Presentation

Presenter: Tanvi Goyal

3731

AGILE 3+ and AGILE 4 scores for the diagnosis of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Kamela Gjini

3768

Incorporating artificial intelligence in portable infrared thermal imaging for the diagnosis and staging of nonalcoholic fatty liver disease

Poster Presentation

Presenter: Yana Davidov

3777

Utilization of fibroscan-AST scoring system to risk-stratify non-alcoholic steatohepatitis patients for clinical trials and novel therapies

Poster Presentation

Presenter: Phillip Leff

3783

Novel artificial intelligence-assisted digital pathology quantitative image analysis predicts the occurrence of liver-related clinical events in the multicentric, European, hepatic outcomes and survival fatty liver registry (HOTSURFR) study

Poster Presentation

Presenter: Vlad Ratziu

## NAFLD: Experimental and pathophysiology

119

Gamma-muricholic acid inhibits steatosis-dependent peroxidative impairment to attenuates nonalcoholic steatohepatitis by activation of FXR/SHP/LXR $\alpha$ /FASN signaling

Poster Presentation

Presenter: Qin Pan

231

Effect of vitamin D receptor signaling on endoplasmic reticulum stress in non-alcohol related steatohepatitis: exploring potential autophagy dependence

Poster Presentation

Presenter: Basma Alaa

257

Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in obesity-related progressive fatty liver disease

Poster Presentation

Presenter: Theresia Sarabhai

259

Improvement of liver fibrosis by a novel long acting Glucagon/GLP-1/GIP triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosis

Poster Presentation

Presenter: Jong Suk Lee

331

Dissecting NAFLD pathomechanisms using primary mouse liver and blood cells in a microfluidic perfusable compartmentalized liver-on-a-chip model

Oral Presentation

Presenter: Hanyang Liu

338

Novel role of macrophage Foxo1-mediated YAP-Notch axis in NASH progression

Poster Presentation

Presenter: Bibo Ke

348



Selective modulation of mitochondrial complex I ameliorates steatosis and hepatic inflammation in MCD-diet fed rats

Poster Presentation

Presenter: Laura Giuseppina Di Pasqua

359

Single-cell transcriptomics depicts metabolism reprogramming and immune landscape of bariatric surgery intervened nonalcoholic fatty liver

Poster Presentation

Presenter: Hanyang Liu

373

Uncovering a novel potential target in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Stine Marie Praestholm

391

Preclinical characterization of HPG7233, a potent, liver-target and highly selective thyroid hormone receptor beta agonist for nonalcoholic steatohepatitis

Poster Presentation

Presenter: Que Liu

399

mTORC1 response to glucose via dihydroxyacetone phosphate is regulated by MAT1A. Role in NAFLD

Poster Presentation

Presenter: María de los Reyes Luque Urbano

439

Efficacy and reproducibility of AI-assisted Gubra Histopathological Objective Scoring Technique (GHOST) in preclinical rodent models of NASH

Poster Presentation

Presenter: Susanne Pors

477

Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves nonalcoholic steatohepatitis (NASH) in a GAN diet-induced and biopsy-confirmed mouse model

Poster Presentation

Presenter: Christopher Jones

538

The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH

Poster Presentation

Presenter: Maider Apodaka-Biguri

596

Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

Poster Presentation

Presenter: Grazia Pennisi

611

Novel bariatric surgery models in mice – differential effects on body weight loss and fatty liver disease

Poster Presentation

Presenter: Louis Onghena

624

APB-R3, a novel long-acting IL-18 binding protein, inhibits IL-18 activity, and thereby ameliorates NASH progress with reduced liver fibrosis

Poster Presentation

Presenter: Eun-Bi Song

635

Intestinal Angptl4 perturbs gut barrier function in NAFLD

Oral Presentation

Presenter: Damien Chua

711

Inhibition of NLRP3 inflammasome activation by MK571, an multidrug resistance-associated protein (MRP) inhibitor

Poster Presentation

Presenter: Oh Seung Seok

838

Cannabidiolic acid (CBDA) regulates energy homeostasis and protects against non-alcoholic fatty liver disease (NAFLD) in mice

Poster Presentation

Presenter: Albert Giralt

839

A N-acylethanolamines mixture counteracts hepatic dysmetabolism induced in high-fat diet-fed obese mice

Poster Presentation

Presenter: Claudio Pirozzi

845

Unravelling an autophagy-dependent role of vitamin D in preserving gut integrity in experimental NASH

Poster Presentation

Presenter: Andrew Hakeem

896

Unravelling the role of iron-catalysed ferroptotic cell death in non-alcoholic steatohepatitis

Poster Presentation

Presenter: Cédric Peleman

918

Macrophage-derived osteopontin protects from non-alcoholic steatohepatitis

Oral Presentation

Presenter: Natalia Nieto

983

mir-22 inhibition as glp1 agonist orthogonal mechanism for nafl and nash treatment

Poster Presentation

Presenter: Riccardo Panella

995

Antagonism of C-C motif chemokine receptor 2 (CCR2) using a novel in silico designed peptide attenuates macrophage infiltration and non-alcoholic steatohepatitis in vivo

Poster Presentation

Presenter: Eline Geervliet

1040

Preclinical efficacy and clinical translatability of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Poster Presentation

Presenter: Michael Feigh

1069

NAFLD is a night-time disease driven by nocturnal hepatic, adipose, and skeletal muscle insulin resistance

Poster Presentation

Presenter: Thomas Marjot

1101

Light cytokine-deficiency effects in immune cells subpopulations in a murine non alcohol-related steatohepatitis model

Poster Presentation

Presenter: María Aguilar Ballester

1185

A new nuclear-erythroid-2-related factor 2 activator for the treatment of nonalcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices

Poster Presentation

Presenter: Adel HAMMOUTENE

1188

In vitro investigation of the role of adipocyte-derived exosomes in the development of non-alcoholic steatohepatitis

Poster Presentation

Presenter: Robim M Rodrigues

1193

Plasma short chain fatty acids are associated with non-alcoholic fatty liver disease and fibrosis severity

Poster Presentation

Presenter: Mira Thing

1215

GTX-011 improves fibrosis and hepatic stellate cells phenotype in human precision cut liver slices

Poster Presentation

Presenter: Jordi Gracia-Sancho

1222

A formulation of palmitoylethanolamide and phenolic compounds improves NAFLD-associated hepatic lipid dysmetabolism and oxidative stress in obese mice

Poster Presentation

Presenter: Stefania Melini

1223

The NRF2/b-TrCP axis: new therapeutic target in non-alcoholic steatohepatitis (NASH)

Poster Presentation

Presenter: Raquel Fernández Ginés

1248

Novel image analysis and immunohistochemistry advances to accompany pathologist driven non-alcoholic fatty liver disease diagnosis

Poster Presentation

Presenter: Maroua Tliba

1269

Utilization of multicellular liver-on-chip to study non-alcohol-related fatty liver disease

Poster Presentation

Presenter: Victoria Palasantzas

1283

Obeticholic acid administration increases hepatic eNOS levels counteracting lipid accumulation and fibrosis in a diet-induced ob/ob mouse model of NASH

Poster Presentation

Presenter: Laura Giuseppina Di Pasqua

1287

Longitudinal ultrasound imaging assessment of murine liver fibrosis in a high fat, fructose, cholesterol (FFC) model and its response to therapy

Poster Presentation

Presenter: Ryan Gessner

1340

High-fat diet exacerbates lipopolysaccharide-induced liver injury in obese KK-Ay mice

Poster Presentation

Presenter: Satoshi Sakuma

1341

Hepatic Apolipoprotein J facilitates metabolic disease progression by promoting mTOR-mediated suppression of autophagy

Poster Presentation

Presenter: Duan Shuangdi

1343

Loss of gut barrier integrity in nonalcoholic fatty liver disease is associated with severe fibrosis

Poster Presentation

Presenter: Punnag Saha

1368

Brain-derived neurotrophic factor knock-out mice develop nonalcoholic steatohepatitis

Poster Presentation

Presenter: Mayuko Shimizu

1390

Deletion of no-sensitive guanylyl cyclase protects from metabolic obesity but not from fibrosis in murine non-alcoholic fatty liver disease

Poster Presentation

Presenter: Muhammad Ashfaq-Khan

1394

A translational rat model to study metabolic associated fatty liver disease with fibrosis and portal hypertension

Poster Presentation

Presenter: María Martell

1428

Statins regulate PNPLA3 through a mechanism that requires SREBF2 in human liver cells

Poster Presentation

Presenter: Osman Ahmed

1445

Cholesterol-free ketogenic diet feeding improves experimental non-alcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Alessia Provera

1452

Co-stimulatory signals mediated by inducible T-cell co-stimulator (ICOS) influence the hepatic expansion auto-aggressive CD8+T-cells in non-alcoholic steatohepatitis (NASH)

Poster Presentation

Presenter: Cristina Vecchio

1466

The PNPLA3 I148M variant aggravates inflammation through dysfunctional LXR and PPAR gamma signalling in macrophages

Poster Presentation

Presenter: Emmanuel Dauda Dixon

1490

The PNPLA3 I148M variant initiates metabolic reprogramming in macrophages

Poster Presentation

Presenter: Emmanuel Dauda Dixon

1508

Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)

Poster Presentation

Presenter: Wenhao Li

1535

Effects of HSD17B13-targeting siRNA - R0737072 on Liver Fibrosis and Steatosis in a mouse model of NASH

Poster Presentation

Presenter: Li Ming Gan

1537

The disturbance of intracellular chloride induces the development and progression of nonalcoholic fatty liver disease

Poster Presentation

Presenter: Biguang Tuo

1571

Characterization of extracellular vesicles derived from human precision-cut liver slices in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Ke Luo

1625

Deletion of mixed lineage kinase domain like pseudokinase aggravate chronic alcohol induced liver injury via increasing apoptosis

Poster Presentation

Presenter: Hyo Young Lee

1629

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

Poster Presentation

Presenter: Eileen Yoon

1752

Artificial neural networks predict via label-free imaging analysis cellular injury in a human steatohepatitis model

Poster Presentation

Presenter: Julian Weihs

1845

Empagliflozin improves non-alcoholic fatty liver disease in a new translational mice model even without impact on weight loss

Poster Presentation

Presenter: Katharina Luise Hupa-Breier

1850

Secretomics identifies IGFBP1 as a stress signaling marker in human models for NAFLD

Poster Presentation

Presenter: Ruth Walker

1893

Mice lacking Cyclophilin B, but not Cyclophilin A, are significantly protected from the development of major features of NAFLD/NASH in a diet and chemical-induced model

Poster Presentation

Presenter: Winston Stauffer

1990

Validation and utility of artificial intelligence-based zonal annotations as an additional assessment tool for the histopathologic review of fibrosis in non-alcoholic steatohepatitis patients

Poster Presentation

Presenter: Gwyneth Soon

1994

IFI16 expression and its genotype variant are associated with NAFLD progression

Poster Presentation

Presenter: Hyun Goo Woo

2011

Quantification of vessel and bile duct parameters using Second Harmonic Generation in patients with NAFLD across fibrosis stages

Poster Presentation

Presenter: Jörn Schattenberg

2013

Anti-inflammatory and anti-fibrotic effects by simultaneous activation of glucagon, GIP, and GLP-1 of efocipegtrutide (HM15211) in thioacetamide-induced mouse model of liver injury and fibrosis

Poster Presentation

Presenter: Jung Kuk Kim

2019

Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models

Poster Presentation

Presenter: Xiaoxiao Wang

2041

Knockdown of a novel target gene enhances liver regeneration and attenuates chronic liver damage related liver fibrosis

Poster Presentation

Presenter: Shainan Hora

2064

The potential role of Omentin-1 in metabolic associated fatty liver disease (MAFLD): evidence from translational studies

Poster Presentation



Presenter: Noel Salvoza

2076

-Growth differentiation factor 15 in plasma and liver is associated with hepatic oxidative stress in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Mikkel Werge

2081

The PNPLA3 p.I148M risk variant was fixed in Neanderthals and segregates neutrally in humans

Poster Presentation

Presenter: Andreas Geier

2104

The effects of lipopolysaccharides on inducing nonalcoholic fatty liver disease in human precision-cut liver slices

Poster Presentation

Presenter: Mei Li

2177

Hepatic lipid flux, and not lipid amount, damages the liver during starvation-induced steatosis

Poster Presentation

Presenter: Sumeet Singh

2179

Quantitative ultrasound for liver steatosis assessment: benefits of measurements over a large two-dimensional region of interest on the performance of image-brightness-based parameters

Poster Presentation

Presenter: Adrien Besson

2188

Two-dimensional versus one-dimensional transient elastography: benefits of ultrasound imaging-based processing for liver stiffness measurements

Poster Presentation

Presenter: Adrien Besson

2207

Serum exosomal mir-4668-5p in Non-alcoholic Fatty liver Disease (NAFLD) patients with significant liver fibrosis

Poster Presentation

Presenter: Jong Eun Yeon

2264

Rilpivirine as an anti-inflammatory agent in non-alcoholic fatty liver disease: evidence from human hepatocytes, hepatic stellate cells and blood cells

Poster Presentation

Presenter: Isabel Fuster-Martínez

2277

The effect of cholesterol and its metabolites on human pluripotent stem cell-derived hepatic stellate cells

Poster Presentation

Presenter: Ingrid Wilhelmsen

2289

A guinea pig model of pediatric non-alcoholic steatohepatitis

Poster Presentation

Presenter: Kamilla Pedersen

2295

Opposite correlations between hepatic  $\beta$ -oxidation activity and triglyceride levels in male and female rats after a high-fat diet supplemented with liquid fructose

Poster Presentation

Presenter: Roger Bentanachs

2304

Inhibition of CCAT/enhancer-binding protein beta - serpinB3 axis by 1-piperidin propionic acid: a new targeted therapy for non-alcoholic steatohepatitis

Poster Presentation

Presenter: Francesca Protopapa

2309

Zebrafish larvae as a model system to characterize effects of metabolic, drug and genetic perturbations on liver fat accumulation

Poster Presentation

Presenter: Endrina Mujica

2375

Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction

Poster Presentation

Presenter: Katja Csarman

2382

Pemafibrate abrogates lipid liver accretion in a dietary model of fatty liver in rat

Poster Presentation

Presenter: Roger Bentanachs

2388

Improvement of NAFLD by Totum-448: effects in the liver, adipose tissue and gut in western-diet fed hamsters

Poster Presentation

Presenter: Vivien Chavanelle

2391

Evaluation of genetic risk score of a dysmetabolic and obese population of southern Italy

Poster Presentation

Presenter: Benedetta Maria Motta

2417

PNPLA3 I148M substitution exacerbate NAFLD under a long-term high fat diet

Poster Presentation

Presenter: Huan Su

2418

Exploring transcriptome profiles to combat non-alcoholic fatty liver disease

Poster Presentation

Presenter: Eva Kocar

2424

Modelling the biological mechanisms of a PNPLA3 polymorphism in a 3D human liver spheroid for NASH progression and drug efficacy

Poster Presentation

Presenter: Francisco Verdeguer

2469

Biomarkers identifying hepatic inflammation in non-alcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Elisabeth Galsgaard

2472

Senescence sensitizes hepatocytes for fatty acid-induced cytotoxicity by compromising the mitochondrial function

Poster Presentation

Presenter: Lilli Rausch

2512

Prophylactic and therapeutic hepatoprotective effects of Istanfibanor in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis

Poster Presentation

Presenter: Jacob Nøhr-Meldgaard

2516

The transcriptional function of TCF7L2 is spatially restricted in liver and regulates zoned metabolic pathways that contribute to NAFLD

Oral Presentation

Presenter: Luke Norton

2518

Characterization of portal inflammation and hepatic fibrosis in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Zobair Younossi

2552

Cyclophilin inhibition with rencofilstat shifts the liver transcriptome and lipidome in preclinical models toward resolution of nonalcoholic steatohepatitis

Poster Presentation

Presenter: Daren Ure

2591

A functional interaction between hepatic estrogen receptor- $\alpha$  and PNPLA3 p.I148M inherited variant drives fatty liver disease susceptibility in women

Poster Presentation

Presenter: Alessandro Cherubini

2649

Uncovering the role of ISOC1 in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Nicolas Goossens

2674

Development of a target engagement biomarker for HSD17B13: preclinical pharmacodynamic studies of small molecule inhibition of HSD17B13 by INI-822

Poster Presentation

Presenter: Heather Hsu

2698

Characterizing the histologic implications of resmetirom-induced liver volume reduction using artificial intelligence-powered digital pathology

Poster Presentation

Presenter: Janani Iyer

2709

A heterozygous N559Y mutation in Semaphorin 7A promotes nonalcoholic fatty liver disease progression through induction of hepatic ROS production and inflammation

Poster Presentation

Presenter: Yao Tong

2850

Targeting Apolipoprotein J restores autophagy and improves metabolic-associated fatty liver disease and diabetic nephropathy

Poster Presentation

Presenter: Wang Hsin-Tzu

2907

A novel HIF2A mutation causes dyslipidemia and promotes hepatic lipid accumulation

Poster Presentation

Presenter: Hongcui Cao

2935

Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr<sup>-/-</sup>.Leiden mice

Poster Presentation

Presenter: Eveline Gart

2939

Tyrosol reduces steatosis, fibrosis and inflammation in a murine model of NASH by modulating the immune hepatic phenotype

Poster Presentation

Presenter: Daniela Gabbia

2960

Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr<sup>-/-</sup>.Leiden mice

Poster Presentation

Presenter: José A. Inia

2964

Spatial proteotranscriptomics identifies macrophage heterogeneity in patients with at-risk non-alcoholic steatohepatitis

Oral Presentation

Presenter: Olivier Govaere

2982

Biomarkers of endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Rocío Montero-Vallejo

3010

Liver-associated dysmetabolism is related to brain structure and perfusion changes in obesity: the BARICO study

Poster Presentation

Presenter: Florine Seidel

3027

Endothelial and platelet-derived microvesicles as a biomarker of cardiovascular risk in patients with metabolic dysfunction-associated fatty liver disease (MAFLD)

Poster Presentation

Presenter: Sheila Gato Zambrano

3056

Single-cell RNA sequencing in DIAMOND mice reveals differentially regulated pathways specifically associated with the transition from simple steatosis towards NASH

Poster Presentation

Presenter: Rocío Gallego-Durán

3074

MicroRNA as novel biomarker for disease severity evaluation and therapeutic target in NAFLD

Poster Presentation

Presenter: Yoonseok Lee

3083

Peroxisome proliferator-activated receptor alpha and estrogen related receptor alpha ligand combinations ameliorate nonalcoholic fatty liver disease

Poster Presentation

Presenter: Milton Antwi

3106

Bridging the gap - how human microphysiological systems improve the translatability of NASH drug discovery

Poster Presentation

Presenter: Raul Silva

3193

Adipose tissue macrophage dysfunction and depletion are associated with a breach of vascular integrity in non-alcoholic steatohepatitis

Poster Presentation

Presenter: Schalk van der Merwe

3195

Increasing gut microbiota produced secondary bile acids to protect against non-alcoholic steatohepatitis

Poster Presentation

Presenter: Justine Gillard

3247

Decoding hepatocyte transcriptional responses in murine non-alcoholic steatohepatitis using single-nucleus RNA-sequencing

Poster Presentation

Presenter: Juliet Luft

3256

Circadian sleep-wake rhythms in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Christine Bernsmeier

3272

E2F2-promoted DNA damage in NASH worsens the metabolic scenario

Poster Presentation

Presenter: Beatriz Gómez Santos

3309

A novel autophagy inducer attenuated nonalcoholic steatohepatitis by regulating the adenylylase 6 in hepatocytes

Poster Presentation

Presenter: Jung Ho Hwang

3322

A novel orally available type IV autotaxin inhibitor, IOA-289, ameliorates steatosis and fibrosis in a preclinical model of non-alcoholic steatohepatitis

Poster Presentation

Presenter: Marit ten Hove

3330

Combined hepatic and adipose tissue transcriptomics highlights circulating NASH biomarkers

Poster Presentation

Presenter: Marica Meroni

3345

The role of chronic ER stress and calcium signalling in NASH associated carcinogenesis

Poster Presentation

Presenter: Muhammad Umair latif

3353

PNPLA3, MBOAT7 and TM6SF2 modify mitochondrial dynamics in NAFLD patients: dissecting the role of cell-free circulating mtDNA and copy number

Poster Presentation

Presenter: Miriam Longo

3372

A novel ALK5 inhibitor (TLR-X) attenuates steatosis and fibrosis in non-alcoholic steatohepatitis in vivo

Poster Presentation

Presenter: Marit ten Hove

3377

Perivascular macrophages contribute to adipose tissue angiogenesis in patients with advanced non-alcoholic fatty liver disease

Poster Presentation

Presenter: Celia Martínez Sánchez

3381

Thermoacoustic assessment of fatty liver disease - an early clinical feasibility study

Poster Presentation

Presenter: Michael Thornton

3391

b-Klotho deficiency in hepatic stellate cells (HSCs) prompts inflammation, oxidative stress and a pro-fibrotic phenotype

Poster Presentation

Presenter: Giada Tria

3420

The overexpression of TM6SF2 and/or MBOAT7 wild-type genes restores the mitochondrial lifecycle and activity in an in vitro NAFLD model

Poster Presentation

Presenter: Erika Paolini

3421

Development of a 2D nonalcohol-related steatohepatitis (NASH) model

Poster Presentation

Presenter: Esther Arnaiz Gonzalez

3429

Evaluating the hepatic efficacy and cardiometabolic profile of PNPLA3, TM6SF2, and other therapeutic targets for NAFLD: a drug-target Mendelian randomization analysis

Poster Presentation



Presenter: Daniel Rosoff

3443

A functional investigation of NASH-associated gene polymorphisms in human liver tissue

Poster Presentation

Presenter: Jelena Mann

3452

NAT10-mediated N4-acetylcytidine of hepatic lipogenesis-associated mRNA contributes to maternal high-fat diet-induced non-alcoholic fatty liver disease in juvenile offspring

Poster Presentation

Presenter: Qianren Zhang

3477

BMP-SMAD pathway upregulation in hepatocytes delays NAFLD-NASH development

Poster Presentation

Presenter: Laura Silvestri

3480

Hepatic inactivation of the epigenetic regulators Suv420h1-h2 mitigates NAFLD development and progression in mice

Poster Presentation

Presenter: Alessia Pagani

3537

Role of TGR5 in fat-to-liver communication during NAFLD

Poster Presentation

Presenter: André L. Simão

3547

The pan-PPAR agonist Lanifibranor improves increased portal pressure, endothelial dysfunction and liver histology in a rat model of early NAFLD

Poster Presentation

Presenter: Shivani Chotkoe

3597

Metabolic effects of n-3 fatty acids administered as Calanus oil to transgenic mice lacking functional peroxisome proliferator-activated receptor alpha

Poster Presentation

Presenter: Martin Rossmeisl

3607

Effect of housing temperature on nonalcoholic fatty liver disease development in C57BL/6N mice

Poster Presentation

Presenter: Olga Horakova

3628

Unraveling the individual contributions of the PPAR isotypes to the pan-PPAR agonist Lanifibranor-induced improvements of the vascular alterations and liver histology in a rat model of early NAFLD

Poster Presentation

Presenter: Shivani Chotkoe

3645

Caspase 8 reverses progression of NASH after hepatocyte-specific JNK deletion

Poster Presentation

Presenter: Ines Volkert

3658

Peculiar monocyte bioenergetic profile in nonalcoholic steatohepatitis (NASH)

Poster Presentation

Presenter: Moris Sangineto

3664

Beneficial effect of extravirgin olive oil on hepatic fatty acid accumulation and fibrogenesis: oleocanthalic acid as a promising compound for the treatment of NAFLD and NASH

Poster Presentation

Presenter: Martina Colognesi

3675

Human skin stem cell-derived hepatic cells with genetic predisposition for liver fat accumulation mimic susceptibility to develop metabolic dysfunction-associated fatty liver disease

Poster Presentation

Presenter: Alexandra Gatzios

3684

Ageing rates and oxidative stress in patients with non-alcoholic fatty liver disease and profound insulin resistance

Poster Presentation

Presenter: Anastasiia Radchenko

3780

Hepatocyte depletion of ERK5 impairs the response to lipotoxic oxidative stress resulting in defective insulin receptor signaling

Poster Presentation

Presenter: Armando Curto

3842

Type I NKT cells are involved in exacerbation of steatohepatitis in aged mice

Poster Presentation

Presenter: Kazuyoshi Kon

## NAFLD: Therapy

306

Hepatic fat and liver volume reductions – impact on non-alcoholic steatohepatitis trials and potential solutions using concomitant fibrosis with ballooning with fibrosis

Poster Presentation

Presenter: Stephen Harrison

366

CVI-301, a potent and selective thyroid hormone receptor beta full agonist, demonstrates profound total cholesterol and LDL-cholesterol reductions in a hyperlipidemic mouse efficacy model

Poster Presentation

Presenter: Jingwen Liu

383

HPG1860 in patients with NASH: a phase II double-blind, placebo-controlled, dose-ranging study

Poster Presentation

Presenter: Naim Alkhouri

508

Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis

Oral Presentation

Presenter: Stephen Harrison

587

A randomized controlled trial of kalmegh supplementation on non-alcoholic fatty liver disease

Poster Presentation

Presenter: Sanket Nandekar

659

Phase 1 study of the RNA interference therapeutic ALN-HSD in healthy adults and patients with nonalcoholic steatohepatitis

Oral Presentation

Presenter: John Gansner

739

The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease

Poster Presentation  
Presenter: Dominic Crocombe

782  
The effects of a novel online app (Noom Weight) on weight loss and liver biomarkers in patients with NAFLD: a single arm proof-of-concept study  
Poster Presentation  
Presenter: Naim Alkhouri

814  
Efficacy of digital health-supported lifestyle modification on patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis  
Poster Presentation  
Presenter: JOO HYUN OH

818  
A novel prescription digital therapeutic for the treatment of non-alcohol related fatty liver disease: feasibility study  
Poster Presentation  
Presenter: Naim Alkhouri

881  
Safety, tolerability, and preliminary efficacy of ascending doses of Human Allogeneic Liver-derived Progenitor Cells (HepaStem®) in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH)  
Poster Presentation  
Presenter: Sven Francque

913  
Efficacy and safety of LPCN 1144 in hypogonadal and eugonadal subjects for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis  
Poster Presentation  
Presenter: Benjamin Bruno

917  
Resmetirom improves the lipid/lipoprotein profile in patients with nonalcoholic fatty liver disease  
Poster Presentation  
Presenter: Naim Alkhouri

930  
Resmetirom helps regulate thyroid hormone levels within the liver in patients with nonalcoholic fatty liver disease  
Poster Presentation  
Presenter: Stephen Harrison

1300

Multicenter, randomized, double-blind, placebo-controlled trial of Fatty Acid Synthase (FASN) inhibitor, denifanstat, versus placebo in the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2B trial

Oral Presentation

Presenter: Rohit Loomba

1504

A deep exploration of bridging fibrosis evolution and individual septa parameters in NASH using quantitative second harmonic generation imaging reveals fibrosis changes in natural history and treatment-induced not seen with conventional histology

Poster Presentation

Presenter: Nikolai Naoumov

1568

Prospective, multi-center, open-label, randomized, omega-3-acid ethyl ester-controlled trial to assess the impact of the pemafibrate on liver function in hypertriglyceridemia patients with non-alcoholic fatty liver disease (Portrait study)

Poster Presentation

Presenter: Yoshio Sumida

1669

Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in F2-F3 NASH patients: secondary analysis of Ph2b HARMONY study

Poster Presentation

Presenter: Jörn Schattenberg

1922

Semaglutide improves non-alcoholic steatohepatitis: a 10-year retrospective study

Poster Presentation

Presenter: Parth Shah

1928

Correlation between severity of hepatic steatosis and markers of cardiometabolic health, and effect of lanifibranor therapy in patients with non-cirrhotic NASH

Poster Presentation

Presenter: Michael Cooreman

1934

SNP-630, a novel compound with multiple mechanisms, reverses liver inflammation and fibrosis in preclinical model and NASH phase 2 clinical trial

Poster Presentation

Presenter: Shin-Wei Chen

1954

Effects of a novel tetra-specific drug (OGB21502) in the obese mice model of liver disease

Poster Presentation

Presenter: Yunki Kim

1986

Barriers for regular exercise in people with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Kedar Deshpande

2196

The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients

Poster Presentation

Presenter: Leen Heyens

2315

A Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide in individuals with nonalcoholic fatty liver disease

Oral Presentation

Presenter: Manuel Romero Gomez

2321

Incidence and risk of dyslipidemia and hyperglycemia in a phase 3 study of obeticholic acid for the treatment of nonalcoholic steatohepatitis

Poster Presentation

Presenter: Manal Abdelmalek

2325

Impact of oral semaglutide on liver pathology and glucose metabolism in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus

Poster Presentation

Presenter: TADAMICHI KAWANO

2327

Lessons for the setting of an international integrated research platform to conduct adaptive trials in non-alcoholic steatohepatitis: results of the EU-PEARL project

Poster Presentation

Presenter: Elena de Sena

2349

Incidence and median times to onset and resolution of pruritus adverse events in a phase 3 study of obeticholic acid in patients with nonalcoholic steatohepatitis

Poster Presentation

Presenter: Zobair Younossi

2351

The influence of probiotics on biologic and imagistic alterations in non-alcoholic steato-hepatitis

Poster Presentation

Presenter: Elena Laura Iliescu

2376

Efficacy of pemafibrate in patients with non-alcoholic fatty liver disease complicated by dyslipidemia: a single-arm prospective study

Poster Presentation

Presenter: Hiroki Ono

2394

Treatment monitoring with the Agile 3+ score in patients with non-alcoholic steatohepatitis: analysis of data from a randomised placebo-controlled trial of semaglutide

Poster Presentation

Presenter: Laurent Castéra

2429

Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests

Poster Presentation

Presenter: Jörn Schattenberg

2440

Characterization of the patterns of resolution of histopathology after efruxifermin treatment of patients with NASH fibrosis (F2/3) for 24 weeks

Poster Presentation

Presenter: Cynthia Behling

2539

Endoscopy sleeve gastropasty is an effective treatment in steatohepatitis patients: a prospective, multicenter, randomized trial

Oral Presentation

Presenter: Javier Abad Guerra

2540

Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial

Oral Presentation

Presenter: Stephen Harrison

2581

Fat versus lean tissue loss in short term versus long term weight loss: a dynamic effect with implications for NASH trials

Poster Presentation

Presenter: Lars Johansson

2740

Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1

Poster Presentation

Presenter: Artur Plonowski

2881

Serological biomarkers PRO-C3 and PRO-C6 reveal the anti-fibrotic and pro-metabolic effects of MSDC-0602K, an insulin sensitizer, in non-alcoholic steatohepatitis patients during the EMMINENCE phase IIb study

Poster Presentation

Presenter: Alejandro Mayorca Guiliani

2932

Different class effects of oral hypoglycemic agents on nonalcoholic fatty liver disease regression and clinical outcomes: a nationwide cohort study

Poster Presentation

Presenter: Heejoon Jang

3023

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic parameters in individuals with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Matthew Armstrong

3376

Comparison of efficacy between liraglutide and phentermine/topiramate in obese patients with nonalcoholic fatty liver disease

Poster Presentation

Presenter: Young Eun Chon

3459



SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study

Poster Presentation

Presenter: Rosa Lombardi

3502

Effectiveness of prebiotic treatment in patients with non-alcoholic fatty liver disease (NAFLD) – a randomized trial

Poster Presentation

Presenter: Yaakov Maor

3549

Safety and efficacy of oral semaglutide in overweight diabetic patients with non-alcoholic fatty liver disease: an interim analysis

Poster Presentation

Presenter: Gauri Unithan

3689

Calorie restriction by time restricted intermittent fasting is better than standard calorie restriction in improving the metabolic profile and hepatic fibrosis in patients with non-alcoholic fatty liver disease

Oral Presentation

Presenter: Deepankshi Aggarwal

3743

B-cell activating factor in non-alcoholic steatohepatitis

Poster Presentation

Presenter: Iris Gines Mir

## Non-invasive assessment of liver disease except NAFLD

123

Safety and signal intensity of a novel liver-specific MRI contrast agent, Orviglance® (manganese chloride tetrahydrate), in adult subjects with mild, moderate, or severe hepatic impairment

Poster Presentation

Presenter: Andreas Norlin

229

Non-invasive assessment of adult bilirubin based on multispectral reconstruction technology and a smartphone platform

Poster Presentation

Presenter: WenQian Geng

426

Negative and positive predictive values of utilizing a two-stage approach to non-invasive fibrosis testing in patients with hepatitis C virus infection

Poster Presentation

Presenter: Rachel Epstein

671

Liver elastography is a useful technique to assess the severity of liver congestion in patients with Budd-Chiari syndrome

Poster Presentation

Presenter: MARCOS ANDRES THOMPSON

808

Screening for hepatic fibrosis in primary care by FIB-4 score, followed in second line by the ELF (enhanced liver fibrosis) test: what are the best thresholds?

Poster Presentation

Presenter: Denis Ouzan

825

Enhanced detection of cirrhosis and risk of advanced fibrosis with dynamic breath analysis

Poster Presentation

Presenter: Giuseppe Ferrandino

1059

Soluble CD163 as a biomarker of liver fibrosis in liver transplant recipients

Poster Presentation

Presenter: Emilie Høegholm Ernst Lauridsen

1122

Diagnosis and treatment of patients with suspected mucinous cystic neoplasms according to the EASL-guidelines: a retrospective cohort study

Poster Presentation

Presenter: Alicia Furumaya

1233

Liver stiffness can monitor disease severity and changes predict decompensation in alcohol-related liver disease

Poster Presentation

Presenter: Katrine Thorhauge

1306

Hepatobiliary manifestations in pediatric COVID-19

Poster Presentation

Presenter: Tetiana Stoieva

1339

Validation of cut-off values proposed by the society of radiologists in ultrasound liver elastography for diagnosis of compensated advanced chronic liver disease using 2D shear wave elastography

Poster Presentation

Presenter: Ji Hun Kang

1518

Fibrosis-4 score less than 2.67 and normal gamma-glutamyl transferase levels are associated with high negative predictive value for high-risk of liver stiffness in patients with primary biliary cholangitis

Poster Presentation

Presenter: Alan Bonder

1762

Dynamics of liver stiffness measurements provide incremental prognostic information in advanced chronic liver disease

Poster Presentation

Presenter: David JM Bauer

1847

Transient elastography efficiently detects severe fibrosis in patients with chronic hepatitis D

Poster Presentation

Presenter: Dominique Roulot

1881

Hospital discharge after percutaneous liver biopsy – less is more?

Poster Presentation

Presenter: Isabel Garrido

2057

Suitability of Fibroscan, APRI and FIB-4 indexes compared with liver biopsy in the evaluation of liver fibrosis: a single-centre retrospective study

Poster Presentation

Presenter: Alvaro Yagüe

2192

Does methotrexate therapy harm the liver in psoriatic patients?

Poster Presentation

Presenter: Isabel Bessa

2222

Use of magnetic resonance elastography for accurate staging of liver fibrosis in children with autoimmune hepatitis

Poster Presentation

Presenter: Wojciech Janczyk

2545

Performance of the scores diagnosis of autoimmune hepatitis in Moroccan patients

Poster Presentation

Presenter: Sara chbourk

2585

Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)

Oral Presentation

Presenter: Federico Ravaioli

2796

Repeatability of liver stiffness measurement by vibration-controlled transient elastography and controlled attenuation parameter in patients with cirrhosis

Poster Presentation

Presenter: Rohit Loomba

3069

Pattern of transient elastography in Egyptian people living with HIV: predictors of hepatic steatosis and fibrosis

Poster Presentation

Presenter: Ahmed Cordie

3208

Fibrosis-4 index is associated with cardiovascular risk in people living with HIV

Poster Presentation

Presenter: Giulia Morsica

3331

Assessment of international normalized ratio to albumin ratio in predicting mortality in decompensated liver disease at a resource limited medical centre

Poster Presentation

Presenter: Marium Fatima Waqar

3596

Diagnostic accuracy of magnetic resonance elastography, transient elastography and predictive scores in cystic fibrosis related liver steatosis and fibrosis

Poster Presentation

Presenter: Carmen Lara Romero

3711

Liver stiffness measurement Baveno VII rule of 5 and risk of hepatocellular carcinoma after HCV eradication in patients with cirrhosis

Poster Presentation

Presenter: Binu John

3759

Moving toward a more perfect liver function test: the next generation of HepQuant tests

Poster Presentation

Presenter: Michael McRae

## Nurses and Allied Health Professionals

308

Mental health, quality of life, and stigmatization in Danish patients with liver disease

Poster Presentation

Presenter: Nadja Østberg

630

Analysis of health-related quality of life in the liver transplant patient conducted more than 10 years ago, statewide study

Poster Presentation

Presenter: Fernando García Pérez

742

Changes in frailty as a predictor of readmission risk in patients with liver cirrhosis. Preliminary results

Poster Presentation

Presenter: Martina Perez

1079

Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)

Oral Presentation

Presenter: Kate Hallsworth

1337

Better strategies are needed to increase engagement of patients with cirrhosis with allied health and community services

Poster Presentation

Presenter: Patricia Valery

1438

Who's testing who? Healthcare professional and patient knowledge of hepatitis delta virus and appropriate testing in an East Midlands hospital

Poster Presentation  
Presenter: Rachel Ryder

1514  
Quality improvement project: improving early identification of liver disease in diabetic patients in a district general hospital with opportunistic FibroScan®  
Poster Presentation  
Presenter: Amy Thatcher

1624  
Value based healthcare: patient perception of the liver cancer advanced practice nurse care at the Barcelona clinic liver cancer  
Poster Presentation  
Presenter: Neus Llarch

1646  
Development of a web-based mobile health application (ReLiver-N App) for patient activation, self-efficacy, and quality of life in patients with liver cirrhosis  
Poster Presentation  
Presenter: Ferya Celik

1656  
Clinical interdisciplinary development of a home-based enteral nutrition initiation and refeeding monitoring model of care for patients with chronic liver disease  
Poster Presentation  
Presenter: Erin Russell

1971  
Pharmacist led telemonitoring and titration of carvedilol for ambulatory patients with compensated cirrhosis and clinically significant portal hypertension  
Oral Presentation  
Presenter: Eliza Flanagan

2233  
Fellowship for hepatology nurses – a new exchange program at Karolinska university hospital  
Poster Presentation  
Presenter: Pia Loqvist

2381  
Refractory ascites in cirrhosis is associated with a major psychological burden in patients with cirrhosis and caregivers  
Oral Presentation  
Presenter: Ana Belen Rubio Garcia

2445

Advanced practice nurses' scope of practice in liver care: evaluation of two different Swiss settings

Poster Presentation

Presenter: Patrizia Kuenzler

2536

Hepatology nursing consultation in a tertiary hospital without liver transplantation: initial experience

Poster Presentation

Presenter: Francisco Jorquera

2603

Hepatitis C education and training for community pharmacists in Ireland

Poster Presentation

Presenter: Miriam Coghlan

2985

Health-related quality of life in a population at-risk of NAFLD or ArLD

Poster Presentation

Presenter: Helle Lindholm Schnefeld

3329

Effectiveness of vaccine education on vaccine awareness and vaccine uptake in patients with cirrhosis of liver of a tertiary care center in South India

Poster Presentation

Presenter: Lt Col (Dr) Ajee K L

3409

Community dispensed hepatitis c virus treatment for 'hard to reach' opiate substitution treatment service users in dublin: an intervention to address hcv infection eradication

Oral Presentation

Presenter: Gillian Farrell

3527

First hepatitis C mass-testing in a category A prison in the United Kingdom

Poster Presentation

Presenter: Alison West

3553

A prospective study to assess medication adherence to systemic therapy among patients with hepatocellular carcinoma

Poster Presentation

Presenter: Suja Kumari

## Public Health: Except viral hepatitis

147

Anti-hepatitis B surface antigen negativity can be a risk factor for SARS-CoV-2 infection in SARS-CoV-2 vaccinated healthcare workers

Poster Presentation

Presenter: Tomohide Kurahashi

249

Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019

Poster Presentation

Presenter: Chi Zhang

337

Socioeconomic disparities and primary liver cancer incidence between 2006 and 2016: analyze by subtypes, a French population-based study

Oral Presentation

Presenter: Bertille Comoz

437

Socio-economic disparities drive the prevalence of non-alcoholic Fatty Liver Disease (NAFLD) among teenagers in the United States

Poster Presentation

Presenter: Zobair Younossi

613

Identify, screen and treat via electronic pathway (I-STEP): an innovative approach to wait list management for general liver hospital outpatient referrals

Poster Presentation

Presenter: Eliza Flanagan

700

Prevalence and predictors of clinically significant pruritus in patients with non-alcoholic fatty liver disease (NAFLD): data from the global NASH registry™ (GNR™)

Poster Presentation

Presenter: Zobair Younossi

760

Influence of the COVID-19 pandemic on liver cancer-related mortality in the United States

Poster Presentation

Presenter: Zhu Zhan



780

A systematic review of interventions for alcohol use disorder in patients with cirrhosis or alcohol-related hepatitis

Poster Presentation

Presenter: Christopher Oldroyd

833

Increased risk of hepatocellular carcinoma among first-degree relatives of patients with biopsy-proven NAFLD - a multigenerational nationwide cohort study

Oral Presentation

Presenter: Fahim Ebrahimi

1062

Exploring attitudes towards non-invasive liver fibrosis tests in secondary care pathways: comparing national surveys between 2014 and 2021

Poster Presentation

Presenter: Kushala Abeysekera

1164

Global burden of common cancers attributable to metabolic risks from 1990 to 2019

Poster Presentation

Presenter: Qing-Qing Xing

1197

A pilot study to improve the uptake of hepatocellular carcinoma surveillance

Poster Presentation

Presenter: Maria Qurashi

1311

Higher ultra-processed food intake positively associated with non-alcoholic fatty liver disease in both adolescents and adults

Poster Presentation

Presenter: Xuehong Zhang

1320

Vulnerable offspring: a nationwide Danish cohort study of adverse health outcomes in offspring of parents with alcohol-related liver disease compared to controls

Oral Presentation

Presenter: Gro Askgaard

1684

Non-alcoholic fatty liver disease awareness, misperception, and their association with healthcare access in Korean general population: a nationally representative survey

Poster Presentation

Presenter: Jun-Hyuk Lee

1699

Non-alcoholic fatty liver disease prevalence has increased in Australia, particularly amongst women

Poster Presentation

Presenter: Karl Vaz

2347

Multiple vitamin co-exposure and mortality risk in metabolic dysfunction-associated fatty liver disease

Poster Presentation

Presenter: Wang Zilong

2387

Machine learning models are superior to FIB-4 as a first line stratification tool for liver disease in the community

Oral Presentation

Presenter: Huw Pursell

2410

Acceptability and feasibility of a multimodal early detection pilot study for liver disease in high risk groups: "Alright My Liver?"

Poster Presentation

Presenter: Ann Archer

2571

Evidence of significant alcohol-associated mortality in a large population cohort in Uganda

Poster Presentation

Presenter: Cori Campbell

2628

Health economics of the enhanced liver fibrosis test in the detection of advanced liver fibrosis in patients with non-alcoholic fatty liver disease in the UK

Poster Presentation

Presenter: Zobair Younossi

2702

Comparison of the opt in vs opt out policy and its impact on the donation rate of liver transplantation in the Colombian healthcare system

Poster Presentation

Presenter: Andres Gomez Aldana

2711

Socioeconomic disparities and survival in patients with primary liver cancer by subtype: a french population-based study

Poster Presentation

Presenter: Thi Thu Nga Nguyen

2720

Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma

Poster Presentation

Presenter: Luis Antonio Diaz

2884

Healthcare resource use and costs among patients with primary sclerosing cholangitis in Sweden - a retrospective population-based cohort study

Poster Presentation

Presenter: Hannes Hagström

2991

Metabolic dysfunction associated fibrosis-5 (MAF-5) score to identify at-risk liver fibrosis and to predict prognosis in a population-based setting

Oral Presentation

Presenter: Willem Pieter Brouwer

3002

Metabolomic and genomic profiling of alcoholic liver disease and cirrhosis of the liver

Poster Presentation

Presenter: Sini Kerminen

3087

Relationships between education and non-alcoholic fatty liver disease

Poster Presentation

Presenter: Florian Koutny

3454

COVID-19 and excess mortality of patients with liver cancer in France, January 2020 - September 2022

Poster Presentation

Presenter: Stylianos Tzedakis

3497

Detection of potential subjects at risk of liver fibrosis in general population in Spain

Poster Presentation

Presenter: María Del Barrio Azaceta

3581

An explainable artificial intelligence model for prediction of high-risk nonalcoholic steatohepatitis

Poster Presentation

Presenter: Basile Njei

3680

Lifestyle-related population-attributable risk for non-alcoholic fatty liver disease in adolescents and youth

Poster Presentation

Presenter: Vanessa Garcia-Larsen

3706

SIRIUS project: sensing probe exploring liver fibrosis in Slovakia

Poster Presentation

Presenter: Lubomir Skladany

3763

Who is safe from chronic liver disease? A population-based approach for early detection in the US

Oral Presentation

Presenter: Nakia Chung

3772

Impact of coronavirus disease pandemic on hospitalizations due to chronic liver disease in Belgrade, Serbia

Poster Presentation

Presenter: Ivana Pantic

## Public Health: Viral hepatitis

145

Occult hepatitis B virus infection among blood donors in northwestern Greece

Poster Presentation

Presenter: Fotios Fousekis

222

Hepatitis C seroconversion rates among individuals with repeated testing – Georgia, 2017-2021

Poster Presentation

Presenter: Davit Baliashvili

340

Micro-elimination of Hepatitis C virus infection in mountainous and remote areas of Taiwan – a multi-center collaborative care model

Poster Presentation

Presenter: Ching-Chu Lo

485

Late presentation of chronic hepatitis C for care in Georgia: data from the national hepatitis C elimination program, 2016-2021

Poster Presentation

Presenter: Tengiz Tsertsvadze

544

Implementation of anti-HDV reflex testing among HBsAg-positive in a tertiary center in South Italy

Poster Presentation

Presenter: Valentina Cossiga

581

Factors associated with HCV reinfection among treated people who inject drugs in the HCV elimination program in Georgia

Poster Presentation

Presenter: Lasha Gulbiani

648

Evaluation of hepatitis B core-related antigen rapid test (HBcrAg-RDT) to identify HBV-infected women eligible for peripartum antiviral prophylaxis in resource-limited countries

Poster Presentation

Presenter: Jeanne Perpétue Vincent

665

Patients with hepatitis B and D are more often linked to medical care than patients with hepatitis C

Poster Presentation

Presenter: Elena Vargas Accarino

708

Burden of hepatitis C in pregnant women and children in the United States

Poster Presentation

Presenter: Paul Wasuwanich

737

HCV screening before endoscopy in hepatogastroenterology outpatient clinic: results of DEPISTC-ENDO study

Poster Presentation

Presenter: André-Jean Remy

745

The impact of hepatitis B and C serologies on the outcomes of non-liver solid organ transplantation

Poster Presentation  
Presenter: Maria Stepanova

811  
Effectiveness of a direct care action strategy at the drug addiction center (and treat in point of care) for the detection and treatment of hepatitis C in drug users on opioid agonist substitution therapy  
Poster Presentation  
Presenter: Inés Sáenz de Miera

859  
Screening for hepatitis C virus using rapid diagnostic test (RDT) coupled with mammography in women aged from 50 to 74 years in Montpellier (France). (Mamm'OC NCT05067374)  
Poster Presentation  
Presenter: Magdalena Meszaros

884  
Improving blood borne virus screening in immigration removal centres in the UK  
Poster Presentation  
Presenter: Katie Abraham

887  
D-Mongolia: new strategy for hepatitis B, D and C screening and linkage to care in Mongolians living in Spain  
Poster Presentation  
Presenter: Adriana Palom

891  
Impact of the anti-HDV reflex testing on the reduction of hepatitis D burden in Spain  
Poster Presentation  
Presenter: Maria Buti

910  
Development of a rapid workflow for detecting HCV RNA from whole blood  
Poster Presentation  
Presenter: Matthew Pauly

984  
Implementing hepatitis C self-testing (HCVST) among the general population in Georgia: preliminary results  
Poster Presentation  
Presenter: Ketevan Stvilia

1028

Low prevalence found in HCV micro-elimination program among HIV-negative MSM and TW in a community center in Spain

Poster Presentation

Presenter: Àngel Rivero Calaf

1055

Who is missing? Analysis of the 2021 Georgian seroprevalence survey to identify the population left to be screened for hepatitis C

Poster Presentation

Presenter: Sophia Surguladze

1060

Hepatitis E virus seroprevalence in immunosuppressed patients in Belgium: a prospective study

Poster Presentation

Presenter: Marie Philippart

1082

Retrospective study of hepatitis C virus antibodies and active viral replication in at-risk population with dual diagnosis in a Spanish university hospital

Poster Presentation

Presenter: Cristina del Rio-Cubilledo

1107

Development of a behaviour-based score predicting hepatocellular carcinoma among patients with chronic hepatitis B virus infection in France (ANRS CO22 HEPATHER)

Oral Presentation

Presenter: Clémence Ramier

1150

Micro-elimination of chronic hepatitis C virus in patients with psychiatric disorders: a multidisciplinary strategy in the outpatient mental health center

Poster Presentation

Presenter: Inés Sáenz de Miera

1183

Engagement of patients with viral hepatitis diagnosed by opt-out universal emergency department testing

Poster Presentation

Presenter: Amy Teague

1199

The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: descriptive results from a cross-sectional study across Italy, Germany, Spain and the US

Poster Presentation  
Presenter: Pietro Lampertico

1205  
Characterization of recent HCV infections and re-infections among the high-risk population from Georgia using global hepatitis outbreak and surveillance technology  
Poster Presentation  
Presenter: Adam Kotorashvili

1216  
Retrospective study of hepatitis C virus antibodies and active viral replication in patients with severe mental illness in a Spanish university hospital  
Poster Presentation  
Presenter: Cristina del Rio-Cubilledo

1241  
Hepatitis D infection in a HBsAg cohorts referred from specialist liver clinics vs. reflex community referred patients in South East London  
Poster Presentation  
Presenter: Ivana Carey

1271  
Late presentation for hepatitis C treatment; prevalence and risk factors in the Swiss hepatitis C cohort  
Poster Presentation  
Presenter: Nathalie Brunner

1288  
Low HBV treatment uptake among Rwandan people with HIV and HCV co-infections: a cohort study from 2016-2019  
Poster Presentation  
Presenter: Makuza Jean Damascene

1291  
Prevalence of chronic hepatitis C on the Swiss organ transplantation list from 2009-2019  
Poster Presentation  
Presenter: Philip Bruggmann

1302  
New and easy strategy for mass screening for hepatitis C in leisure spaces  
Poster Presentation  
Presenter: Sonia Albertos Rubio



1576

The impact of removing all hepatitis B virus (HBV) testing and treatment restrictions

Poster Presentation

Presenter: Homie Razavi

1614

Simple treatment eligibility score for chronic HBV infection at peripheral health facilities in sub-Saharan Africa

Poster Presentation

Presenter: Nicolas MINIER

1788

Incidence of hepatitis C virus antibody seroconversion among people who inject drugs in Tbilisi, Georgia

Poster Presentation

Presenter: Tengiz Tsertsvadze

1799

Are primary healthcare facilities ready to provide hepatitis delta services in Mongolia: service availability and readiness assessment findings

Poster Presentation

Presenter: Azzaya Oktyabri

1812

Prevalence and incidence of delta hepatitis in HIV-HBV coinfecting patients in the Dat'AIDS cohort

Poster Presentation

Presenter: Dulce Alfaiate

1819

Spontaneous clearance of hepatitis C virus infection in the country of Georgia, 2015-2021

Poster Presentation

Presenter: George Kamkamidze

1820

Hepatitis C screening and elimination strategy: implementation of the FOCUS program in Almería, Spain

Poster Presentation

Presenter: Marta Casado

1829

Opt-out testing for hepatitis B and C infections in adults attending the emergency department of a London Hospital

Poster Presentation

Presenter: Jingwei Zeng

1925

Cascade of care among people with an HBV notification in New South Wales, Australia, including diagnosis, specialist assessment, and treatment uptake

Poster Presentation

Presenter: Syed Hassan Bin Usman Shah

1993

Zero-HCV before end stage renal disease (ESRD): a collaborative “treat-all” approach to eliminate HCV in chronic kidney disease population in Taiwan

Poster Presentation

Presenter: Tsung-Hui Hu

1996

Characterizing individuals who remain to be screened and those lost to follow-up from Georgia’s HCV elimination program

Poster Presentation

Presenter: Sophia Surguladze

1997

HCV screening automation at hospitals level based on extrahepatic manifestations and risk profile.

Preliminary results from the Hospitals without\_ C programme (hospitales sin C)

Poster Presentation

Presenter: ANTONIO GARCIA HEROLA

1999

Tailored message intervention by nudge theory increases the number of the viral hepatitis screening for Japanese workers and consultation behavior of positive patients - Consideration of 1.7 million general check-up participants

Poster Presentation

Presenter: Masaaki Korenaga

2095

Progress in hepatitis C screening as part of the hepatitis C elimination program in Georgia

Poster Presentation

Presenter: Maia Tsereteli

2114

Innovation linkage model to re-engage lost-to-follow-up individuals in the national hepatitis C elimination program in Georgia

Poster Presentation

Presenter: Vladimer Getia

2127

Screening, confirmation, and treatment rates of hepatitis C virus infections in patients undergoing surgery in a single tertiary academic centre

Poster Presentation

Presenter: Jae Seung Lee

2145

What is the most effective strategy to identify HBV-infected pregnant women eligible for antiviral prophylaxis in Burkina Faso? A modelling study on different testing strategies

Poster Presentation

Presenter: Andréa Gosset

2193

Effectiveness of birth-dose vaccine in preventing mother-to-child transmission of hepatitis B virus in Ethiopia

Poster Presentation

Presenter: Mebrihit Arefaine

2320

Patients with persistently abnormal liver biochemistry are under-investigated and can be rapidly identified using a novel case-finding database

Poster Presentation

Presenter: Almuthana Mohamed

2378

One step closer to the goal: mobile InfoHep centre offering detection, protection, prevention and treatment / linkage-to care services in Croatian penalty institutions

Poster Presentation

Presenter: Tatjana Reic

2434

Hepatitis B, C and D infections among nine high-risk populations in Burkina Faso, West Africa

Poster Presentation

Presenter: Armel Moumouni SANOU

2498

Risk of developing cancer - comparison of HBV, HCV and smoking

Poster Presentation

Presenter: Homie Razavi

2509

Complete and maintained elimination of hepatitis C in patients in methadone substitution program

Poster Presentation

Presenter: Esther Rodríguez Candelaria

2551

Final results of a hepatitis C micro-elimination campaign in a highly endemic, well-defined demographic area of peri-urban Karachi, Pakistan

Poster Presentation

Presenter: Saeed Sadiq Hamid

2580

Hepatocellular carcinoma associated with chronic hepatitis C: a case for an annual mortality and morbidity review

Poster Presentation

Presenter: Neil McInnes

2607

The impact of Covid-19 on hepatocellular carcinoma screening in British Columbia

Poster Presentation

Presenter: Makuza Jean Damascene

2610

Exploring the impacts of the COVID-19 pandemic on access to HCV-related care and support: findings from a survey of people with lived experience of incarceration and/or substance use in British Columbia, Canada

Poster Presentation

Presenter: Terri Buller-Taylor

2624

Chronic hepatitis B virus infection and risk of stroke types: a prospective cohort study of 0.5 million chinese adults

Oral Presentation

Presenter: Elizabeth Hamilton

2627

Reimplementation of a revamped cost-effective national elimination strategy is the only way Brazil moves towards eliminating HCV

Poster Presentation

Presenter: Alexis Voeller

2652

New tools reaching hepatitis C elimination: automatic hepatitis C virus detection in presurgical evaluations

Poster Presentation

Presenter: MARINA ELIANA MILLAN LORENZO

2654

Late diagnosis of hepatitis C in Quebec, Canada, 1990-2018: a population-based study

Poster Presentation

Presenter: Ana Maria Passos-Castilho

2659

Metabolic-associated fatty liver disease in socio-economic vulnerable population with chronic hepatitis B and C

Poster Presentation

Presenter: Speranta Iacob

2663

Acceptance and feasibility of hepatitis C screening by assisted self-testing in high-risk and general population: a randomized clinical trial

Poster Presentation

Presenter: Federica Benitez Zafra

2681

Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona

Poster Presentation

Presenter: Anna Pocerull

2687

Cantabria on the way to HCV elimination. Differential prevalence of hepatitis C in Cantabria:

@CohorteCantabria vs ETHON cohort

Poster Presentation

Presenter: Joaquin Cabezas

2701

Survey to evaluate the implementation of the recommendations on the comprehensive diagnosis of viral hepatitis in a single extraction: where are we?

Poster Presentation

Presenter: Joaquin Cabezas

2703

The evaluation of people suspected of sexually transmitted diseases requires tools for the comprehensive diagnosis of viral hepatitis and HIV

Poster Presentation

Presenter: Joaquin Cabezas

2777

Impact of hepatitis B family screening, counselling and education program on active case detection: a step towards elimination through preventive hepatology clinic in India

Poster Presentation  
Presenter: Ajeet Singh Bhadoria

2816  
Prevalence of hepatitis B and C viral infections among transgenders and men who have sex with men in Pakistan  
Poster Presentation  
Presenter: Hassan Mahmood

2822  
Strategies to eliminate hepatitis C virus infection in the Americas  
Poster Presentation  
Presenter: Luis Antonio Diaz

2844  
Comparison of HCVRNA results using plasma separation card with gold standard veni-puncture  
Poster Presentation  
Presenter: Huma Qureshi

2847  
Pandemic preparedness and viral hepatitis - Global survey of hepatitis program managers and healthcare providers  
Poster Presentation  
Presenter: Nida Ali

2981  
New hepatitis C diagnoses in 2022. Who and where. Referral efficiency  
Poster Presentation  
Presenter: Cristina Suárez Montesdeoca

3028  
Low coverage of hepatitis D virus testing in individuals with HIV and HBV in the Netherlands: a retrospective, cross-sectional and longitudinal study  
Poster Presentation  
Presenter: Anders Boyd

3058  
The impact of hepatitis C and socio-demographic variables on Health-related quality of life among patients in Pakistan  
Poster Presentation  
Presenter: Siwaporn Niyomsri

3071

A nationwide study on the core indicators related to elimination of viral hepatitis B and C in Korea  
Poster Presentation  
Presenter: In Hee Kim

3081  
HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network  
Poster Presentation  
Presenter: Massimo Puoti

3093  
Qualitative interviews to assess the impact of chronic hepatitis delta virus infection on health-related quality of life in untreated patients from the US, Italy, Spain, and Germany  
Poster Presentation  
Presenter: Pietro Lampertico

3105  
Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States  
Poster Presentation  
Presenter: Douglas T Dieterich

3131  
Results from a community-based intervention to increase viral hepatitis screening among at-risk African migrants in Catalonia, Spain (2020-2022)  
Poster Presentation  
Presenter: Camila Picchio

3168  
An international coalition to eliminate hepatitis B virus (ICE-HBV) survey confirms inadequate HBV/HDV screening and diagnosis diminishing elimination targets in resource limited settings  
Poster Presentation  
Presenter: Daryl Lau

3305  
Tenofovir prophylaxis during pregnancy for the elimination of mother-to-child transmission of hepatitis B virus: a cost-effectiveness analysis  
Poster Presentation  
Presenter: Pisit Tangkijvanich

3306  
Care cascade for children with hepatitis C virus exposure in the United States and implications of early ribonucleic acid testing  
Poster Presentation

Presenter: Megan Curtis

3308

A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: the 1969-1989 birth-cohort

Poster Presentation

Presenter: Roberta D'Ambrosio

3328

Hepatitis delta virus infection in Turkey: A meta analysis of prevalence

Poster Presentation

Presenter: Mehlika Toy

3334

Finding undiagnosed hepatitis C cases: using machine learning to identify clinical attributes and social determinants of health to improve the screening-to-diagnosis ratio and improve efficiency and linkage to care

Oral Presentation

Presenter: Linda Chen

3428

Population adjusted prevalence of hepatitis delta virus in 21 countries and territories

Poster Presentation

Presenter: Devin Razavi-Shearer

3457

Trends in hepatitis B and hepatitis C related hepatocellular carcinoma, 2015 to 2030

Poster Presentation

Presenter: Devin Razavi-Shearer

3474

Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers

Poster Presentation

Presenter: Henry Njuguna

3514

Hepatitis C screening program in Lithuania: first results and scenarios for virus elimination

Poster Presentation

Presenter: Limas Kupcinskas

3526



A modelling study of the impact of scaling up of HCV case finding and treatment for people who inject drugs in English region of Bristol and Severn

Poster Presentation

Presenter: Zoe Ward

3529

The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: feasibility, vaccination coverage and two-dose vaccine effectiveness

Oral Presentation

Presenter: Iza Ciglemecki

3546

Challenges and strategies to improve linkage to care and treatment for hepatitis C in pregnancy: perspectives from a global community of practice

Poster Presentation

Presenter: Neil Gupta

3558

Hepatitis C seroprevalence screening and linkage to care of unknown infected patients admitted to a tertiary care emergency department: on the road to achieve the WHO 2030 virus elimination target

Poster Presentation

Presenter: Roberta Lasco

3565

Estimation of prevalence of chronic HCV infection in EU/EEA countries using multiparameter evidence synthesis

Poster Presentation

Presenter: Georgios Nikolopoulos

3578

Estimating the economic value allocation of the social surplus generated by the utilization of second-generation direct-acting antivirals for hepatitis C in the United States, 2015-2019

Poster Presentation

Presenter: Jens Grueger

3611

Multidisciplinary approaches to increase hepatitis C screening rates in a New York City primary care clinic

Poster Presentation

Presenter: Carolina Villarroel

3612

Microbiological analysis of acute hepatitis of unknown aetiology in children in Spain

Poster Presentation

Presenter: Ana Avellon Calvo

3698

Consider schistosomiasis screening in hepatitis B patients from endemic regions: a hepatic comorbidity that should not be neglected

Poster Presentation

Presenter: Marie-Noëlle Hilleret

3727

Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial part 2

Poster Presentation

Presenter: Brian CONWAY

3741

Cascade of care and HCV treatment of inner city populations engaged in care through community pop-up clinics (CPCs)

Poster Presentation

Presenter: Brian CONWAY

3786

Health outcomes of hepatitis C direct-acting antivirals: beyond real life sustained viral response data

Poster Presentation

Presenter: Carmen Alonso Martin

3799

Estimating the residual risk of hepatitis B mother-to-child transmission in The Gambia, 30 years after HBV vaccine implementation

Oral Presentation

Presenter: Rohey Bangura

3807

Automation of hepatitis C screening through electronic health record algorithm

Poster Presentation

Presenter: Vítor Magno Pereira

3822

Emergency department contribution to hepatitis C elimination through opportunistic screening in Cascais, Portugal

Poster Presentation

Presenter: Inês Vaz Pinto

3844

Treatment start resilience but testing decrement in a coordinated statewide HCV treatment program during COVID: lessons learned and future steps

Poster Presentation

Presenter: Yvonne Lynch-Hill

## Rare liver diseases (including paediatric and genetic)

38

Effects of tetrathiomolybdate, trientine, and penicillamine on intestinal copper uptake: a randomized placebo-controlled <sup>64</sup>Cu PET/CT study

Poster Presentation

Presenter: Frederik Teicher Kirk

40

Understanding the experience of patients with alpha-1 antitrypsin deficiency (AATD)-associated liver disease

Poster Presentation

Presenter: Virginia Clark

41

Differences in the rates of liver-related clinical events in paediatric patients with alpha-1 antitrypsin deficiency-associated liver disease in the United States

Poster Presentation

Presenter: Ed G. Marins

47

Final results from a phase 1/2, 48-month, open-label extension study of givosiran in patients with acute intermittent porphyria

Oral Presentation

Presenter: Eliane Sardh

60

Clinical characteristics and pathogenic mechanism of five new ABCB4 missense mutations in progressive familial intrahepatic cholestasis type 3

Poster Presentation

Presenter: yuhang weng

142

Effects of tetrathiomolybdate on copper distribution and biliary excretion: a controlled <sup>64</sup>CuCl<sub>2</sub> PET/MRI

Poster Presentation

Presenter: Frederik Teicher Kirk

268

Liver transplantation for Wilson disease: single center experience

Poster Presentation

Presenter: amnah Alhanaee

287

Incidence of hemochromatosis in HFE p.H63D homozygote and p.C282Y/H63D compound heterozygote individuals

Poster Presentation

Presenter: Lorenz Michael Pammer

303

Targeting CCL24 in primary sclerosing cholangitis with CM101: rationale and study design

Poster Presentation

Presenter: Douglas Thorburn

370

Does earlier introduction of azathioprine result in a reduced cumulative dose of corticosteroid therapy in the treatment of autoimmune hepatitis (AIH) and does this result in the same degree of biochemical response?

Poster Presentation

Presenter: Sital Shah

396

Impact of suffering Wilson disease in Spain: an observational cross-sectional multicenter study

Poster Presentation

Presenter: Zoe Mariño

475

Association of circulating Z-polymer with adverse clinical outcomes and liver fibrosis in adults with the PiZZ alpha-1 antitrypsin deficiency genotype

Poster Presentation

Presenter: Malin Fromme

507

Performance of spleen stiffness measurement by vibration-controlled transient elastography to rule out high-risk varices in patients with porto-sinusoidal vascular disorder

Oral Presentation

Presenter: Lucile Moga

530

The ancestral haplotype HLA-A3 does not influence the likelihood of advanced hepatic fibrosis or cirrhosis in C282Y homozygous hemochromatosis

Poster Presentation

Presenter: John Olynyk

534

Extrahepatic iron loading and disease complications in HFE haemochromatosis

Poster Presentation

Presenter: John Olynyk

664

Identification of correctors for traffic-defective ABCB4 variants by a high-throughput screening approach

Poster Presentation

Presenter: Mounia Lakli

712

Human cytomegalovirus (HCMV) infection of macrophages induced abnormal development of cholangiocytes in an organoid co-culture model for biliary atresia

Poster Presentation

Presenter: Syed Mushfiqur Rahaman

763

Albumin levels are associated with portal hypertension in patients with porto sinusoidal vascular disorder

Poster Presentation

Presenter: Lucia Lapenna

765

Role of gut-derived endotoxins in porto-sinusoidal vascular disease

Poster Presentation

Presenter: Stefania Gioia

834

Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study

Oral Presentation

Presenter: Virginia Clark

856

Quality of life in patients with Wilson disease treated with Trientine dihydrochloride: a prospective study

Poster Presentation

Presenter: Karl Heinz Weiss

861

Four-fold increased mortality rate in patients with Wilson's disease: a population-based cohort study of 151 patients

Poster Presentation

Presenter: Hannes Hagström

882

Recent splanchnic vein thrombosis occurring during Sars-Cov-2 infection – The VALDIG study

Poster Presentation

Presenter: Pierre Deltenre

886

Liver-related clinical events among adult patients with alpha-1 antitrypsin deficiency-associated liver disease: a longitudinal retrospective study using linked insurance claims data and electronic medical records in the United States

Poster Presentation

Presenter: Ed G. Marins

912

Efficacy and safety outcomes with odevixibat treatment: Pooled data from the phase 3 ASSERT and ASSERT-EXT studies in patients with Alagille syndrome

Poster Presentation

Presenter: Madeleine Aumar

963

Transcriptomic analysis of biliary atresia finds ongoing hepatic hematopoiesis with elevated IGF2

Poster Presentation

Presenter: Jake Mann

967

Common, non-pathogenic variants in genes from monogenic disorders confer additional risk of liver injury later in life

Poster Presentation

Presenter: Jake Mann

970

Deep learning quantification reveals fundamental prognostic role for ductular reaction in biliary atresia

Poster Presentation

Presenter: Iiris Nyholm

1013

Long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results with 96 weeks or more of treatment

Poster Presentation  
Presenter: Ekkehard Sturm

1017  
Odevixibat therapy following liver transplantation in patients with FIC1-deficient progressive familial intrahepatic cholestasis: a retrospective case series  
Poster Presentation  
Presenter: Georg-Friedrich Vogel

1031  
Outcomes in adult patients with progressive familial intrahepatic cholestasis treated with odevixibat: subgroup analysis from the PEDFIC 2 study  
Poster Presentation  
Presenter: Janis M. Stoll

1039  
Real-world experience of Odevixibat in adults with genetic disorders of cholestasis  
Poster Presentation  
Presenter: Palak Trivedi

1052  
Porto sinusoidal vascular liver disorder: natural history and long-term outcome  
Oral Presentation  
Presenter: Marta Magaz

1067  
Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis  
Poster Presentation  
Presenter: Marwan Sleiman

1159  
Long-term outcomes of patients with Wilson disease: a single center analysis of 361 Korean patients  
Poster Presentation  
Presenter: Hyo Jin Nam

1190  
ARBM-101 as an emerging potent therapeutic option for Wilson disease  
Poster Presentation  
Presenter: Hans Zischka

1200  
In vivo adenine base editing reverts C282Y in an HFE- mouse model and improves iron metabolism  
Poster Presentation

Presenter: Simon Krooss

1257

Main clinical characteristics and evolutionary events among patients suffering Wilson disease in Spain: first results from the Spanish Wilson registry

Poster Presentation

Presenter: Zoe Mariño

1261

The impact of a complete biochemical response on health-related quality of life in patients with autoimmune hepatitis: a multicentre prospective cross-sectional study

Poster Presentation

Presenter: Romée Snijders

1262

Ultrasonographic liver characteristics among patients with Wilson disease

Poster Presentation

Presenter: Zoe Mariño

1294

Clinical features, histology and outcome of pediatric porto-sinusoidal vascular disease

Poster Presentation

Presenter: Angelo Di Giorgio

1323

Odevixibat therapy in patients with MYO5B mutations: a retrospective case series

Poster Presentation

Presenter: Emmanuel Gonzalès

1325

Inhibition of the renal apical sodium-dependent bile acid transporter prevents cholemic nephropathy

Poster Presentation

Presenter: Ahmed Ghallab

1345

Serum bile acids are associated with native liver survival in patients with Alagille syndrome: results from the GALA study group

Poster Presentation

Presenter: Carla Fiorella Murillo Perez

1383

High-dose oral thiamine was not superior to placebo in reducing fatigue in patients with primary biliary cholangitis: a randomised, double-blinded, placebo-controlled crossover trial



Poster Presentation  
Presenter: Palle Bager

1401  
Alpha-1 antitrypsin inclusions sequester 78 kDa glucose-regulated protein in a bile-acid inducible manner  
Poster Presentation  
Presenter: Igor Spivak

1447  
Human induced pluripotent stem cells-derived hepatocytes: a very effective tool for functional studies of rare liver diseases  
Poster Presentation  
Presenter: Benedetta Blarasin

1471  
Cancer incidence and survival in HFE hemochromatosis – A population-based cohort study  
Poster Presentation  
Presenter: Benedikt Schaefer

1492  
Symptom severity measured by polycystic liver disease-specific questionnaire score partly correlates with both total number of liver cysts and the presence of dominant cysts  
Poster Presentation  
Presenter: Avisnata Das

1509  
Patient experience with acute hepatic porphyria before and after long-term givosiran treatment: a qualitative interview study  
Poster Presentation  
Presenter: Stephen Lombardelli

1511  
Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database  
Poster Presentation  
Presenter: Bettina Hansen

1579  
The non-invasive evaluation of vascular liver disease in patients with cystic fibrosis: a prospective cross-sectional study  
Poster Presentation  
Presenter: Elton Dajti

1623

Clinical features of portal hypertension and their prognostic implication in patients with Wilson's disease

Poster Presentation

Presenter: Lukas Burghart

1633

Deep tissue exposure of antibiotics at the target site of infection in patients with cystic liver disease: a randomized pharmacokinetic trial

Poster Presentation

Presenter: Marten A. Lantinga

1636

Novel pathogenic ABCC2 variants identified in patients with Dubin-Johnson syndrome and further functional evidence in abnormal bilirubin metabolism

Poster Presentation

Presenter: Wenting Tan

1644

Metabolomic profiles facilitate differential diagnosis of porto-sinusoidal vascular disorder versus liver cirrhosis

Poster Presentation

Presenter: Bernhard Scheiner

1738

Intrahepatic cholestasis of pregnancy: genetic testing and genotype-phenotype relations in a cohort from a Danish tertiary liver center

Poster Presentation

Presenter: Henning Grønbaek

1784

Acute liver failure due neonatal hemochromatosis: case with fatal outcome despite early diagnosis and treatment

Poster Presentation

Presenter: LIUDMYLA SHOSTAKOVYCH

1838

Exploring pregnancy, breastfeeding and contraception among women with Wilson disease in Spain: results from the Spanish Wilson registry

Poster Presentation

Presenter: Zoe Mariño

1853

Hepatobiliary malignancies in Wilson Disease: data from an Italian national reference centre

Poster Presentation

Presenter: Lorenzo Canova

1911

Demographics, outcomes, and costs of Wilson's disease hospitalizations: a nationwide cohort study

Poster Presentation

Presenter: Ankoor Patel

1956

Rescue of PKU disease phenotype using hepatic progenitor by cytosine base editor and prime editor in vitro

Poster Presentation

Presenter: Myounghoi Kim

2083

Longitudinal assessment of gut microbiota, metabolome and intestinal barrier dysfunction in biliary atresia

Poster Presentation

Presenter: Vandana Jain

2102

Endogenous ethanol production in biliary atresia and its association with clinical outcomes, liver disease severity, fibrosis, bacterial translocation and intestinal permeability

Poster Presentation

Presenter: Vandana Jain

2152

CD73<sup>high</sup> biliary tract cancer (BTC): a molecularly-defined subtype with distinct clinical implications

Poster Presentation

Presenter: pietro carotenuto

2212

Longitudinal assessment of plasma immune and bacterial translocation markers in biliary atresia

Poster Presentation

Presenter: Vandana Jain

2305

Efficacy and safety of tiomolibdate choline versus standard of care in patients with Wilson disease with and without compensated cirrhosis: sub-analysis of an ongoing phase 3, randomized, controlled study

Poster Presentation

Presenter: Aftab Ala

2308

Impact of extrahepatic portal vein obstruction on fertility and pregnancy outcomes- a tertiary center experience

Poster Presentation

Presenter: Ankita Singh

2342

Efficacy and safety of tiomolibdate choline in patients with an incomplete or intolerant response to prior Wilson disease therapy: subgroup analysis of the phase 3 FoCus trial

Poster Presentation

Presenter: Karl Heinz Weiss

2345

Immune cell incompetence and hepatocyte differentiation defects explain mild fibrosis in a model of Alagille syndrome

Poster Presentation

Presenter: Jan Mašek

2403

Immortalized patient-derived cell models for analysis of liver disease

Poster Presentation

Presenter: Matthias Weiland

2454

Role of transient elastography to identify Fontan-associated liver disease (FALD) and novel risk-score to predict failing Fontan

Poster Presentation

Presenter: Luisa Cavalletto

2475

Endoscopic ultrasound direct portal pressure measurement in patients with porto-sinusoidal vascular disorder and clinically significant portal hypertension: a comparison with hepatic venous pressure gradient measurement

Poster Presentation

Presenter: Lucia Giuli

2499

Blood markers of immune activation help distinguish paediatric activated T-cell hepatitis from other causes

Poster Presentation

Presenter: Tamir Diamond

2517

SARS-CoV-2 productively infects human hepatocytes and induces cell death

Poster Presentation

Presenter: Cho-Chin Cheng

2522

First nationwide genetic study on Wilson disease (spanish Wilson registry): high diversity in mutations and in use of genetic evaluation, association with clinical data and influence on diagnosis and health costs

Poster Presentation

Presenter: Pablo Alonso Castellano

2538

Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease

Poster Presentation

Presenter: Alexandra Alexopoulou

2586

Alkaline phosphatase on admission to the intensive care unit as a new early prognostic biomarker for the development of COVID-19-associated secondary sclerosing cholangitis

Poster Presentation

Presenter: Schmid Stephan

2639

High diagnostic uptake of a targeted panel sequencing in adult patients with chronic hereditary liver disorders

Poster Presentation

Presenter: Luisa Ronzoni

2690

Efficacy and safety of vaccination against SARS-CoV-2 in patients with vascular liver disease

Poster Presentation

Presenter: Valeria Perez-Campuzano

2714

The adequacy and safety of liver biopsy performed during cardiac catheterization in patients with Fontan and non-Fontan heart disease

Poster Presentation

Presenter: Edward Cytryn

2736

Association of liver injury and prognosis in patients with severe fever with thrombocytopenia syndrome

Poster Presentation  
Presenter: Rui Huang

2766  
Characterizing the role of human cytomegalovirus infection associated with biliary atresia  
Poster Presentation  
Presenter: Allen KL Cheung

2809  
Digital pathology using stain-free imaging indices as a tool for fibrosis quantification in patients with congestive hepatopathy  
Poster Presentation  
Presenter: Matthew Yeh

2818  
Proteomics for the study of biomarkers in Wilson's disease  
Poster Presentation  
Presenter: LI LI

2900  
Risk of cirrhosis and hepatocellular carcinoma in hemochromatosis: a Swedish nationwide cohort study  
Poster Presentation  
Presenter: Hanne Åström

2921  
Impact of alcohol consumption on the liver phenotype in alpha-1 antitrypsin deficiency  
Poster Presentation  
Presenter: Malin Fromme

2936  
Bacterial vesicles associated virulence factors and epitope mimics in autoimmune hepatitis patients  
Poster Presentation  
Presenter: SWATI THANGARIYAL

3011  
Lessons from population genomics for Wilson disease: Prevalence, penetrance of mutations, clinical implications and design of regional screening programmes  
Poster Presentation  
Presenter: Pablo Alonso Castellano

3014  
Schistosoma mansoni infection-associated oxidative stress triggers hepatocellular proliferation

Poster Presentation

Presenter: Verena von Buelow

3050

Online education yields significant gains in gastroenterologists' knowledge of clinical manifestations of Wilson disease

Poster Presentation

Presenter: Sukhbir Bahra

3109

CRISPR/Cas9-mediated gene correction of Wilson disease H1069Q mutation in an iPS cell model

Poster Presentation

Presenter: Vanessa Sandfort

3155

Genetic findings and magnetic resonance imaging of multiple biliary hamartomas

Poster Presentation

Presenter: Juliana Goediker

3225

Ancillary diagnostic biomarkers in autoimmune hepatitis

Poster Presentation

Presenter: Chhagan Bihari

3281

Progressive familial intrahepatic cholestasis: KFSH & RC

Poster Presentation

Presenter: Muath Najmi

3337

A longitudinal study of epidemiology and treatment management of Wilson disease in France based on the French national claims database SNDS

Poster Presentation

Presenter: Jean Philippe Combal

3382

Current transition management of adolescents and young adults with liver diseases: an European reference network rare liver survey

Poster Presentation

Presenter: Joao Madaleno

3392

Phytoestrogens as a possible hidden driver of cysts proliferation in polycystic liver disease in men and women after menopause

Poster Presentation

Presenter: Miki Scaravaglio

3437

Performance of blood based non-invasive tests for liver fibrosis prediction by transient elastography in Alpha-1 antitrypsin deficiency

Poster Presentation

Presenter: Hassaan Yousuf

3471

Genetic modifiers of liver phenotypes in pediatric Wilson disease: liver biopsy and transient elastography based study

Poster Presentation

Presenter: Marcin Krawczyk

3541

Biliary atresia human cholangiocyte organoids demonstrate increased oxidative stress response

Poster Presentation

Presenter: yara hamody

3563

Modeling Alagille syndrome in vitro using complex induced pluripotent stem cell-derived human liver organoids

Poster Presentation

Presenter: Massimiliano Paganelli

3627

Clinical picture of acute hepatitis in children - single center observations

Poster Presentation

Presenter: Anna Mania

3647

Trans-jugular intrahepatic Porto-systemic shunt for Budd Chiari syndrome: single center experience

Poster Presentation

Presenter: amnah Alhanaee

3661

State of knowledge of alpha 1 anti-trypsin deficiency among practitioners specialized in liver transplantation in France : a national survey

Poster Presentation

Presenter: Manon Evain



3739

Alpha-1 antitrypsin deficiency is underdiagnosed in cirrhotic liver transplant patients : a retrospective multicenter study

Poster Presentation

Presenter: Manon Evain

3753

Surveillance of cystic echinococcosis in France: report of the first 103 cases from the French observatory OFREKYS

Poster Presentation

Presenter: Solange BRESSON-HADNI

3765

Emphysematous pancreatitis: a sporadic sequela of necrotizing pancreatic infections

Poster Presentation

Presenter: Audrey Fonkam

3773

Hepatic alterations in COVID-19: a comparative autopsy study

Poster Presentation

Presenter: Sigurd Lax

3793

Chronic hepatitis B infection and porto-sinusoidal vascular disorder, a non-negligible coexistence

Poster Presentation

Presenter: Pol Olivas Alberch

3813

Myeloproliferative neoplasms and splanchnic vein thrombosis: results of a long-term UK prospective cohort study

Poster Presentation

Presenter: Rupen Hargreaves

3857

Monitoring, dosing and clinical outcomes of CFTR modulator triple combination therapy in children with CF post liver transplantation

Poster Presentation

Presenter: Daniel Leung

## Viral Hepatitis: Experimental and pathophysiology

927

Chimeric bio-nanoparticles induce targeted HBeAg seroclearance in a HBV hydrodynamic injection mouse model

Poster Presentation

Presenter: Peter Revill

956

The TLR8 agonist Selgantolimod modulates Kupffer cell differentiation status and indirectly impairs HBV entry into hepatocytes via an IL-6-dependent mechanism

Poster Presentation

Presenter: Armando Andres Soares

1072

COVID-19 vaccination alters NK cell dynamics and transiently reduces HBsAg titers among patients with chronic hepatitis B

Poster Presentation

Presenter: Hyunjae Shin

1118

Rat hepatitis E virus infection in a rat model has multiphasic viral replication kinetics

Poster Presentation

Presenter: Harel Dahari

1121

Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study

Poster Presentation

Presenter: Pietro Lampertico

1242

(N)one size fits all: Genotype-matched analysis of different disease phases of chronic hepatitis B virus infection

Poster Presentation

Presenter: Michael Basic

1268

Automated high-throughput image-based screen discovers members of the Akt serine/threonine kinase family as potential targets for treatment of hepatitis E virus infection

Poster Presentation

Presenter: Mara Klöhn

1280

A PKA-associated liver-tissue rheostat curbs T cell receptor signalling and effector function of virus-specific CD8 T cells in chronic viral hepatitis

Oral Presentation

Presenter: Miriam Bosch

1285

Intrahepatic CD8+ T cells correlate with significant declines in HBV viral load and S antigen following a single vaccination with VRON-0200 in an AAV mouse model

Poster Presentation

Presenter: Hildegund Ertl

1334

Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver

Poster Presentation

Presenter: Kusum Gupta

1406

HBsAg level defines different clinical phenotypes of chronic HBV infection eAg(-) related to the quality of the HBV-specific CD8 cell response

Poster Presentation

Presenter: Henar Calvo Sánchez

1489

The hepatitis E virus ORF2 protein forms amyloid-like protein aggregates which may be pathogenic in human neurons

Poster Presentation

Presenter: Jungen Hu

1553

RBD1016 – a novel anti-HBV GalNAc-siRNA drug resulted in sustained HBsAg reduction and seroconversion in mice models

Poster Presentation

Presenter: Li Ming Gan

1653

Identification of resistance-associated variants after sofosbuvir treatment in chronic hepatitis E patients

Poster Presentation

Presenter: Andre Gömer

1880

Hepatitis B pre-genomic RNA level has a prospective supporting role for predicting the outcomes of the hepatitis B virus inactive carrier phase

Poster Presentation

Presenter: Prooksa Ananchuensook

2063

An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients

Poster Presentation

Presenter: Yannick Debing

2065

Epigenetic modulation by DNA methyltransferase inhibition may enhance the effect of immune checkpoint inhibitors to restore HBV-specific T cell responses

Poster Presentation

Presenter: Melanie Urbanek-Quaing

2093

Hepatitis B virus infected hepatocytes are resistant to cell death induction by virus-specific T cells

Poster Presentation

Presenter: Emely Springer

2132

HBsAg kinetics at month 9 after analogue treatment discontinuation in chronic hepatitis B eAg(-) predicts long-term HBV control

Poster Presentation

Presenter: Henar Calvo Sánchez

2138

Rapid functional secretome analysis of HBV-specific T cells to guide clinical management of CHB patients

Poster Presentation

Presenter: Nina Le Bert

2155

Detection and functional analysis of HBV-specific stem cell memory T cells (Tscm)

Poster Presentation

Presenter: Hiromi Abe-Chayama

2160

Quadruple mutation GCAC1809-1812TTCT leads to a better prognosis by decreasing HBV-mediated fibrogenic activity

Poster Presentation

Presenter: Esra Görgülü

2208

A novel imaging approach to investigate hepatitis E virus entry

Poster Presentation  
Presenter: Rebecca Fu

2219  
Identification and functional analysis of miR-4461 associated with hepatitis B-derived hepatocellular carcinomas  
Poster Presentation  
Presenter: Masaya Sugiyama

2363  
Nucleotide analogue therapy does not reverse the hyperexpression of innate-like markers on activated T cells consistent with immunopathology in chronic hepatitis B  
Poster Presentation  
Presenter: Lung Yi Loey Mak

2420  
CTLA4 inhibits anti-HBs secretion by blocking BCR signaling pathway in chronic hepatitis B infection  
Poster Presentation  
Presenter: Minxin Mao

2437  
Reduced hepatic bile acid uptake and blocked hepatitis B viral infection after oral administration of novel small molecule inhibitors of the sodium taurocholate co-transporting polypeptide (NTCP)  
Poster Presentation  
Presenter: Stan van de Graaf

2458  
Fas/Fas-ligand induced apoptosis of CD8(+) lymphocytes in the placenta of women with chronic hepatitis B plays a twofold role in the protection of fetus  
Poster Presentation  
Presenter: Dionysia Mandilara

2461  
A primary human hepatocyte system to evaluate antisense oligonucleotide activity against clinically identified hepatitis b virus variants that contain mismatches in the bepirovirsen binding site  
Poster Presentation  
Presenter: Alexander Koenig

2530  
A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice  
Poster Presentation  
Presenter: Jin Hong

2553

Droplet digital PCR can quantify cccDNA in plasma of naive chronic HBV infected patients with low HBsAg levels

Poster Presentation

Presenter: Ravinder Singh

2712

A new glyco-biomarker for measuring infectious hepatitis B virus targeting surface antigen glycan isomer (HBsAgGi)

Poster Presentation

Presenter: Kiyohiko Angata

2734

The divergent C-terminus of L-HDAg regulates the dynamic life cycle of HDV and the responses to lonafarnib treatment

Poster Presentation

Presenter: Hongbo Guo

2747

Transcriptional analysis of HBV infected liver after treatment with selgantolimod reveals longitudinal changes in both inflammation-related pathways and B cell receptor repertoire

Poster Presentation

Presenter: Nikita Kolhatkar

2779

Serum metabolite reveal mitochondrial dysfunction and energy metabolism disruption in chronic hepatitis C virus infection

Poster Presentation

Presenter: AMAR DEEP

2789

Dating the origin and evolution dynamics of hepatitis D virus

Poster Presentation

Presenter: Wenshi Wang

2837

Pregnancy zone protein as a promising biomarker for HEV-related acute liver failure

Poster Presentation

Presenter: Jian Wu

2860

PD-1 does not suppress effector CD8 T cell differentiation during acute HBV infection and is not required for the induction of HBV-specific CD8 T cell exhaustion in HBV persistent mice

Poster Presentation

Presenter: Jia Liu

2885

Reduction in quantity and function of HBcAg-specific B cells indicates the response to anti-viral therapy in chronic HBV-infected patients receiving ETV or TDF treatment

Poster Presentation

Presenter: Li Wang

2912

HBsAg induces mild activation, but not suppression, of intrahepatic immune cells as shown by single-cell RNA sequencing of fine-needle aspirates in chronic HBV patients

Poster Presentation

Presenter: Zgjim Osmani

2941

Intrahepatic hepatitis B virus cccDNA amount and transcriptional activity in a well-characterized cohort of Gambian chronically infected patients: correlation with emerging serum viral markers

Poster Presentation

Presenter: Barbara Testoni

2948

A novel recombinant HBV based selection system allows for a systematic genomic knock-out screening and the identification of host factors involved in HBV infection

Poster Presentation

Presenter: Bo-Hung Liao

2979

miR-26a targets USP15 to robustly suppress hepatitis E virus replication via the enhancement of RIG-I-mediated type I interferon response

Poster Presentation

Presenter: Wenshi Wang

3032

Application of magnetic nanoparticle on boosting HBV infection system effectiveness

Poster Presentation

Presenter: Bo-Hung Liao

3040

Altered metabolic program initiates immune activation leading to hepatitis B surface antigen seroconversion in mild and severe hepatitis B reactivation patients

Poster Presentation

Presenter: Jayesh Kumar Sevak

3041

Impact of pegylated interferon-alpha in combination with Bulevirtide in HBV/HDV infected humanized mice

Poster Presentation

Presenter: Maura Dandri

3043

Impact of cirrhosis and long-term follow-up on the inflammatory milieu after hepatitis C virus (HCV) elimination by direct-acting antiviral (DAA) therapy

Poster Presentation

Presenter: Moana Witte

3059

HBs-directed T cell engager antibodies foster efficient recruitment of T cells and lead to strong reduction of hepatitis B virus infection in livers of human liver chimeric mice

Poster Presentation

Presenter: Annika Volmari

3060

Identification of unique liver NK cells in HBV and a new perspective on exhaustion-related NK cell phenotypes by single-cell RNA sequencing

Poster Presentation

Presenter: Boris Beudeker

3120

Characterization of biomarker kinetics in a novel in vitro HBV infection model with the cell line HepG2-hNTCP-sec+ revealed stable HBsAg composition during short- and long-term infection up to four weeks

Poster Presentation

Presenter: Maria Pfefferkorn

3135

Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models

Poster Presentation

Presenter: Tongfei Wu

3159

Growth factor stimulation enhances NTCP expression and improves in vitro HBV infection in hepatoma cells

Poster Presentation

Presenter: Rodrigue Kanga Wouambo



3170

Hepatitis B virus antigens induce a dramatic LPS-like activation of inflammasome dependent on viral variability

Poster Presentation

Presenter: EVE TODESCO

3173

HBV and HDV interaction and variability in a superinfection mouse model: role of type I interferon

Poster Presentation

Presenter: Beatriz Pacín Ruiz

3211

Extracellular vesicle-derived microRNA signature in chronic hepatitis C patients with different stages of liver fibrosis

Poster Presentation

Presenter: Amanda Fernández Rodríguez

3219

Proteomics analysis of HBV cccDNA-bound proteins for therapeutic targeting in liver biopsies from hepatitis B patients

Poster Presentation

Presenter: Purnima Tyagi

3224

The role of gamma delta T cells in chronic hepatitis B virus infection

Poster Presentation

Presenter: Katja Steppich

3226

Baseline plasma lipidome correlates with direct-acting antiviral therapy non-response for HCV in HIV-HCV coinfecting patients

Poster Presentation

Presenter: Vasundhra Bindal

3235

Host Sequence snatching identified in-vivo enhances hepatitis E viral replication

Poster Presentation

Presenter: Daniel Todt

3303

A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease

Oral Presentation

Presenter: Cassandra Gorsuch

3398

Low intraindividual viral evolution is linked to disease progression and need of antiviral treatment initiation in chronic hepatitis B

Poster Presentation

Presenter: Magnus Illum Dalegaard

3494

Recombinant hepatitis E viruses harboring a split luciferase tag in the ORF2 capsid protein

Poster Presentation

Presenter: Maliki Ankavay

3554

Thiourea derivatives exhibit antiviral property by inhibiting hepatitis B virus DNA replication and HBx-induced gene transcription

Poster Presentation

Presenter: Jitendra Kumar

3779

Prophylactic vaccine against hepatitis D virus (HDV) superinfection

Poster Presentation

Presenter: Matti Sällberg

3885

HBV infection reshapes host chromatin accessibility and affects choline and iron metabolism

Poster Presentation

Presenter: Vincenzo Alfano

Viral hepatitis A/E: Clinical aspects

36

Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: a nationwide population study, 1998-2020

Poster Presentation

Presenter: Paul Wasuwanich

201

High prevalence of HEV related to the progression and prognosis of patients with acute pancreatitis: a multicentre cross-sectional and cohort study in China

Poster Presentation

Presenter: Jian Wu

3550

Hepatitis E virus infection before and after liver transplantation

Poster Presentation

Presenter: Petra Dinjar Kujundžić

## Viral hepatitis B and D: Clinical aspects

82

HBsAg seroclearance decreases risk of hepatocellular carcinoma but not hepatic decompensation in nucleos(t)ide analogue-treated cirrhotic patients with complete hepatitis B virus suppression: a territory-wide cohort study

Poster Presentation

Presenter: Terry Cheuk-Fung Yip

98

Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease

Poster Presentation

Presenter: Youwen Tan

199

Negligible 10-year risk of liver-related events in chronic hepatitis B patients with low liver stiffness

Poster Presentation

Presenter: Lesley Patmore

214

Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan

Poster Presentation

Presenter: Osama Mohamed

250

An online web-based calculator accurately diagnoses immune tolerant phase in chronic HBV-infected patients

Poster Presentation

Presenter: Chi Zhang

315

IP10 and anti-HBc can predict virological relapse and HBsAg loss for chronic hepatitis B patients after nucleos(t)ide analogue discontinuation

Poster Presentation

Presenter: Yandi Xie

344

Epidemiological landscape and clinical spectrum of chronic hepatitis B in East Africa

Poster Presentation

Presenter: abate shewaye

365

Utilizing machine learning-based predictive models to identify early virological recurrence in Chinese chronic hepatitis B patients following entecavir withdrawal

Poster Presentation

Presenter: Xiaoke Li

410

Incidence of hepatitis D virus super-infection in HBsAg positive patients (The Inci-D cohort study)

Poster Presentation

Presenter: Ingiliz Patrick

440

A retrospective observational cohort study of liver-related events among individuals with hepatitis B virus infection with and without hepatitis delta virus infection

Poster Presentation

Presenter: Laura Telep

453

Passive transfer of hepatitis B core antibody after intravenous immunoglobulin administration in adult patients: a retrospective review

Poster Presentation

Presenter: Sital Shah

462

Hepatitis D screening in HBsAg positive individuals in Germany: insufficient implementation results in a large number of undiagnosed cases

Poster Presentation

Presenter: Toni Herta

478

HDV full genome sequencing and sensitive HBV genotyping from a large cohort of HBV/HDV co-infected patients

Poster Presentation

Presenter: Savrina Manhas

493

Systematic review and meta-analysis: the proportion of chronic hepatitis B patients with different alanine transaminase upper limits and significant hepatic histology

Poster Presentation

Presenter: Yuhao Yao

614

Secular trends of newly diagnosed chronic hepatitis B in 2000-2022 – a territory-wide study

Poster Presentation

Presenter: Grace Lai-Hung Wong

647

Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors

Poster Presentation

Presenter: Kathryn M Kitrinis

672

Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort

Poster Presentation

Presenter: Loreta Kondili

701

Clinical evaluation of highly sensitive iTACT hepatitis B core-related antigen and hepatitis B surface antigen assays in the management of HBV reactivation

Poster Presentation

Presenter: Takako Inoue

718

Eliminating viral hepatitis one island at a time – the Hainan experience

Poster Presentation

Presenter: Biao Wu

747

Prevalence and predictors of HDV viremia in anti-HDV positive patients of the Hellenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)

Poster Presentation

Presenter: George Papatheodoridis

815

HBcrAg-based risk score predicts HCC better than HBV DNA-based risk scores in HBeAg-negative grey zone patients

Poster Presentation

Presenter: Tai-Chung Tseng

828

Eight weeks or less of tenofovir alafenamide to prevent the perinatal hepatitis B transmission: a multicenter, prospective, randomized study

Poster Presentation

Presenter: Qing-Lei Zeng

851

B cell phenotype, Toll-Like receptor 9 expression and proinflammatory cytokines profile in patients with chronic hepatitis B with HBsAg loss or persistent

Poster Presentation

Presenter: Nour Nasser

890

In patients with chronic hepatitis D, the decline of  $\geq 2$ log HDV-RNA levels that remain detectable is associated with better clinical outcomes

Poster Presentation

Presenter: Adriana Palom

914

Long-term outcome of hepatitis delta in different regions world-wide: results of the hepatitis delta international network (HDIN)

Poster Presentation

Presenter: Anika Wranke

935

Steadily decline of HBV DNA load under NAs in lymphoma patients and higher level of qAnti-HBc predict HBV reactivation

Poster Presentation

Presenter: Yi-Qi Liu

942

Effect of Tenofovir and Entecavir on occurrence of hepatocellular carcinoma depends on duration of antiviral treatment and hierarchical PAGE-B risk score

Poster Presentation

Presenter: Yi-Hsiang Huang

1032

Self-stigma in chronic hepatitis B: content and psychometric validation of a new patient-reported outcome instrument

Poster Presentation

Presenter: Robert G. Gish

1034

Treatment with siRNA JNJ-73763989 plus nucleos(t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study

Oral Presentation

Presenter: Heiner Wedemeyer

1141

Programmed cell death protein 1/ligand 1 inhibitor versus tyrosine kinase inhibitor in the efficacy of HBsAg reduction in chronic hepatitis B patients with hepatocellular carcinoma

Poster Presentation

Presenter: Te-Wei Tseng

1265

High prevalence of hepatic steatosis in adults living with hepatitis B, with and without HIV co-infection, in London, UK

Poster Presentation

Presenter: Claire Mullender

1356

Significant disparities in risk of cirrhosis and hepatocellular carcinoma among non-cirrhotic, treatment naïve, e-antigen negative hepatitis B patients with low levels of serum alanine aminotransferase

Poster Presentation

Presenter: Robert Wong

1359

Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naïve chronic hepatitis B in the immune tolerant phase

Poster Presentation

Presenter: Robert Wong

1379

Novel serum biomarkers for risk stratification in chronic hepatitis B - what do they bring to the table?

Poster Presentation

Presenter: Louise Downs

1417

Hepatitis flare appeared to be more severe with poorer outcome in chronic hepatitis B patients with recent COVID vaccination during the COVID pandemic

Poster Presentation

Presenter: Jennifer Tai

1430

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: a nationwide cohort study

Poster Presentation

Presenter: Moon Haeng Hur

1460

Healthcare resource use and costs associated with hepatitis delta virus infection compared to hepatitis B virus mono-infection among commercially insured patients in the US

Poster Presentation

Presenter: Chong Kim

1467

Increased baseline comorbidity burden among commercially insured patients with hepatitis delta virus infection vs hepatitis B virus mono-infection in the United States

Poster Presentation

Presenter: Chong Kim

1469

Significantly higher clinical and economic burden following diagnosis of hepatitis delta virus infection among commercially insured adults with chronic hepatitis B in the United States

Poster Presentation

Presenter: Chong Kim

1475

Hepatitis delta treatment utilization in the United States: an analysis of commercially insured adults with hepatitis delta virus infection

Poster Presentation

Presenter: Chong Kim

1481

Patients with chronic hepatitis delta virus coinfections have higher risk of disease progression than chronic hepatitis B virus mono-infection – results from a Spanish national hospital database

Poster Presentation

Presenter: Chong Kim

1499

Assessment of clinical and patient reported outcome measures in individuals with chronic hepatitis B who clear HBsAg, followed by the Canadian hepatitis B network

Poster Presentation

Presenter: Carla Coffin

1602

Prediction of hepatocellular carcinoma in chronic hepatitis B patients following HBsAg seroclearance: Lage score

Poster Presentation

Presenter: Jonggi Choi

1605

Comparison of HCC incidence between entecavir and tenofovir in a chronic hepatitis B cohort with balanced censoring



Poster Presentation  
Presenter: Jang Han Jung

1679  
Novel, high accuracy prediction models of hepatocellular carcinoma based on longitudinal data and cell-free DNA signatures  
Oral Presentation  
Presenter: Rong Fan

1774  
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection  
Poster Presentation  
Presenter: Lisa Sandmann

1785  
aMAP score and its combination with liver stiffness measurement accurately assess liver fibrosis in virologically suppressed CHB patients  
Poster Presentation  
Presenter: Jinlin HOU

1794  
Current status of hepatitis delta in Andalusia: multicenter study  
Poster Presentation  
Presenter: Marta Casado

1886  
Persistent detectable serum hepatitis B virus RNA is associated with increased risk of hepatocellular carcinoma in nucleos(t)ide analogues treated patients with chronic hepatitis B  
Poster Presentation  
Presenter: Shi Liu

1919  
Improved prediction for liver fibrosis of Fibrosis-4 using machine learning in patients with chronic hepatitis B  
Poster Presentation  
Presenter: Zhiyi Zhang

1976  
Identification of liver-associated gene signatures from serum exosomes in patients with chronic hepatitis B  
Poster Presentation  
Presenter: Mario Cortese

1992

Distribution of the natural history stages of pregnant women with chronic hepatitis B virus infection and its association with pregnancy complications and adverse pregnancy outcomes

Poster Presentation

Presenter: Zhihua Liu

2030

Influence of viral load and fibrotic burden on hepatocellular carcinoma risk at phase change to immune-active phase in chronic hepatitis B

Poster Presentation

Presenter: Ho Soo Chun

2067

Identification and external validation of the optimal ALT thresholds for ruling in significant histologic disease in chronic hepatitis B

Poster Presentation

Presenter: Zhiyi Zhang

2107

The impact of hepatitis B infection and advanced liver disease on health utility and health related quality of life in The Gambia: a cross-sectional study

Poster Presentation

Presenter: Yazan Haddadin

2117

Extrahepatic mortality in patients with chronic hepatitis B infection: a large population-based cohort study

Poster Presentation

Presenter: Young Eun Chon

2120

Treatment experience and acceptability in a UK HBV cohort– why personalised regimens may be necessary in chronic hepatitis B

Poster Presentation

Presenter: Jane Abbott

2157

Overcoming barriers to care for Delta infected patients

Poster Presentation

Presenter: Marina Berenguer

2165

Can we better characterize HBeAg-negative chronically infected hepatitis B patients using novel biomarkers?

Poster Presentation

Presenter: Thais Leonel Couto

2269

Dynamic monitoring of HBsAg-specific B cells in CHB patients and its clinical significance in predicting interferon therapy efficacy

Poster Presentation

Presenter: Yu Geng

2332

Comparison of hepatitis B reactivation in patients with resolved hepatitis B infection receiving rituximab or non-rituximab based immunosuppressive therapy: does presence of hepatitis b surface antibody reduce the risk of reactivation?

Poster Presentation

Presenter: Wei-Lun Liou

2356

Predominance of genotype 5 hepatitis delta virus infection in a portuguese centre

Poster Presentation

Presenter: Mariana Cardoso

2365

Contrasting immune fingerprints of chronic hepatitis B Virus infection in adults from South Africa and the United Kingdom

Poster Presentation

Presenter: Marion Delphin

2415

Clinical characteristics and phase transition of chronic hepatitis B patients with HBeAg and anti-HBe coexistence

Poster Presentation

Presenter: Ruifei Xue

2465

Association of liver fibrosis and hypophosphatemia in treatment-naïve patients with chronic hepatitis B

Poster Presentation

Presenter: Jian Wang

2490

Lower HBV DNA levels is associated more severe liver fibrosis in chronic hepatitis B with serological immune-tolerant phase

Poster Presentation  
Presenter: Jian Wang

2507  
Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions  
Poster Presentation  
Presenter: Valerie Ohlendorf

2582  
Novel serum markers of cccDNA transcriptional activity – HBcrAg and pre-genomic RNA and CXCL10 pro-inflammatory chemokine levels can reduce uncertainty of HBeAg-negative chronic hepatitis B phases  
Poster Presentation  
Presenter: Ivana Carey

2604  
HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes  
Poster Presentation  
Presenter: Ivana Carey

2613  
Treatment eligibility and initiation among chronic hepatitis B patients in a real-world setting in the United States  
Poster Presentation  
Presenter: Mark A Schmidt

2678  
Long-term outcomes of patients with chronic HBsAg positive/HBe-negative infection: differences and transition between inactive carriers and low viremic carriers  
Poster Presentation  
Presenter: Giacomo Emanuele Maria Rizzo

2700  
Distinct virologic trajectories in chronic hepatitis B patients identify heterogeneity in response to nucleotide analogue therapy  
Poster Presentation  
Presenter: Tingyan Wang

2708  
The performance of the cobas® HBV RNA assay for use on the cobas® 5800/6800/8800 Systems (RUO) against genomic variants and transcript heterogeneity  
Poster Presentation  
Presenter: Thomas Meister

2765

HBV infected pregnant woman received antiviral treatment and discontinued it postpartum can benefit from retreatment

Poster Presentation

Presenter: Qiao Tang

2767

Effects of tenofovir alafenamide fumarate on serum lipids in patients with chronic hepatitis B

Poster Presentation

Presenter: Yilin Liu

2770

Higher risk of disease progression in the gray zone relative to hepatitis B e antigen negative chronic hepatitis B infection

Poster Presentation

Presenter: YunLing Xue

2771

A novel nomogram for predicting HBeAg clearance in HBeAg-positive chronic hepatitis B patients after nucleos(t)ide analogues treatment

Poster Presentation

Presenter: Yan Gu

2815

Analysis of disease progression in patients with chronic hepatitis B using a large nationwide database

Poster Presentation

Presenter: Nobuharu Tamaki

2826

Serum CXCL16 serves as the predictor for liver inflammation functioning through a NKT cell-dependent way in chronic hepatitis B patients

Poster Presentation

Presenter: Yawen Wan

2962

Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort

Poster Presentation

Presenter: Massimo Puoti

3089

Systematic screening for hepatitis B at emergency department and linkage to care in Barcelona, Spain

Poster Presentation

Presenter: Juan Carlos Ruíz-Cobo

3177

Detection of hepatitis delta virus in seminal fluid and female genital tract

Poster Presentation

Presenter: Naranjargal Dashdorj

3213

Off-therapy events in hepatitis B e antigen-negative patients with sustained HBV surface antigen <100 and <50 IU/mL

Poster Presentation

Presenter: Yen-Chun Liu

3217

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Poster Presentation

Presenter: Yu Jun Wong

3227

Aspirin use and risk of hepatocellular carcinoma and gastrointestinal bleeding in patients with HBV-related cirrhosis: a landmark analysis

Poster Presentation

Presenter: Mi Na Kim

3236

Association of TLR7 polymorphisms in Caucasians with disease stages and HBsAg loss in hepatitis virus B infections

Poster Presentation

Presenter: Janett Fischer

3238

Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli

Poster Presentation

Presenter: Lorenzo Piermatteo

3252

Dried blood spot (DBS): a new tool for screening, diagnosis and monitoring of hepatitis D virus (HDV) infection

Poster Presentation

Presenter: Rola Matar

3258

Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage

Poster Presentation

Presenter: Leonardo Duca

3261

Driving improvements in hepatitis B care in Africa: profile of the hepatitis B in Africa collaborative network (HEPSANET)

Poster Presentation

Presenter: Asgeir Johannessen

3288

The comparisons of clinical relapse timing and severity after cessation of prophylactic nucleos(t)ide analogue between chronic hepatitis B patients with lymphoma receiving chemotherapy with and without Rituximab

Poster Presentation

Presenter: Yen-Chun Liu

3298

Long-term outcomes of untreated chronic hepatitis B patients with persistent HBsAg <100 IU/mL

Poster Presentation

Presenter: Rachel Wen-Juei Jeng

3341

The prognosis of hepatitis delta infections in Belgium is poor and determined by the hepatitis delta viremia

Poster Presentation

Presenter: Arno Furquim d'Almeida

3364

Serum thrombospondin-2 for predicting liver fibrosis in patients with chronic hepatitis B virus infection

Poster Presentation

Presenter: Yun Chen

3366

The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir

Poster Presentation

Presenter: Romina Salpini

3367

Risk factors for viral reactivation in patients with overt or occult Hepatitis B Virus infection receiving immunosuppressive treatments: a systematic review and meta-analysis

Poster Presentation

Presenter: Ciro Celsa

3384

Characterizing chronic hepatitis delta in Spain and the gaps in its management

Poster Presentation

Presenter: Sergio Rodriguez-Tajes

3438

Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression

Poster Presentation

Presenter: Romina Salpini

3469

The benefit of a local hepatitis B reactivation guideline to improve screening and prophylaxis for patients initiated on rituximab

Poster Presentation

Presenter: Helen Boothman

3490

Study of hepatitis delta virus replication markers in anti-HBc positive patients with chronic hepatitis C

Poster Presentation

Presenter: Francisco Javier Garcia-Samaniego Rey

3622

Barriers to hepatitis B treatment from the patient's perspectives: survey study by the canadian hepatitis B network

Poster Presentation

Presenter: Hin Hin Ko

3660

Ten years follow-up of patients with chronic hepatitis B and hepatitis D infection

Poster Presentation

Presenter: Andreea Dobroaia

3730

The role of PAGE-B score in predicting the development of hepatocellular cancer in patients with chronic delta hepatitis

Poster Presentation



Presenter: Cihan Yurdaydin

3788

T-cell responses to PreS1 and PreS2 are correlated to anti-HBs antibody titres, which are higher and persist longer in volunteers vaccinated with 3-antigen than with 1-antigen hepatitis B vaccine in the PROTECT Study:3.5 year follow up

Poster Presentation

Presenter: Francisco Diaz-Mitoma

3791

Clinical phenotypes of hepatocellular carcinoma in patients with chronic hepatitis D compared to patients with chronic hepatitis B

Poster Presentation

Presenter: Christoph Schramm

3801

HDV RNA levels <1000 IU/ml and total anti-HDV titers <1:1000 identify chronic hepatitis D subjects without active liver disease

Poster Presentation

Presenter: Gabriele Ricco

3808

Risk stratification for hepatocellular carcinoma in patients with chronic hepatitis D

Poster Presentation

Presenter: Christoph Schramm

3809

Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D

Poster Presentation

Presenter: Soo Aleman

3817

Long-term outcomes of a population-based cohort of chronic hepatitis B (CHB) patients in West Africa

Poster Presentation

Presenter: Gibril Ndow

## Viral Hepatitis B and D: Current therapies

546

Predictors of severe flares after nucleos(t)ide analogue cessation - results of a global cohort study (RETRACT-B study)

Oral Presentation

Presenter: Edo Dongelmans

725

Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Poster Presentation

Presenter: Heiner Wedemeyer

855

Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy

Poster Presentation

Presenter: Milan Sonneveld

923

Stopping bulevirtide in long-term HDV-RNA suppressed patients seems safe and may enable long treatment-free intervals

Poster Presentation

Presenter: Mathias Jachs

1073

NTCP genetic variants may influence early virological response to bulevirtide monotherapy in patients with HDV related cirrhosis

Poster Presentation

Presenter: Pierluigi Toniutto

1123

Association of post-treatment virologic relapse and biochemical flares with HBV serum biomarkers in long-term virologically suppressed HBeAg-negative patients stopping NA treatment: Exploratory analyses from the control arm of the REEF-2 study

Poster Presentation

Presenter: Florian van Bömmel

1169

Tenofovir is associated with a better prognosis of hepatocellular carcinoma compared with entecavir in patients with chronic hepatitis B

Poster Presentation

Presenter: Hyun Jun Um

1237

Comparable risk of cardiovascular events in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

Poster Presentation

Presenter: Hyeyeon Hong

1260

Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide in chronic hepatitis B patients

Poster Presentation

Presenter: Pin-Nan Cheng

1277

HDV-RNA decline less than 1 log after 6 months of BLV 2mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort

Oral Presentation

Presenter: Victor de Lédighen

1454

The different immune response of B cells specific for hepatitis B virus core and envelope antigen in chronic hepatitis B patients with pegylated interferon-alpha treatment

Poster Presentation

Presenter: Qi Zheng

1456

Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection, a systematic review

Poster Presentation

Presenter: Vera Gielen

1465

Model-based meta-analysis of pegylated IFN-alpha induced HBsAg loss at end of treatment and 24 weeks post treatment in chronic hepatitis B virus infection

Poster Presentation

Presenter: Vera Gielen

1775

Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response

Poster Presentation

Presenter: Katja Deterding

1920

Switching to Besifovir in chronic hepatitis B patients receiving Tenofovir Disoproxil Fumarate: 96 weeks results of phase 4 trial

Poster Presentation

Presenter: Hyung Joon Yim

2187

Effect of first-line nucleot(s)ide analogues on blood lipids in patients with chronic hepatitis B: a network meta-analysis

Poster Presentation

Presenter: kexin tong

2199

Comparison of kidney function decline between chronic hepatitis B patients with versus without antiviral therapy

Poster Presentation

Presenter: Jae Seung Lee

2318

Predictors of Baveno VII criteria for recompensation in patients with hepatitis B-related decompensated cirrhosis

Poster Presentation

Presenter: Vicki Wing-Ki HUI

2371

Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies

Oral Presentation

Presenter: Maria Buti

2373

The efficacy of peginterferon alpha in Chinese inactive hepatitis B carriers and nucleoside analogs-experienced patients: a real world research

Poster Presentation

Presenter: chaojing Wen

2380

Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response

Poster Presentation

Presenter: Stefano D'Anna

2448

Long-term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 Phase 3 studies

Poster Presentation

Presenter: Young-Suk Lim

2727

Incomplete response with/without genotypic resistance to prior antivirals is not associated with a higher risk of hepatocellular carcinoma during tenofovir treatment for chronic hepatitis B

Poster Presentation

Presenter: Ju Yeon Kim

2814

Utility of partial cure as an endpoint after nucleos(t)ide analogue withdrawal among chronic hepatitis B patients (RETRACT-B study)

Poster Presentation

Presenter: Grishma Hirode

2959

Effects of tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B : a nationwide claims study

Poster Presentation

Presenter: Eunju Kim

3323

Similarly low risk of chronic kidney disease (CKD) progression in chronic hepatitis B patients with Stage 2 CKD on tenofovir alafenamide versus entecavir

Poster Presentation

Presenter: Yan Liang

3567

Effects of interferon-based therapies in functional cure and hepatocellular carcinoma risk reduction in patients with chronic hepatitis B: real-world evidence from 2-year data of OASIS project

Poster Presentation

Presenter: Qiran Zhang

3734

Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study

Oral Presentation

Presenter: Heiner Wedemeyer

## Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

239

Consolidation treatment with Tiaogan-Buxu-Jiedu granule (Traditional Chinese Medicine compound) plus entecavir reduces virological relapse following entecavir withdrawal in Chinese patients with chronic hepatitis B: a randomized, controlled trial

Poster Presentation

Presenter: Xiaoke Li

1097

Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: preliminary results from a randomized, blinded, Phase 1b study

Poster Presentation

Presenter: Edward Gane

1116

The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers

Poster Presentation

Presenter: Edward Gane

1127

A novel class of orally-available small molecules potently inhibiting hepatitis B and D virus entry

Poster Presentation

Presenter: Marc Windisch

1140

Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China

Poster Presentation

Presenter: Grace Wang

1157

Efficacy and safety of celecoxib add on nucleos(t)ide analogues on the hepatitis B surface antigen of virally suppressed patients with chronic hepatitis B - interim analysis

Poster Presentation

Presenter: Feng Xue

1160

Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B

Poster Presentation

Presenter: Jinlin HOU

1173

Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program

Poster Presentation

Presenter: Victor de Lédighen

1270

Cell-mediated immunity analysis to assess the characteristics of immune response to bepirovirsen: Examples from the B-Clear study

Poster Presentation

Presenter: Jenn Singh

1273

Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial

Oral Presentation

Presenter: Edward Gane

1281

Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836

Poster Presentation

Presenter: Christine L. Espiritu

1305

Single dose pharmacokinetics of VIR-3434, a novel neutralizing monoclonal antibody, in participants with chronic hepatitis B virus infection

Poster Presentation

Presenter: Sneha V. Gupta

1333

VIR-2218 and VIR-3434 therapy is efficacious in preclinical models of hepatitis delta virus infection

Poster Presentation

Presenter: Florian Lempp

1543

Efficacy and prediction analysis of pegylated interferon alpha-2b in treatment-naive HBeAg negative chronic hepatitis B patients with normal ALT: a multicenter real-world study (Ice-breaking Project in China) - Interim analysis

Poster Presentation

Presenter: Chong Zhang

1650

Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta

Oral Presentation

Presenter: Ohad Etzion

1703

The safety and efficacy of hepalatide (L47) treatment combined with pegylated interferon-alpha 2a in patients with chronic hepatitis B: the preliminary data from a double-blind, RCT phase II trial

Poster Presentation

Presenter: Xiaolu Tang

2024

The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients

Poster Presentation

Presenter: Asgeir Johannessen

2113

Quantification of serum HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0 and Eurobioplex

Poster Presentation

Presenter: Maria Paola Anolli

2324

Significant improvement of non-invasive fibrosis tests in HDV compensated cirrhotic patients with clinically significant portal hypertension treated with BLV monotherapy up to 96 weeks

Poster Presentation

Presenter: Elisabetta Degaspero

2328

Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - a long term follow-up study

Poster Presentation

Presenter: Che To Lai

2359

Kinetics of hepatitis B core related antigen in patients with compensated HDV cirrhosis treated with Bulevirtide monotherapy for 72 weeks: a single-center study

Poster Presentation

Presenter: Elisabetta Degaspero

2399

Modeling-based response-guided therapy with bulevirtide monotherapy for chronic hepatitis D to identify patients for finite treatment duration

Poster Presentation

Presenter: Harel Dahari

2432



Treatment with Bulevirtide, with or without PEG-interferon, in HIV-HBV/HDV co-infected patients in a real-life setting

Poster Presentation

Presenter: Victor de Lédighen

2441

Positive impact of reflex testing in performing hepatitis delta serology in HBsAg+ patients

Poster Presentation

Presenter: Régine Truchi

2492

Deep learning cluster analysis reveals subtypes in response to antisense oligonucleotide therapy in chronic hepatitis B

Poster Presentation

Presenter: Caroline Weis

2515

Therapeutic vaccine candidate CLB-3000 (CLB-405 and CLB-505 adjuvanted with Alhydrogel): a Good Laboratory Practice (GLP)-compliant 15-week intramuscular toxicity study in rabbits with a 4-week recovery

Poster Presentation

Presenter: Aileen Rubio

2543

A monoclonal antibody 4G2 exhibits anti-viral activity in mouse models of chronic hepatitis B

Poster Presentation

Presenter: Aditi Deshpande

2588

Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B

Poster Presentation

Presenter: Alina Jucov

2668

Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial

Poster Presentation

Presenter: Florian van Bömmel

2841

Safety and antiviral activity of RBD1016, a RNAi therapeutic, in chinese subjects with chronic hepatitis B virus (HBV) infection

Poster Presentation

Presenter: Wai-Kay Seto

2887

A phase 2 study of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B patients with 12-week treatment

Poster Presentation

Presenter: Jinlin HOU

2944

AHB-137, a novel hepatitis B virus antisense oligonucleotide with substantially enhanced in vitro and in vivo antiviral activity

Poster Presentation

Presenter: Xiaoli Wu

3022

Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV immunotherapy (VTP-300) combined with low-dose nivolumab (LDN) in virally suppressed patients with CHB on nucleos(t)ide analogues

Poster Presentation

Presenter: Tom Evans

3039

AHB-137, a novel and potent hepatitis B virus antisense oligonucleotide with a favorable preclinical pharmacokinetics and safety profile

Poster Presentation

Presenter: Tingting Lu

3257

Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks

Poster Presentation

Presenter: Elisabetta Degasperi

3352

Frequency of bepirovirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepirovirsen (Phase 2b B-Clear study)

Poster Presentation

Presenter: Jerome Bouquet

3424

Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg

Poster Presentation

Presenter: Marc Bourliere

3433

Preliminary results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B

Poster Presentation

Presenter: Kosh Agarwal

3451

Analysis of HBV genotype association to bepirovirsen treatment response in patients with chronic HBV infection (Phase 2b B-Clear study)

Poster Presentation

Presenter: Jerome Bouquet

3495

Safety and efficacy of REP 2139-Mg in association with TDF in chronic hepatitis delta patients with decompensated cirrhosis

Poster Presentation

Presenter: Christiane Stern

## Viral Hepatitis C: Clinical aspects including follow up after SVR

63

Predicting vertical transmission of hepatitis C in pregnant women using a composite score: a multicenter study

Poster Presentation

Presenter: Paul Wasuwanich

143

Serum myostatin decreased after direct acting antivirals for cirrhotic patients

Poster Presentation

Presenter: Tomoyuki Suehiro

159

Most vulnerable HCV patient groups treated with direct acting antivirals achieve high response rates and gain quality of life – data from the German hepatitis C-registry (DHC-R)

Poster Presentation

Presenter: Stefan Christensen

166

Real-world data on long-term quality of life after Glecaprevir/Pibrentasvir therapy: data from the German hepatitis C registry (DHC-R)

Poster Presentation

Presenter: Markus Cornberg

207

Results of the hepatitis B and C screening within the "Check-Up35+" in the German primary care setting one year after implementation by the federal joint committee

Poster Presentation

Presenter: Johannes Wiegand

253

The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry

Poster Presentation

Presenter: Chung-Feng Huang

312

Impact of direct-acting antiviral therapy on tumor progression and survival in intermediate to advanced hepatocellular carcinoma patient with HCV infection

Poster Presentation

Presenter: Chen-Ta Chi

441

Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong

Poster Presentation

Presenter: Victor Yung Sin Chow

650

Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

Poster Presentation

Presenter: Alison Boyle

721

Sustained virologic response outcomes in patient with hemodialysis - hepatitis c receiving treatment with direct-acting antivirals agents

Poster Presentation

Presenter: Fardhah Akil

752

Ethnic disparity in mortality related to extrahepatic manifestations among people with chronic HCV infection: a large, linked administrative population-based study in British Columbia, Canada

Poster Presentation

Presenter: Dahn Jeong

759

Analysis of mortality rate in the patients after hepatitis C virus elimination using direct acting antivirals and comparison with the general population

Poster Presentation

Presenter: Satoshi Miuma

798

Impact of direct-acting antiviral therapy on survival in patients with liver cirrhosis and ascites. Data from the hepa-C registry

Poster Presentation

Presenter: Álvaro Hidalgo Romero

848

The prevalence of hepatitis C virus infection in high-risk patients with high normal alanine aminotransferase (ALT) in Israel: a bio bank analysis

Poster Presentation

Presenter: Amir Shlomai

875

The impact of 5 years of testing for hepatitis C in prisons in the north east of England

Poster Presentation

Presenter: Amy Johnson

1014

Clinical outcomes after hepatitis C treatment in patients with advanced chronic liver disease

Poster Presentation

Presenter: Fabio Correia

1170

Mortality risk following HCV cure among people with HIV coinfection

Poster Presentation

Presenter: Naveed Janjua

1299

HCV screening rates in reproductive age women after universal screening guidelines

Poster Presentation

Presenter: Roshni Singh

1321

Network transmission of hepatitis C genotype 2c and 4d in men who have sex with men in Cape Town, South Africa

Poster Presentation

Presenter: Mark Sonderup

1404

External validation of models to predict hepatocellular carcinoma (HCC) in HCV SVR F3-F4 patients

Poster Presentation

Presenter: Marina Berenguer

1494

What is the impact of a Hepatitis C 'test and trace' pilot using peer workers?

Poster Presentation

Presenter: Stuart Mcpherson

1559

Post-treatment liver function, but not baseline liver function, predicts survival in hepatitis C virus patients with decompensated cirrhosis after direct-acting antiviral treatment

Poster Presentation

Presenter: Yuki Tahata

1569

Achieving a hepatitis C cure in those with hepatocellular carcinoma is associated with an improvement in overall survival: real world data

Oral Presentation

Presenter: Maria Guerra Veloz

1603

Hepatitis C virus (HCV) infection and neurocognitive impairment in subjects with mild liver disease

Poster Presentation

Presenter: Marcia Maria Amendola Pires

1609

Prognostic factors of post-sustained virological response outcome in patients with chronic hepatitis C treated with direct-acting antivirals

Poster Presentation

Presenter: Won Sohn

1637

Long term normalization of systemic inflammation and endothelial activation after hepatitis C virus (HCV) eradication in HIV/HCV coinfecting, HCV monoinfected patients and HCV-infected liver transplant recipients

Poster Presentation

Presenter: laura benitez gutierrez

1733

Direct-acting antivirals reduce disease burden in patients with chronic hepatitis C: a Korean nationwide, multicentre, retrospective cohort study

Poster Presentation

Presenter: Won Sohn

1741

The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure

Poster Presentation

Presenter: Veronika Pitova

1790

The influence of direct acting antiviral treatment in chronic hepatitis C virus infection on arterial stiffness

Poster Presentation

Presenter: Mircea Istrate

1926

A large-scale, centralized viral hepatitis screening model in Hainan province of China during the COVID-19 pandemic

Poster Presentation

Presenter: Tao Wu

1969

Usefulness of serum CCL20 as a post sustained viral response biomarker for HCV-associated liver fibrosis

Poster Presentation

Presenter: Atsumasa Komori

2021

Hepatitis C micro-elimination program in Zhuhai: a concerted citywide effort to eliminate hepatitis C by 2030

Poster Presentation

Presenter: Xinchun Zheng

2046

Evaluation of the follow-up in patients with advanced fibrosis after achieve sustained viral response with direct-acting antivirals. Screening and risk of hepatocellular carcinoma

Poster Presentation

Presenter: Vanesa Bernal Monterde

2366

HCV screening: shortening read time of point-of-care rapid diagnostic test does not effect detection rates of antibodies against hepatitis C virus

Poster Presentation

Presenter: Muhammad Nabeel Shafqat

2430

Achieving hepatitis C micro-eliminating in 4 female prisons through a nurse led test and treat approach of pathway optimisation and whole prison testing

Poster Presentation

Presenter: Nichola Royal

2460

MAFLD (metabolic associated fatty liver disease) outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct antiviral agents

Poster Presentation

Presenter: Serena Pelusi

2601

Cholestatic HCV-related cryoglobulinemia, a new clinical and pathological entity: a case-control study

Poster Presentation

Presenter: Sara Romeo

2605

Hepatitis C virus (HCV) infection and neurocognitive impairment in subjects with mild liver disease: the role of neuropsychological and cognitive provoked P300 tests

Poster Presentation

Presenter: CARLOS BRANDÃO-MELLO

2621

HCV elimination: reengagement of previously diagnosed but unlinked patients with chronic hepatitis C to initiate treatment

Poster Presentation

Presenter: Maria Guerra Veloz

2634

The risks of first hepatic decompensation and HCC remain constant during long-term follow-up and can be stratified by a one-time assessment after HCV-cure

Oral Presentation

Presenter: Georg Semmler

2676

Chronic hepatitis C and aging: search for cognitive changes

Poster Presentation

Presenter: CARLOS BRANDÃO-MELLO

2704

Hospitalisation - missing an opportunity to link to hepatitis C care: a retrospective study at a regional Australian health service

Poster Presentation



Presenter: Joseph DOYLE

2953

Utilising peer support workers in hepatitis C screening in emergency departments: a pilot study

Poster Presentation

Presenter: Alex Caulder

3033

Hepatitis C virus infection follow-up of people who use drugs in the Balearic Islands, Spain

Poster Presentation

Presenter: Jeffrey Lazarus

3422

Impact of hepatitis C treatment on biochemical and metabolic parameters in HIV/HCV coinfecting patient

Poster Presentation

Presenter: Misael Osmar Garcia Martin

3456

Clinical outcomes after therapy with direct acting antiviral in patients with HCV-related B-cell Non-Hodgkin lymphomas and/or mixed cryoglobulinemia

Poster Presentation

Presenter: Marco Tizzani

3519

Digital pathology quantification of cirrhosis severity continuum in human HCV liver biopsies and its correspondence with Laennec and Beijing stages

Poster Presentation

Presenter: Louis Petitjean

3531

Differences in baseline characteristics of direct acting antiviral (DAA)- treated Greek HCV patients according to source of infection

Poster Presentation

Presenter: Spyridon (Spyros) SIAKAVELLAS

3542

One year of HCV/HBV/HIV screening in a psychiatric population consulting in the emergency room (Beaujon Hol/REVHEPAT)

Poster Presentation

Presenter: Tarik Asselah

3551

Hepatitis C and monoclonal gammopathy of undetermined significance: clinical and hematological outcome after eradication with direct acting antivirals

Poster Presentation

Presenter: Rosa Claudia Stasio

3572

A prospective, pragmatic post-authorisation safety study of early recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after direct-acting antiviral (DAA) therapy: DAA-PASS

Poster Presentation

Presenter: Amit Singal

3748

Incidence and associations of HCV reinfection in the era of direct acting antivirals

Poster Presentation

Presenter: Sofia Vasileiadi

3810

HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care

Poster Presentation

Presenter: Maria Torner

## Viral hepatitis C: Therapy and resistance

83

Retreatment of patients experiencing failure with Hepatitis C direct-acting antivirals

Poster Presentation

Presenter: Nessa Quinn

335

Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 – December 2022

Poster Presentation

Presenter: Tengiz Tsertsvadze

409

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemia and monoclonal gammopathy

Poster Presentation

Presenter: Sofia Gavrisheva

570

An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan

Poster Presentation  
Presenter: Ming-Lung Yu

1012  
The most difficult to cure with pangenotypic regimens HCV infected population  
Poster Presentation  
Presenter: Robert Flisiak

1449  
Unusual HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients  
Oral Presentation  
Presenter: Julia Dietz

1828  
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients with prior failure to DAA treatment  
Oral Presentation  
Presenter: Christiana Graf

1846  
Efficacy and safety of Sofosbuvir Plus Daclatasvir bilayer tablet with or without Ribavirin in patients with chronic hepatitis C genotype 4 Infection  
Poster Presentation  
Presenter: Mohamed Hassany

2738  
Sofosbuvir/Velpatasvir plus Ribavirin for chronic hepatitis C virus genotype 3 infected cirrhotic patients with or without HIV or HBV coinfection: real-world experience from southwest China  
Poster Presentation  
Presenter: Yongrui Yang

2785  
Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir  
Poster Presentation  
Presenter: Stuart C Gordon

2965  
Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis  
Poster Presentation  
Presenter: Devan Pooja

3031

Concomitant use of proton pump inhibitors and Sofosbuvir/Velpatasvir: evidence from randomized clinical trials and real-world data

Poster Presentation

Presenter: Maria Buti

3140

Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

Poster Presentation

Presenter: Juan Carlos Ruíz-Cobo

3221

Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: results from the HCV-TARGET study

Oral Presentation

Presenter: Wesam Aleyadeh

3802

Resistance-associated substitutions described after failure of anti-NS5A direct-acting antiviral treatment in 58 hepatitis C virus (HCV) infected patients in cameroon

Poster Presentation

Presenter: serge Tchamgoue

## Late breaker

3927

Concurrent nivolumab and external beam radiation therapy for patients with advanced hepatocellular carcinoma with vascular invasion: a phase 2, single-arm NEXTRAH trial

Poster Presentation

Presenter: Joong-Won Park

3933

Modelling intrahepatic bile duct morphogenesis in vitro using synthetic hydrogels

Poster Presentation

Presenter: Iona Thelwall

3939

Evaluation of 8 non-invasive models in predicting NAFLD severity and progression in a one-year prospective study based on MRI-PDFF

Poster Presentation

Presenter: Yanhua Ding

3946

Long-term trends of circulating hepatitis B virus RNA and hepatitis B core-related antigen levels in persons with HIV and functional hepatitis B cure during tenofovir therapy

Poster Presentation

Presenter: Lorin Bégré

3949

Further decompensation as a new prognostic stage in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements

Poster Presentation

Presenter: Gennaro D'Amico

3962

Assessing progress towards achieving regional hepatitis B control goal – nationwide serosurvey among children, Uzbekistan, 2022

Poster Presentation

Presenter: Nino Khetsuriani

3968

Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up

Oral Presentation

Presenter: Man-Fung Yuen

3977

Mycophenolate mofetil is superior to azathioprine for the induction of remission in treatment-naive autoimmune hepatitis [CAMARO trial]

Oral Presentation

Presenter: Romée Snijders

3982

Pegzofermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)

Oral Presentation

Presenter: Rohit Loomba

3987

Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: a proof-of-concept study

Poster Presentation

Presenter: Rifaat Safadi

3988

Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

Oral Presentation

Presenter: Qinghe Zeng

3993

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)

Oral Presentation

Presenter: Michael Trauner

4005

Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease

Poster Presentation

Presenter: Katja Deterding

4030

Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy: the retrospective multicenter European study (Save-D)

Poster Presentation

Presenter: Elisabetta Degasperi

4035

Effects of intermittent fasting on metabolic dysfunction-associated fatty liver disease are transmissible through fecal transplants

Poster Presentation

Presenter: junhong su

4038

Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: risk of HCC recurrence from a large, multicentre retrospective study from Italy

Oral Presentation

Presenter: Patrizia Burra

4041

Oral vancomycin induces remission in PSC-IBD, which is associated with a reduction in bile salt hydrolase and colonic amine oxidase activity

Poster Presentation

Presenter: Palak Trivedi

4043

Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH a phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo

Poster Presentation

Presenter: Stephen Harrison

4045

Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): data from the MARCH-ON study

Poster Presentation

Presenter: Richard Thompson

4054

Safety and efficacy of anti-pre-S1 domain monoclonal antibody (HH-003) treatment in patients with co-infection of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV): a single center, open-label, phase 2 trial

Poster Presentation

Presenter: Junqi Niu

4057

Intestinal bacterial vesicles cause fibrosis progression and serum albumin levels reduction in cirrhosis

Poster Presentation

Presenter: Atsunori Tsuchiya

4070

Prospective direct comparisons of four widespread noninvasive fibrosis tests (NITs) in outpatients with type-2 diabetes (T2D) using EPOS histological staging as reference

Poster Presentation

Presenter: Olivier Deckmyn

4080

Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial

Poster Presentation

Presenter: Rohit Loomba

4088

Safety, pharmacokinetics and antiviral efficacy of freethiadine, a novel capsid assembly modulator, in healthy volunteers and patients with chronic hepatitis B virus infection

Poster Presentation

Presenter: Yanhua Ding

4094

A global research priority agenda to advance public health responses to fatty liver disease

Poster Presentation

Presenter: Jeffrey Lazarus

4102

Analytical and clinical validation of AIM-NASH: a digital pathology tool for artificial intelligence-based measurement of nonalcoholic steatohepatitis histology

Oral Presentation

Presenter: Stephen Harrison

4105

Evaluation of noninvasive tests to identify precirrhotic fibrosis due to NASH in patients screened for the phase 3 REGENERATE and REVERSE studies of obeticholic acid

Poster Presentation

Presenter: Mary Rinella

4112

Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection

Poster Presentation

Presenter: Man-Fung Yuen

4114

Evaluation of the hepatitis B virus liver reservoir with fine needle aspirates

Poster Presentation

Presenter: Armando Andres Roca Suarez

4115

Validation of the R3-AFP model for risk prediction of HCC recurrence after liver transplantation in the SILVER clinical trial

Poster Presentation

Presenter: Charlotte Costentin

4122

High prevalence of short telomeres in patients with idiopathic porto-sinusoidal vascular disorder

Poster Presentation

Presenter: Alexander Coukos

4131

A new risk model outperforms FIB-4 when predicting incident cirrhosis in the general population: a cohort study of 504,000 persons

Poster Presentation

Presenter: Rickard Strandberg

4132

Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report

Poster Presentation

Presenter: Robert Elston

4135

Ethanol-producing Lactobacillaceae contribute to liver damage in metabolic disease and counteract effects of lifestyle intervention

Poster Presentation

Presenter: junhong su

4136

Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial

Oral Presentation

Presenter: Elisa Pose

4139

Continued treatment of early nonresponder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses

Poster Presentation

Presenter: Pietro Lampertico

4144

Investigating the potential of the primary cilium as an immunomodulatory organelle in intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Sara Teles

4152

HCV and HBV prevalence and associated risk factors among people who inject drugs in Kenya

Poster Presentation



Presenter: Matthew Akiyama

4156

Preventing liver disease with policy measures to tackle alcohol consumption and obesity: a microsimulation study

Poster Presentation

Presenter: Maria Buti

4160

Predictors of long-term mortality after HCV eradication among PLWH

Poster Presentation

Presenter: Alessia Siribelli

4162

Hepatocellular carcinoma surveillance improves early detection and curative treatment in chronic hepatitis C patients treated with direct acting antivirals

Poster Presentation

Presenter: Cassia Regina Guedes Leal

4163

Improving hepatitis B screening and linkage to care rates via the electronic medical record, provider engagement, and patient navigation in a large, urban health system

Poster Presentation

Presenter: Anna Mageras

4166

Dramatic reductions in hepatic steatosis accompanied by improved HbA1c following a 4-week treatment of obese/diabetic/NAFLD patients with DD01, a novel long-acting GLP-1/glucagon receptor agonist

Poster Presentation

Presenter: Adam Bell

4169

Safety and efficacy of continuous infusion terlipressin (BIV201) in patients with decompensated cirrhosis and refractory ascites: a phase 2, randomized, controlled, open-label study

Poster Presentation

Presenter: Jasmohan Bajaj

4174

ALG-000184, a capsid assembly modulator, dosed with entecavir for up to 28 weeks is well tolerated and resulted in substantial declines in surface antigen levels in untreated Hepatitis B e antigen positive subjects with chronic hepatitis B

Poster Presentation

Presenter: Jinlin Hou

4176

Using FIB-4's parameters an explainable black-box machine learning model outperforms FIB-4 index on the diagnosis of advanced fibrosis of non alcohol related fatty liver disease patients in three cohorts from China, Malaysia and India

Poster Presentation

Presenter: Athanasios Angelakis